Publications: Prof Gavin Giovannoni
Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D et al.
(
2024
)
.
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells
.
Clinical Immunology
vol.
269
,
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G et al.
(
2024
)
.
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis
.
Neurology Neuroimmunology & Neuroinflammation
vol.
11
,
(
6
)
Derfuss T, Bermel R, Lin C-J, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G et al.
(
2024
)
.
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials
.
Therapeutic Advances in Neurological Disorders
vol.
17
,
Eyre M, Absoud M, Abdel‐Mannan O, Crichton S, Hacohen Y, Rossor T, Rudebeck S, Giovannoni G et al.
(
2024
)
.
Academic outcomes before and after clinical onset of acquired demyelinating syndromes in children: a matched cohort data linkage study
.
Annals of Clinical and Translational Neurology
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
(
2024
)
.
FROM BENCH TO BEDSIDE: A SNAIL IN TREACLE?
.
Multiple Sclerosis and Related Disorders
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A et al.
(
2024
)
.
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
.
BMJ Open
vol.
14
,
(
9
)
Yeh EA, Levy M, Hawkes C, Lechner-Scott J, Giovannoni G
(
2024
)
.
The risks and benefits of using AI for diagnosis: beware of unconscious bias
.
Multiple Sclerosis and Related Disorders
vol.
90
,
Levy M, Yeh A, Hawkes C, Lechner-Scott J, Giovannoni G
(
2024
)
.
Mr. Machiavelli's Choice for Treatment of MOG Antibody Disease: Do the benefits of long-term corticosteroids justify the means?
.
Multiple Sclerosis and Related Disorders
vol.
89
,
Scalfari A, Traboulsee A, Oh J, Airas L, Bittner S, Calabrese M, Dominguez JMG, Granziera C et al.
(
2024
)
.
Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions
.
Annals of Neurology
Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, Butzkueven H, Cutter GR et al.
(
2024
)
.
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)
.
Neurology and Therapy
vol.
13
,
(
5
)
1385
-
1401
.
Zaloum SA, Mahesh M, Cetin MA, Ganesh S, Horne R, Giovannoni G, Dobson R
(
2024
)
.
Diversity and representation within the literature on sexual dysfunction in multiple sclerosis: A systematic review
.
Multiple Sclerosis and Related Disorders
vol.
89
,
Lechner-Scott J, Giovannoni G, Hawkes CH, Levy M, Yeh EA
(
2024
)
.
Depression and anxiety in MS: symptoms or comorbidity?
.
Multiple Sclerosis and Related Disorders
vol.
88
,
Thomson A, Horne R, Chapman C, Bharadia T, Burke P, Colwell E, Harrington M, Boskovic B et al.
(
2024
)
.
Engaging a community to focus on upper limb function in people with multiple sclerosis: the ThinkHand campaign case study
.
Research Involvement and Engagement
vol.
10
,
(
1
)
Zhang Q, Noyce AJ, Robson J, Giovannoni G, Marshall CR, Dobson R
(
2024
)
.
No association between oral contraceptive exposure and subsequent MS: A population-based nested case–control study in primary care
.
Multiple Sclerosis Journal
vol.
30
,
(
9
)
1221
-
1226
.
Mistry N, Hobart J, Rog D, Muhlert N, Mathews J, Baker D, Giovannoni G
(
2024
)
.
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis
.
Multiple Sclerosis and Related Disorders
vol.
88
,
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Pepper G, Schmierer K
(
2024
)
.
Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?
.
Multiple Sclerosis and Related Disorders
vol.
87
,
Shephard A, Kolaczkowski L, Barker N, Nahal D, Oreja-Guevara C, Reyes S, Gray H, Salloukh H et al.
(
2024
)
.
Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals
.
Neurology and Therapy
vol.
13
,
(
4
)
1015
-
1038
.
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
(
2024
)
.
Open access publishing and the future of scientific communication
.
Multiple Sclerosis and Related Disorders
vol.
86
,
Hauser S, Kappos L, Filippi M, Wolinsky J, Weber M, Nicholas J, Chognot C, Schneble H-M et al.
(
2024
)
.
10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)
.
Neurology
vol.
102
,
(
17_supplement_1
)
Vermersch P, Saubadu S, Truffinet P, Arnould B, Hakimi-Hawken N, Minor C, Araujo L, Gourlain S et al.
(
2024
)
.
Efficacy of Frexalimab on Physical and Psychological Impacts and Fatigue in Relapsing Multiple Sclerosis: Findings from MSIS-29v2 and PROMIS-Fatigue-MS-8a Assessments in a Phase 2 Trial (P10-6.001)
.
Neurology
vol.
102
,
(
17_supplement_1
)
Ammoscato F, Skonieczna J, Bestwick J, Holden D, Aboulwafa M, Andrews M, Turner B, Marta M et al.
(
2024
)
.
Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 Weeks (P10-6.008)
.
Neurology
vol.
102
,
(
17_supplement_1
)
Giovannoni G, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S et al.
(
2024
)
.
Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)
.
Neurology
vol.
102
,
(
17_supplement_1
)
Schneble H-M, Weber MS, Kappos L, Hauser SL, Nicholas JA, Giovannoni G, Filippi M
(
2024
)
.
Impact pour le patient de 10 ans de traitement par ocrelizumab dans la sclérose en plaques : données à long terme des études de phase III OPERA et ORATORIO
.
Revue Neurologique
vol.
180
,
Wiendl H, Foley J, Defer G, Ryerson LZ, Cohen JA, Arnold D, Butzkueven H, Cutter G et al.
(
2024
)
.
Résultats de l’étude d’extension NOVA évaluant la préférence des patients pour l’administration sous-cutanée (SC) versus intraveineuse (IV) de natalizumab (NTZ) avec le schéma Q6W (toutes les 6 semaines)
.
Revue Neurologique
vol.
180
,
Maltby VE, Scott RJ, Giovannoni G, Hawkes CH, Levy M, Yeh EA, Lechner-Scott J
(
2024
)
.
Where does multiple sclerosis come from?
.
Multiple Sclerosis and Related Disorders
vol.
85
,
Giovannoni G
(
2024
)
.
Targeting Epstein–Barr virus in multiple sclerosis: when and how?
.
Current Opinion in Neurology
vol.
37
,
(
3
)
228
-
236
.
Leary S, Brownlee W, Barker N, Chard D, Chataway J, Chung K, Ciccarelli O, Giovannoni G et al.
(
2024
)
.
Multiple Sclerosis and Demyelinating Diseases
.
Neurology
,
Wiley
Yeh EA, Giovannoni G, Hawkes C, Sergott RC, Levy M, Lechner-Scott J
(
2024
)
.
OCT-Angiography in AQP4-positive NMOSD: finding subclinical disease using a new tool
.
Multiple Sclerosis and Related Disorders
vol.
84
,
Thomson A, Stennett A, Metin C, Bestwick J, Giovannoni G, Dobson R
(
2024
)
.
Under & Over: A randomised controlled study to develop an upper limb rehabilitation tool for people with Multiple Sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
85
,
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S et al.
(
2024
)
.
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
.
New England Journal of Medicine
vol.
390
,
(
7
)
589
-
600
.
Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, Roldan E, Beecher C et al.
(
2024
)
.
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial
.
BMJ Open
vol.
14
,
(
2
)
Kalincik T, Malpas C, Penner I-K, Giovannoni G, Chitnis T, Vermersch P, Arnould S, Maca J et al.
(
2022
)
.
2325 Cognitive processing speed predicts disease progression in secondary progressive multiple sclerosis: post hoc analysis from the EXPAND study
.
Conference:
Abstractsa39.1
-
a3a39
.
Giovannoni G, Ford HL, Schmierer K, Middleton R, Stennett AM, Pomeroy I, Fisniku L, Scalfari A et al.
(
2024
)
.
MS care: integrating advanced therapies and holistic management
.
Frontiers in Neurology
vol.
14
,
Jacobs BM, Vickaryous N, Giovannoni G, Proitsi P, Waters S, Dobson R
(
2024
)
.
Plasma proteomic profiles of UK Biobank participants with multiple sclerosis
.
Annals of Clinical and Translational Neurology
vol.
11
,
(
3
)
698
-
709
.
Lechner-Scott J, Probst Y, Giovannoni G, Hawkes CH, Levy M, Yeh EA
(
2024
)
.
What is the role of diet for multiple sclerosis? Why epidemiological studies don't give the full answer
.
Multiple Sclerosis and Related Disorders
vol.
83
,
Drosu N, Bjornevik K, Bilodeau PA, Yeh A, Lechner-Scott J, Hawkes CH, Giovannoni G, Levy M
(
2024
)
.
In the era of antiviral trials for MS, the answer lies in the details
.
Multiple Sclerosis and Related Disorders
vol.
82
,
Oh J, Capezzuto L, Kriara L, Schjodt-Eriksen J, van Beek J, Bernasconi C, Montalban X, Butzkueven H et al.
(
2024
)
.
Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study
.
Scientific Reports
vol.
14
,
(
1
)
Dobson R
(
2023
)
.
A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis
.
Multiple Sclerosis Journal
Baker D, Kang AS, Giovannoni G, Schmierer K
(
2023
)
.
Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
82
,
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA
(
2023
)
.
Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
81
,
Vermersch P, Giovannoni G, Wolinsky J, Arnold DL, Kamudoni P, Meier DP, Thangavelu K, Kinkolykh A et al.
(
2023
)
.
Effect of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Patient-Reported Vitality and Mental Health in Patients with Relapsing Multiple Sclerosis in a Phase 2 Trial
.
Multiple Sclerosis and Related Disorders
vol.
80
,
Giovannoni G, Vermersch P, Arnould B, Hakimi-Hawken N, Araujo L, Saubadu S, Truffinet P, Gourlain S et al.
(
2023
)
.
PCR122 Psychometric Evaluation of Multiple Sclerosis Impact Scale 29 Version 2 in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab
.
Value in Health
vol.
26
,
(
12
)
Vermersch P, Giovannoni G, Arnould B, Hakimi-Hawken N, Araujo L, Saubadu S, Truffinet P, Gourlain S et al.
(
2023
)
.
PCR66 Psychometric Validation of PROMIS-Fatigue-MS-8a Questionnaire in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab
.
Value in Health
vol.
26
,
(
12
)
Giovannoni G, Leist T, Jack D, Galazka A, Alexandri N, Nolting A
(
2023
)
.
Post-Approval Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: 2023 Update
.
Multiple Sclerosis and Related Disorders
vol.
80
,
Giovannoni G
(
2023
)
.
What is the role of Epstein Barr Virus (EBV) infection – would a vaccine “end” multiple sclerosis?
.
Journal of the Neurological Sciences
vol.
455
,
Alghanimy AA, Giovannoni G, Lechner-Scott J, Levy M, Yeh EA, Hawkes CH
(
2023
)
.
Is multiple sclerosis a glymphaticopathy?
.
Multiple Sclerosis and Related Disorders
vol.
80
,
Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S et al.
(
2023
)
.
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
.
Therapeutic Advances in Neurological Disorders
vol.
16
,
Yeh EA, Giovannoni G, Hawkes C, Levy M, Lechner-Scott J
(
2023
)
.
Can we improve outcomes in MS around the world? Access and global considerations across income strata
.
Multiple Sclerosis and Related Disorders
vol.
79
,
Bernard Healey SA, Giovannoni G, Noyce A, Dobson R, Jacobs BM
(
2023
)
.
Impact of multiple sclerosis risk alleles on the plasma proteome
.
Brain
vol.
147
,
(
2
)
e17
-
e21
.
Dubuisson N, de Maere d'Aertrijcke O, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G et al.
(
2023
)
.
Anaesthetic management of people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
80
,
Oreja-Guevara C, Potra S, Bauer B, Centonze D, Giambastiani M-P, Giovannoni G, Kesselring J, Langdon D et al.
(
2023
)
.
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care
.
Advances in Therapy
vol.
40
,
(
12
)
5131
-
5136
.
Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G et al.
(
2023
)
.
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
.
Therapeutic Advances in Neurological Disorders
vol.
16
,
Wilson D, Chan D, Chang L, Mathis R, Verberk I, Montalban X, Comabella M, Fissolo N et al.
(
2023
)
.
Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury
.
Clinical Chemistry and Laboratory Medicine
vol.
62
,
(
2
)
322
-
331
.
Lechner-Scott J, Maltby V, Giovannoni G, Hawkes C, Levy M, Yeh A
(
2023
)
.
Are we there yet? The holy grail: A biomarker for Multiple Sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
78
,
Jacobs BM, Tank P, Bestwick JP, Noyce AJ, Marshall CR, Mathur R, Giovannoni G, Dobson R
(
2023
)
.
Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case–control study in an English population-based cohort
.
Journal of Neurology
vol.
271
,
(
1
)
241
-
253
.
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA
(
2023
)
.
CNS resilience in the progression of MS
.
Multiple Sclerosis and Related Disorders
vol.
77
,
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D et al.
(
2023
)
.
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study
.
Neurodegenerative Disease Management
vol.
13
,
(
5
)
261
-
268
.
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA
(
2023
)
.
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?
.
Multiple Sclerosis and Related Disorders
vol.
78
,
Giovannoni G
(
2023
)
.
Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary
.
Multiple Sclerosis Journal
vol.
29
,
(
9
)
1068
-
1069
.
Gold R, Barnett M, Chan A, Feng H, Fujihara K, Giovannoni G, Montalbán X, Shi F-D et al.
(
2023
)
.
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
.
Therapeutic Advances in Neurological Disorders
vol.
16
,
Dobson R
(
2023
)
.
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination
.
Multiple Sclerosis Journal
Baker D
(
2023
)
.
Neuroprotection in an
Experimental Model of Multiple
Sclerosis via Opening of Big
Conductance, Calcium-Activated
Potassium Channels
.
Pharmaceuticals
vol.
16
,
972
-
972
.
Pryce G, Sisay S, Giovannoni G, Selwood DL, Baker D
(
2023
)
.
Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels
.
Pharmaceuticals (Basel)
.
vol.
16
,
Levy M, Yeh A, Hawkes C, Lechner-Scott J, Giovannoni G
(
2023
)
.
Is using ChatGPT to help write papers and grants is useful, and ethical?
.
Multiple Sclerosis and Related Disorders
vol.
76
,
Greenberg B, Giovannoni G
(
2023
)
.
A place for biosimilars in the changing multiple sclerosis treatment landscape
.
Multiple Sclerosis and Related Disorders
vol.
77
,
Jiang X, Shen C, Teunissen CE, Wessels M, Zetterberg H, Giovannoni G, Singh CM, Caba B et al.
(
2023
)
.
Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation
.
Multiple Sclerosis Journal
vol.
29
,
(
9
)
1070
-
1079
.
Simonet C, Mahlknecht P, Marini K, Seppi K, Gill A, Bestwick JP, Lees AJ, Giovannoni G et al.
(
2023
)
.
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease
.
Movement Disorders
vol.
38
,
(
9
)
1636
-
1644
.
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA
(
2023
)
.
Beyond the B-cell as a treatment target in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
75
,
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
(
2023
)
.
Migraine and multiple sclerosis: The final answer?
.
Multiple Sclerosis and Related Disorders
vol.
74
,
Kalatskaya I, Giovannoni G, Leist T, Cerra J, Boschert U, Rolfe PA
(
2023
)
.
Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
.
Scientific Reports
vol.
13
,
(
1
)
Jacobs BM, Schalk L, Dunne A, Scalfari A, Nandoskar A, Gran B, Mein CA, Sellers C et al.
(
2023
)
.
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK
.
BMJ Open
vol.
13
,
(
5
)
Giovannoni G, Alvarez E, Tutton E, Hoffmann O, Xu Y, Vermersch P, Oreja-Guevara C, Trojano M et al.
(
2023
)
.
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
.
Digital Health
vol.
9
,
Yeh EA, Giovannoni G, Hawkes C, Levy M, Lechner-Scott J
(
2023
)
.
Equity, diversity and inclusion in academic publishing: Can we move the needle?
.
Multiple Sclerosis and Related Disorders
vol.
73
,
Weber M, Kappos L, Hauser S, Schneble H-M, Wang Q, Giovannoni G
(
2023
)
.
Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (S46.003)
.
Neurology
.
vol.
100
,
Bagnato F, Scalfari A, Oh J, Airas L, Bittner S, Calabrese M, Dominguez JMG, Granziera C et al.
(
2023
)
.
International Consensus on Smoldering Disease in Multiple Sclerosis using the Delphi Method (P11-3.013)
.
Neurology
.
vol.
100
,
Leist T, Giovannoni G, Jack D, Galazka A, Nolting A
(
2023
)
.
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Liver Safety (P7-3.010)
.
Neurology
.
vol.
100
,
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D et al.
(
2023
)
.
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study
.
Multiple Sclerosis Journal
vol.
29
,
(
6
)
719
-
730
.
Arnold D, Foley J, Defer G, Zhovtis RL, Cohen JA, Butzkueven H, Cutter G, Giovannoni G et al.
(
2023
)
.
Critères d’évaluation exploratoires à l’IRM de l’étude NOVA : étude randomisée et contrôlée de l’efficacité de l’administration de natalizumab toutes les 6 semaines (Q6W) vs la poursuite d’une administration toutes les 4 semaines (Q4W) dans la SEP
.
Revue Neurologique
vol.
179
,
s145
-
s146
.
Lechner-Scott J, Agland S, Giovannoni G, Hawkes C, Levy M, Yeh EA
(
2023
)
.
Inequality in accessing healthcare for people with MS
.
Multiple Sclerosis and Related Disorders
vol.
72
,
Levy M, Molazadeh N, Bilodeau PA, Vishnevetsky A, Lotan I, Salky R, Anderson M, Romanow G et al.
(
2023
)
.
Multiple types of relapses in MOG antibody disease
.
Multiple Sclerosis and Related Disorders
vol.
72
,
Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, Kleinschnitz C, Havrdova EK et al.
(
2023
)
.
Expert Opinion on Long-Term Use of Cladribine Tablets for Multiple Sclerosis: Systematic Literature Review of Real-World Evidence
.
Multiple Sclerosis and Related Disorders
vol.
71
,
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA
(
2023
)
.
Are we ready for CD19-targeted CAR T-cell therapies in MS?
.
Multiple Sclerosis and Related Disorders
vol.
70
,
Dobson R, Jacobs B, Marshall C
(
2023
)
.
Polygenic risk score prediction of Multiple Sclerosis in individuals of South Asian ancestry
.
Brain Communications
Hiyoshi A, Hawkes CH, Neffendorf JE, Olsson T, Giovannoni G, Montgomery S
(
2023
)
.
Myopia in late adolescence and subsequent multiple sclerosis among men
.
Multiple Sclerosis and Related Disorders
vol.
71
,
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G et al.
(
2023
)
.
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
72
,
Aloisi F, Giovannoni G, Salvetti M
(
2023
)
.
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy
.
The Lancet Neurology
vol.
22
,
(
4
)
338
-
349
.
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
(
2023
)
.
Cancer risk and mortality in multiple sclerosis: The need for vigilance
.
Multiple Sclerosis and Related Disorders
vol.
69
,
Barnett M, Chan A, Feng H, Fujihara K, Giovannoni G, Gold R, Montalban X, Shi F-D et al.
(
2023
)
.
An Update on the Clinical use of Dimethyl Fumarate, Including as a Recently Licensed Therapy in China, Using a Modified Delphi Method: Interim Results
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
29
,
NP23
-
NP24
.
Dreyer-Alster S, Achiron A, Giovannoni G, Jacobs BM, Dobson R
(
2022
)
.
No evidence for an association between alcohol consumption and Multiple Sclerosis risk: a UK Biobank study
.
Scientific Reports
vol.
12
,
(
1
)
Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, Kleinschnitz C, Havrdova EK et al.
(
2022
)
.
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
.
Multiple Sclerosis and Related Disorders
vol.
69
,
Gold J, Holden D, Parratt J, Yiannikas C, Ahmad R, Sedhom M, Giovannoni G
(
2022
)
.
Effect of teriflunomide on Epstein–Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study
.
Multiple Sclerosis and Related Disorders
.
vol.
68
,
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA
(
2022
)
.
What are T-cells telling us about how EBV causes MS?
.
Multiple Sclerosis and Related Disorders
vol.
68
,
Baker D, Forte E, Pryce G, Kang AS, James LK, Giovannoni G, Schmierer K
(
2022
)
.
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
.
Multiple Sclerosis and Related Disorders
vol.
69
,
Dobson R
(
2022
)
.
Social determinants of health and their impact in multiple sclerosis
.
Nature Reviews Neurology
Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sørensen PS, Vermersch P et al.
(
2022
)
.
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
.
Neurodegenerative Disease Management
vol.
13
,
(
1
)
5
-
13
.
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
(
2022
)
.
The biological rabbit hole: Only for the blind
.
Multiple Sclerosis and Related Disorders
vol.
67
,
Giovannoni G
(
2022
)
.
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model
.
Multiple Sclerosis and Related Disorders
vol.
68
,
Brittain G, Coles AJ, Giovannoni G, Muraro PA, Palace J, Petrie J, Roldan E, Scolding NJ et al.
(
2022
)
.
Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?
.
Practical Neurology
vol.
23
,
(
2
)
Yeh EA, Giovannoni G, Hawkes C, Levy M, Lechner-Scott J
(
2022
)
.
Linking X to MS: Immunity and demyelination on the X-chromosome in MS
.
Multiple Sclerosis and Related Disorders
vol.
66
,
Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K et al.
(
2022
)
.
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
.
Multiple Sclerosis Journal
vol.
28
,
(
14
)
2263
-
2273
.
Jacobs BM, Peter M, Giovannoni G, Noyce AJ, Morris HR, Dobson R
(
2022
)
.
Towards a global view of multiple sclerosis genetics
.
Nature Reviews Neurology
vol.
18
,
(
10
)
613
-
623
.
Giovannoni G, Vanderdonckt P, Hartung H-P, Lassmann H, Comi G
(
2022
)
.
EBV and multiple sclerosis: Setting the research agenda
.
Multiple Sclerosis and Related Disorders
vol.
67
,
Mrabet S, Wafa M, Giovannoni G
(
2022
)
.
Multiple sclerosis and migraine: Links, management and implications
.
Multiple Sclerosis and Related Disorders
vol.
68
,
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Jack D, Vermersch P
(
2022
)
.
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary
.
Neurodegenerative Disease Management
vol.
12
,
(
6
)
295
-
301
.
Stefano ND, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N et al.
(
2022
)
.
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary
.
Neurodegenerative Disease Management
vol.
12
,
(
6
)
303
-
310
.
Rees R, Philpot C, Gane S, McLelland L, Gill A, Giovannoni G, Simonet C-T, Lees A et al.
(
2022
)
.
096 Motor and non-motor features of prodromal Parkinson’s in idiopathic anosmia
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Rees R, Simonet C, Gill A, Giovannoni G, Lees A, Bestwick J, Noyce AJ, Schrag A
(
2022
)
.
097 Transcranial sonography in the prodromal phase of PD
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Rees R, Simonet C, Gill A, Giovannoni G, Bestwick J, Lees A, Noyce A, Schrag A
(
2022
)
.
101 Motor and non-motor features of prodromal PD
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Jacobs B, Giovannoni G, Noyce A, Morris H, Dobson R
(
2022
)
.
121 The ADAMS project: protocol and baseline results
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Foley J, Defer G, Ryerson LZ, Cohen J, Arnold D, Butzkueven H, Cutter G, Giovannoni G et al.
(
2022
)
.
136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Penner I-K, Giovannoni G, Chitnis T, Vermesch P, Arnould S, DeLasHeras V, Karlsson G, Piani-Meier D et al.
(
2022
)
.
141 Cognitive processing speed predicts disease progression in SPMS: post hoc analysis from the EXPAND study
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
D’Souza M, Giovannoni G, Vermersch P, Maca J, Ansari S, Karlsson G, Piani-Meier D, Kappos L
(
2022
)
.
143 Effect of siponimod on disability progression measured by ambulation score: post hoc analysis of EXPAND
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Giovannoni G, Ryan S, Jones E, Castro PD, Bezlyak V, Piani-Meier D, Heras VDL, Lines C
(
2022
)
.
146 MRI activity versus relapses as markers of SPMS disease activity: real world and pivotal trials
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Vermesch P, Gold R, Bar-Or A, Cree B, Fox R, Giovannoni G, Li B, Piani-Meier D et al.
(
2022
)
.
147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Schmierer K, Redha I, Hammond V, Baker D, Barkhof F, Hooper R, Rashid W, Singh-Curry V et al.
(
2022
)
.
152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Lechner-Scott JS, Davis JS, Hawkes C, Giovannoni G, Levy M, Yeh A
(
2022
)
.
Vaccine hesitancy in people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
65
,
Ziemssen T, Vandercappellen J, Mondragon VJ, Giovannoni G
(
2022
)
.
MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression
.
Journal of Clinical Medicine
vol.
11
,
(
15
)
Samjoo IA, Klotz L, Giovannoni G, Drudge C, Haltner A, Worthington E, Zhao M, Brennan R et al.
(
2022
)
.
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
66
,
K A-P, A S, T B, AC J, A M, S G, R D, G G et al.
(
2022
)
.
Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
65
,
Drosu N, Giovannoni G, Lechner-Scott J, Hawkes C, Yeh A, Levy M
(
2022
)
.
EBV as the “gluten of MS” hypothesis provides a rationale for trialing antiviral therapies
.
Multiple Sclerosis and Related Disorders
vol.
64
,
Hobart J, Butzkueven H, Haartsen J, Ziemssen T, Lane T, Giovannoni G
(
2022
)
.
Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool
.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
.
vol.
8
,
Maple PA, Ascherio A, Cohen JI, Cutter G, Giovannoni G, Shannon-Lowe C, Tanasescu R, Gran B
(
2022
)
.
The Potential for EBV Vaccines to Prevent Multiple Sclerosis
.
Frontiers in Neurology
vol.
13
,
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA
(
2022
)
.
Multiple sclerosis is one disease
.
Multiple Sclerosis and Related Disorders
vol.
63
,
Adams A, Tilden W, Bestwick J, Holden D, Bianchi L, Smets I, Giovannoni G, Gnanapavan S
(
2022
)
.
The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis
.
European Journal of Neurology
vol.
29
,
(
9
)
2754
-
2760
.
Beynon V, George IC, Elliott C, Arnold DL, Ke J, Chen H, Zhu L, Ke C et al.
(
2022
)
.
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
.
BMJ Neurology Open
vol.
4
,
(
1
)
Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R, Evangelou N et al.
(
2022
)
.
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
64
,
Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL et al.
(
2022
)
.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
.
Journal of Neurology
vol.
269
,
(
9
)
5093
-
5104
.
Vermersch P, Giovannoni G, Soelberg-Sorensen P, Rammohan K, Cook S, Keller B, Roy S
(
2022
)
.
015 Reduced risk of secondary progressive multiple sclerosis by treatment with clad- ribine tablets: CLARITY study analysis
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a18.2
-
a1a18
.
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Vermersch P, Dangond F-N, Keller B, Jack D
(
2022
)
.
016 Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a18.3
-
a1a18
.
Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, Moor CD et al.
(
2022
)
.
018 Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a19.1
-
a1a19
.
Giovannoni G, Kappos L, Seze JD, Hauser SL, Overell J, Koendgen H, Prajapati K, Manfrini M et al.
(
2022
)
.
020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a19.3
-
a1a20
.
Cook S, Giovannoni G, Leist T, Comi G, Syed S, Nolting A, Damian D, Schick R et al.
(
2022
)
.
022 Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a20.2
-
a2a20
.
Jacobs B, Noyce A, Bestwick J, Belete D, Giovannoni G, Dobson R
(
2022
)
.
026 Gene-environment interactions in multiple sclerosis: a UK Biobank study
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a21.3
-
a2a22
.
Gold R, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Rouyrre N, Karlsson G et al.
(
2022
)
.
043 Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a27.1
-
a2a27
.
Arnold DL, Fox RJ, Bar-Or A, Cree BA, Giovannoni G, Gold R, Vermersch P-R, Meier DP et al.
(
2022
)
.
045 Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a27.3
-
a2a27
.
Christmas T, Singh N, Reyes S, Allen-Philbey K, Giovannoni G
(
2022
)
.
048 Postprandial somnolence in people with multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a28.2
-
a2a28
.
Anderson V, Bentley E, Loveless S, Bianchi L, Harding KE, Thomas RW, Giovannoni G, Robertson NP et al.
(
2022
)
.
058 Serum neurofilament-light concentration and real-world outcome in MS
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a30.3
-
a3a31
.
Kuri A, Jacobs BM, Leddy S, Schmierer K, Turner B, Allen-Philbey K, Stennett A, Giovannoni G et al.
(
2022
)
.
091 Evaluation of remote assessments for multiple sclerosis in a real-world setting
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a129.1
-
a1a129
.
Penner K, Giovannoni G, Cree B, Fox R, Bar-ors A, Gold R, Vermesch P, Piani-Meier D et al.
(
2022
)
.
114 Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a136.3
-
a1a136
.
Arnold D, Bar-Or A, Cree B, Giovannoni G, Gold R, Vermersch P, Piani-Meier D, Arnould S et al.
(
2022
)
.
115 Impact of siponimod on myelination across SPMS subgroups: post-hoc analysis from EXPAND MRI substudy
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a137.1
-
a1a137
.
Giovannoni G, Kappos L, Fox R, Vermersch P, Cree B, Benedict R, Bar-Or A, Piani-Meier D et al.
(
2022
)
.
118 Sustained reduction of disability and cognitive decline with long-term siponimod in EXPAND active SPMS patients
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a138.1
-
a1a138
.
Giovannoni G, Hobart J, Mazibrada G, Bateman K, Marta M
(
2022
)
.
125 Towards an optimal multiple sclerosis patient case-load for a full-time MSologist
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a140.1
-
a1a140
.
Adegboyega G, Lobo R, Alsousa I, Salman R, Lobo S, Uppal E, Ali S, Schmierer K et al.
(
2022
)
.
170 Did the atraumatic lumbar puncture needle campaign have any effect?
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a62.1
-
a6a62
.
Sousa I, Salman R, Lobo R, Adegboyega G, Lobo S, Uppal E, Ali S, Schmierer K et al.
(
2022
)
.
178 Atraumatic lumbar puncture campaign – effect on complications
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a64.2
-
a6a64
.
Taylor T, Jacobs B, Giovannoni G, Dobson R
(
2022
)
.
211 The prevalence and characteristics of multiple sclerosis-associated uveitis in UK biobank
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a74.2
-
a7a74
.
Li H, Ismail A, Azevedo H, Castrejon-Pita R, Giovannoni G, Noyce A
(
2022
)
.
229 Developing novel smell test for Parkinson’s disease using microencapsulation of essential oils in alginate
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a79.3
-
a7a79
.
Belete D, Jacobs BM, Bestwick JP, Dobson R, Hardy J, Giovannoni G, Lees A, Schrag A et al.
(
2022
)
.
Parkinson’s disease determinants, prediction and gene-environment interac- tions: a UK Biobank study
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a7.3
-
a7a8
.
Allen-Philbey K, Trane SD, Yildiz O, Adams A, Turner B, Marta M, Mathews J, Altmann D et al.
(
2022
)
.
Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
6
)
a2.3
-
a2a2
.
Yamout BI, Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sørensen PS et al.
(
2022
)
.
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
.
Multiple Sclerosis and Related Disorders
vol.
59
,
Heesen C, Magyari M, Stellmann JP, Lederer C, Giovannoni G, Scalfari A, Daumer M
(
2022
)
.
The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR)––Critical review facing the 20 anniversary
.
Multiple Sclerosis and Related Disorders
vol.
63
,
Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R
(
2022
)
.
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
.
Clin Exp Immunol
vol.
207
,
(
3
)
263
-
271
.
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh A
(
2022
)
.
Onset of multiple sclerosis is preventable – time to act now!
.
Multiple Sclerosis and Related Disorders
vol.
62
,
Hone L, Jacobs BM, Marshall C, Giovannoni G, Noyce A, Dobson R
(
2022
)
.
Age-specific effects of childhood body mass index on multiple sclerosis risk
.
Journal of Neurology
vol.
269
,
(
9
)
5052
-
5060
.
Penner I-K, Giovannoni G, Chitnis T, Vermersch P, Arnould S, Maca J, DeLasHeras V, Karlsson G et al.
(
2022
)
.
Cognitive Processing Speed Predicts Disease Progression in Secondary Progressive Multiple Sclerosis: Post Hoc Analysis from the EXPAND Study (P5-4.006)
.
Neurology
vol.
98
,
(
18_supplement
)
D’Souza M, Giovannoni G, Vermersch P, Maca J, Ansari S, Karlsson G, Piani-Meier D, Kappos L
(
2022
)
.
Effect of Siponimod on Disability Progression as Measured by the Ambulation Score, a Subscore of the Neurostatus-EDSS: Post hoc Analysis of the EXPAND Trial in SPMS (P6-4.001)
.
Neurology
vol.
98
,
(
18_supplement
)
Cree B, Rouyrre N, Fox R, Vermersch P, Giovannoni G, Bar-Or A, Gold R, Maca J et al.
(
2022
)
.
Estimating long-term effect of siponimod on disability progression versus virtual placebo in SPMS using RPSFT model: EXPAND data up to 7 years (P6-4.004)
.
Neurology
vol.
98
,
(
18_supplement
)
Gaviria M, Ferreira C, Reyes S, Duque A, Giovannoni G
(
2022
)
.
Factors associated with Influenza vaccination rates among people with Multiple Sclerosis (S40.010)
.
Neurology
vol.
98
,
(
18_supplement
)
Giovannoni G, Houchen E, Sobisek L, Karu H, Ryan S, Jones E, Castro PD, Bezlyak V et al.
(
2022
)
.
MRI Activity versus Relapses as Markers of Disease Activity in SPMS: Data from Adelphi Real-World MS Disease Specific Programme and The Phase 3 EXPAND Study (S14.010)
.
Neurology
vol.
98
,
(
18_supplement
)
Foley J, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G et al.
(
2022
)
.
Primary Results of NOVA: a Randomized Controlled Study of the Efficacy of 6 - Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (S14.005)
.
Neurology
vol.
98
,
(
18_supplement
)
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G et al.
(
2022
)
.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
.
The Lancet Neurology
vol.
21
,
(
7
)
608
-
619
.
Yeh EA, Giovannoni G, Hawkes C, Lechner-Scott J, Levy M
(
2022
)
.
High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes
.
Multiple Sclerosis and Related Disorders
vol.
61
,
Simonet C, Bestwick J, Jitlal M, Waters S, Ben-Joseph A, Marshall CR, Dobson R, Marrium S et al.
(
2022
)
.
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population
.
JAMA Neurology
vol.
79
,
(
4
)
359
-
369
.
Giovannoni G
(
2022
)
.
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
.
Multiple Sclerosis and Related Disorders
vol.
63
,
Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D et al.
(
2022
)
.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
.
Multiple Sclerosis Journal
vol.
28
,
(
10
)
1591
-
1605
.
Lechner-Scott J, Yeh A, Levy M, Hawkes C, Giovannoni G
(
2022
)
.
Do we need more clinical trials in secondary progressive MS?
.
Multiple Sclerosis and Related Disorders
vol.
60
,
(
Mult Scler Relat Disord. 2017
)
Sandroff BM, Motl RW, Yong VW, Cutter GR, Giovannoni G
(
2022
)
.
Exercise training in multiple sclerosis
.
The Lancet Neurology
vol.
21
,
(
4
)
Foley J, Defer G, Ryerson LZ, Cohen JA, Arnold D, Butzkueven H, Cutter G, Giovannoni G et al.
(
2022
)
.
Résultats primaires de NOVA : une étude contrôlée randomisée comparant l’administration de natalizumab toutes les 6 semaines versus une administration continue toutes les 4 semaines dans le traitement de la sclérose en plaques
.
Revue Neurologique
vol.
178
,
s119
-
s120
.
Giovannoni G, Mathews J
(
2022
)
.
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
.
Neurology and Therapy
vol.
11
,
(
2
)
571
-
595
.
Zaratin P, Vermersch P, Amato MP, Brichetto G, Coetzee T, Cutter G, Edan G, Giovannoni G et al.
(
2022
)
.
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions
.
Multiple Sclerosis and Related Disorders
vol.
61
,
Levy M, Yeh EA, Hawkes CH, Lechner-Scott J, Giovannoni G
(
2022
)
.
Implications of Low-Titer MOG Antibodies
.
Multiple Sclerosis and Related Disorders
vol.
59
,
Signori A, Ponzano M, Alexandri N, Giovannoni G, Sormani MP
(
2022
)
.
Prevalence of disability improvement in relapsing–remitting multiple sclerosis patients treated with cladribine tablets
.
European Journal of Neurology
vol.
29
,
(
7
)
2144
-
2147
.
Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P et al.
(
2022
)
.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
.
Multiple Sclerosis Journal
vol.
28
,
(
10
)
1526
-
1540
.
Giovannoni G, Leist T, Aydemir A, Di Cantogno EV
(
2022
)
.
Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study
.
Multiple Sclerosis and Related Disorders
vol.
59
,
Foley J, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G et al.
(
2022
)
.
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
59
,
Bothongo PLK, Jitlal M, Parry E, Waters S, Foote IF, Watson CJ, Cuzick J, Giovannoni G et al.
(
2022
)
.
Dementia risk in a diverse population: A single-region nested case-control study in the East End of London
.
The Lancet Regional Health - Europe
vol.
15
,
Hone L, Giovannoni G, Dobson R, Jacobs BM
(
2022
)
.
Predicting Multiple Sclerosis: Challenges and Opportunities
.
Frontiers in Neurology
vol.
12
,
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Gold J
(
2022
)
.
Is EBV the cause of multiple sclerosis?
.
Multiple Sclerosis and Related Disorders
vol.
58
,
Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobaeus E, Jensen MB, García-Domínguez JM, Sousa L et al.
(
2022
)
.
Smouldering multiple sclerosis: the ‘real MS’
.
Therapeutic Advances in Neurological Disorders
vol.
15
,
Ploughman M, Yong VW, Spermon B, Goelz S, Giovannoni G
(
2022
)
.
Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair
.
Multiple Sclerosis and Related Disorders
vol.
58
,
Hawkes CH, Giovannoni G, Levy M, Lechner-Scott J, Yeh A
(
2022
)
.
Diagnosis of multiple sclerosis: Progress or confusion?
.
Multiple Sclerosis and Related Disorders
vol.
57
,
Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA et al.
(
2022
)
.
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary
.
Neurodegenerative Disease Management
vol.
12
,
(
1
)
1
-
7
.
Allen-Philbey K, Andrews M, Redha I, Papachatzaki M, Marta M, Gnanapavan S, Mathews J, Turner B et al.
(
2022
)
.
CLADRIPLAS: Does cladribine Target CNS plasma cells and reduce neuro-axonal damage in people with MS?
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
769
-
770
.
Vickaryous N, Rios F, Schalk L, Asardag AN, George K, Kang A, Baker D, Giovannoni G et al.
(
2022
)
.
COVID-19 humoral and T-cell mediated vaccination responses in people with multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
680
-
680
.
Penner I, Giovannoni G, Chitnis T, Vermersch P, Arnould S, Doerken S, Ansari S, Maca J et al.
(
2022
)
.
Does Cognitive Impairment Predict Physical Disability Progression? Evidence from EXPAND, a Phase 3 Long-Term SPMS Study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
29
,
142
-
142
.
Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, Cree B, Ansari S et al.
(
2022
)
.
Dynamics of progression to wheelchair in SPMS and impact of siponimod: Subgroup analyses from the EXPAND study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
29
,
207
-
208
.
Mah H, Dobson R, Giovannoni G, Thomson A, Pepper G, Sloan R, Thompson E, DiMauro S
(
2022
)
.
Experiences of post-traumatic stress disorder in people living with multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
482
-
482
.
Arnold DL, Foley J, Defer G, Zhovtis-Ryerson L, Cohen JA, Butzkueven H, Cutter G, Giovannoni G et al.
(
2022
)
.
Exploratory magnetic resonance imaging endpoints from NOVA: a randomized controlled study of the efficacy of 6-week dosing of natalizumab vs continued 4-week treatment for multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
370
-
371
.
Gaviria M, Ferreira C, Reyes S, Duque A, Giovannoni G
(
2022
)
.
Factors associated with Influenza vaccination rates among people with Multiple Sclerosis
.
NEUROLOGY
.
vol.
98
,
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al.
(
2022
)
.
Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
33
-
34
.
Giovannoni G
(
2022
)
.
Flipping the pyramid and beyond
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
5
-
5
.
Upcott M, Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R et al.
(
2022
)
.
Humoral and T- cell response to multiple COVID-19 booster vaccinations in people with MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
365
-
366
.
Giovannoni G
(
2022
)
.
MS-Selfie: a subscription-based online portal to assist people in the self-management of multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
215
-
215
.
Hobart J, O'Brien L, Andrich D, Giovannoni G
(
2022
)
.
Multiple sclerosis science: a unique opportunity to advance scientific developments and patient care
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
170
-
170
.
Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D
(
2022
)
.
Post-Approval Safety of Cladribine Tablets with Particular Reference to COVID-19 Outcomes: An Update
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
68
-
69
.
Leist T, Giovannoni G, Aydemir A, Di Cantogno EV
(
2022
)
.
Primary Results from 8-11 Years of Follow-up in the CLASSIC-MS Study Show Long-term Efficacy for Patients Who Received Cladribine Tablets in ORACLE MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
69
-
69
.
Leist T, Giovannoni G, Aydemir A, Di Cantogno EV
(
2022
)
.
Primary Results from 8-11 Years' Follow-up in CLASSIC-MS Show Long-term Efficacy With Cladribine Tablets in ORACLE MS
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
29
,
460
-
460
.
Derfuss T, Bermel R, Lin C, Hauser S, Kappos L, Vollmer T, Comi G, Giovannoni G et al.
(
2022
)
.
Risk factors for serious infections in patients with MS receiving long-term ocrelizumab treatment: Multivariate analyses
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
29
,
637
-
638
.
Mrabet S, Conesa-Garcia E, Giovannoni G
(
2022
)
.
Stratification of Long-term prognosis in patients with multiple sclerosis: a systematic review
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
172
-
172
.
Thomson A, Stennett A, Bestwick J, Giovannoni G, Dobson R
(
2022
)
.
Under and Over: Findings from a remote upper limb rehabilitation study in people with MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
408
-
409
.
Thomas S, Giovannoni G
(
2022
)
.
Update on NHS Reset and Reform achievements in 2021
.
British Journal of Neuroscience Nursing
vol.
18
,
(
Sup1
)
s20
-
s24
.
Giovannoni G, Leist T, Jack D, Galazka A, Nolting A
(
2022
)
.
Updated post-approval safety of cladribine tablets in the treatment of multiple sclerosis, with particular reference to liver safety
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
364
-
364
.
LE van Kempen Z, Toorop AA, Sellebjerg F, Giovannoni G, Killestein J
(
2021
)
.
Extended dosing of monoclonal antibodies in multiple sclerosis
.
Multiple Sclerosis Journal
vol.
28
,
(
13
)
2001
-
2009
.
Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C et al.
(
2021
)
.
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
.
Frontiers in Immunology
vol.
12
,
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G et al.
(
2021
)
.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
.
Multiple Sclerosis Journal
vol.
28
,
(
5
)
842
-
846
.
Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sørensen PS, Vermersch P et al.
(
2021
)
.
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
.
Therapeutic Advances in Neurological Disorders
vol.
14
,
Baker D
(
2021
)
.
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
Bestwick JP, Auger SD, Simonet C, Rees RN, Rack D, Jitlal M, Giovannoni G, Lees AJ et al.
(
2021
)
.
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm
.
npj Parkinson's Disease
vol.
7
,
(
1
)
Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al.
(
2021
)
.
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
.
Therapeutic Advances in Neurological Disorders
vol.
14
,
Yeh EA, Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M
(
2021
)
.
It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology
.
Multiple Sclerosis and Related Disorders
vol.
56
,
Smets I, Giovannoni G
(
2021
)
.
Derisking CD20-therapies for long-term use
.
Multiple Sclerosis and Related Disorders
vol.
57
,
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al.
(
2021
)
.
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study
.
Multiple Sclerosis and Related Disorders
vol.
57
,
Puentes F, Benkert P, Amor S, Kuhle J, Giovannoni G
(
2021
)
.
Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
.
BMJ Neurology Open
vol.
3
,
(
2
)
Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, de Moor C et al.
(
2021
)
.
Measuring treatment response to advance precision medicine for multiple sclerosis
.
Annals of Clinical and Translational Neurology
vol.
8
,
(
11
)
2166
-
2173
.
Dobson R, Baker D, Kang A, Schmierer K, Giovannoni G
(
2021
)
.
COVID-19 vaccine response in people with multiple sclerosis
.
Annals of Neurology
Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P
(
2021
)
.
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
.
Multiple Sclerosis Journal
vol.
28
,
(
8
)
1219
-
1228
.
Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño RR et al.
(
2021
)
.
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey
.
Journal of Medical Internet Research
vol.
23
,
(
10
)
Marta M, Baker D, Creeke P, Pryce G, Gnanapavan S, Giovannoni G
(
2021
)
.
Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report
.
Multiple Sclerosis and Related Disorders
vol.
56
,
Bestwick J, Auger S, Schrag A, Grosset DG, Kanavou S, Giovannoni G, Lees AJ, Cuzick J et al.
(
2021
)
.
Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features
.
npj Parkinson's Disease
Hone L, Jacobs BM, Marshall C, Giovannoni G, Noyce A, Dobson R
(
2021
)
.
Age-specific effects of childhood Body Mass Index on multiple sclerosis risk
.
Lechner-Scott J, Levy M, Hawkes C, Yeh A, Giovannoni G
(
2021
)
.
Long COVID or post COVID-19 syndrome
.
Multiple Sclerosis and Related Disorders
vol.
55
,
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh EA
(
2021
)
.
How not to get your article published
.
Multiple Sclerosis and Related Disorders
vol.
54
,
Smets I, Aboulwafa M, Mah H, Giovannoni G
(
2021
)
.
Missed MS or MIMS not prodromal MS: Expanding the diagnostic MS spectrum
.
Multiple Sclerosis and Related Disorders
vol.
55
,
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P
(
2021
)
.
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
.
Advances in Therapy
vol.
38
,
(
9
)
4975
-
4985
.
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Baker D
(
2021
)
.
COVID-19 vaccines and multiple sclerosis disease-modifying therapies
.
Multiple Sclerosis and Related Disorders
vol.
53
,
Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA et al.
(
2021
)
.
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
.
Multiple Sclerosis Journal - Experimental Translational and Clinical
vol.
7
,
(
3
)
Kuri A, Jacobs BM, Leddy S, Schmierer K, Turner B, Allen-Philbey K, Stennett A, Giovannoni G et al.
(
2021
)
.
Evaluation of remote assessments for multiple sclerosis in an in-home setting
.
Multiple Sclerosis and Related Disorders
vol.
54
,
Grisold W, Moro E, Ferretti MT, Aamodt AH, Arabia G, Lebedeva ER, Carvalho V, Rakusa M et al.
(
2021
)
.
Gender issues during the times of COVID‐19 pandemic
.
European Journal of Neurology
vol.
28
,
(
10
)
e73
-
e77
.
Drosu N, Giovannoni G, Pohl D, Hawkes C, Lechner-Scott J, Levy M
(
2021
)
.
Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective
.
Multiple Sclerosis and Related Disorders
vol.
52
,
Reyes S, Cunningham AL, Kalincik T, Havrdová EK, Isobe N, Pakpoor J, Airas L, Bunyan RF et al.
(
2021
)
.
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
.
Journal of Neuroimmunology
vol.
357
,
Baker D, Hadjicharalambous C, Gnanapavan S, Giovannoni G
(
2021
)
.
Can rheumatologists stop causing demyelinating disease?
.
Multiple Sclerosis and Related Disorders
vol.
53
,
Jacobs BM, Noyce AJ, Bestwick J, Belete D, Giovannoni G, Dobson R
(
2021
)
.
Gene-Environment Interactions in Multiple Sclerosis: A UK Biobank Study
.
Neurology Neuroimmunology & Neuroinflammation
vol.
8
,
(
4
)
Petzold A, Albrecht P, Balcer L, Bekkers E, Brandt AU, Calabresi PA, Deborah OG, Graves JS et al.
(
2021
)
.
Artificial intelligence extension of the OSCAR‐IB criteria
.
Annals of Clinical and Translational Neurology
vol.
8
,
(
7
)
1528
-
1542
.
Hawkes CH, Baker MD, Pohl D, Lechner-Scott J, Levy M, Giovannoni G
(
2021
)
.
Melatonin and multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
51
,
Dobson R, ALLEN-PHILBEY K, Giovannoni G, Baker D, Schmierer K
(
2021
)
.
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B et al.
(
2021
)
.
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
.
Multiple Sclerosis Journal
vol.
28
,
(
1
)
111
-
120
.
Butzkueven H, Spelman T, Horakova D, Hughes S, Solaro C, Izquierdo G, Havrdová EK, Grand'Maison F et al.
(
2021
)
.
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
.
European Journal of Neurology
vol.
29
,
(
4
)
1082
-
1090
.
Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q et al.
(
2021
)
.
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
.
European Journal of Neurology
vol.
29
,
(
4
)
1238
-
1242
.
Schmierer K, Giovannoni G
(
2021
)
.
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
.
Multiple Sclerosis Journal
vol.
27
,
(
7
)
1006
-
1007
.
Kappos L, Cree BAC, Bar-Or A, Gold R, Vermersch P, Fox RJ, Benedict R, Arnould S et al.
(
2021
)
.
A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non-active Secondary Progressive Multiple Sclerosis (4458)
.
Neurology
vol.
96
,
(
15_supplement
)
Giovannoni G, Aydemir A, Di Cantogno EV, Leist T
(
2021
)
.
CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis who Received Cladribine Tablets in Phase III Parent Trials (1919)
.
Neurology
vol.
96
,
(
15_supplement
)
Giovannoni G, Boster AL, Berkovich R, Selmaj KW, Chung L, Shiota D, Afsar S
(
2021
)
.
Cases of COVID-19 in Alemtuzumab-Treated Patients With MS: Pharmacovigilance Report (2059)
.
Neurology
vol.
96
,
(
15_supplement
)
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up (2528)
.
Neurology
vol.
96
,
(
15_supplement
)
Ziemssen T, Alvarez E, Bhan V, Burton J, Hoffmann O, Oreja-Guevara C, Robles-Cedeño R, Trojano M et al.
(
2021
)
.
Development and Usability Testing of a Patient-based Digital Tool to Understand Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire (2118)
.
Neurology
vol.
96
,
(
15_supplement
)
Fox RJ, Kappos L, Cree BAC, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Dahlke F et al.
(
2021
)
.
Gray Matter Volume and Myelination Assessed by Magnetization Transfer Ratio Predict Disease Progression in Secondary Progressive Multiple Sclerosis: Exploratory Analyses from the EXPAND Study (2054)
.
Neurology
vol.
96
,
(
15_supplement
)
Arnold DL, Kappos L, Vermersch P, Gold R, Bar-Or A, Giovannoni G, Cree BAC, Meier DP et al.
(
2021
)
.
Long-term Effect of Siponimod on MRI Outcomes in SPMS: Analyses from the EXPAND Study up to 5 Years (2217)
.
Neurology
vol.
96
,
(
15_supplement
)
Oh J, Cohen S, Isenberg D, Maurer M, Galanter J, Chu T, Teterina A, Goodyear A et al.
(
2021
)
.
The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS) (4564)
.
Neurology
vol.
96
,
(
15_supplement
)
Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D
(
2021
)
.
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections and COVID-19 (1927)
.
Neurology
vol.
96
,
(
15_supplement
)
Bestwick JP, Auger SD, Simonet C, Rees RN, Rack D, Jitlal M, Giovannoni G, Lees AJ et al.
(
2021
)
.
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm
.
npj Parkinson's Disease
vol.
7
,
(
1
)
Giovannoni G, Kappos L, De Sèze J, Hauser SL, Köndgen H, Schneble H-M, Wolinsky JS
(
2021
)
.
Réduction à long terme du taux de poussées et de progression du handicap confirmée à 48 semaines (CDP48) après 6,5 ans de traitement par ocrelizumab (OCR) chez des patients atteints de sclérose en plaques récurrente (SEP-R)
.
Revue Neurologique
vol.
177
,
s104
-
s105
.
Gold R, Giovannoni G, Phillips T, Bar-Or A, Fox RJ, Mokliatchouk O, Parks B, Lyons J et al.
(
2021
)
.
Sécurité et efficacité chez les patients traités par le diméthyl fumarate et suivis pendant 13 ans : résultats finaux d’ENDORSE
.
Revue Neurologique
vol.
177
,
Groen K, Lechner-Scott J, Pohl D, Levy M, Giovannoni G, Hawkes C
(
2021
)
.
Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
50
,
Simmons SB, Schippling S, Giovannoni G, Ontaneda D
(
2021
)
.
Predicting disability worsening in relapsing and progressive multiple sclerosis
.
Current Opinion in Neurology
vol.
34
,
(
3
)
312
-
321
.
Vishnevetsky A, Hawkes C, Lechner-Scott J, Giovannoni G, Levy M, Pohl D
(
2021
)
.
B cell therapy and the use of RNA-based COVID-19 vaccines
.
Multiple Sclerosis and Related Disorders
vol.
49
,
Smets I, Marino S, Giovannoni G
(
2021
)
.
Amyloidoma mimicking multiple sclerosis
.
Practical Neurology
vol.
21
,
(
4
)
344
-
345
.
Smets I, Reyes S, Baker D, Giovannoni G
(
2021
)
.
Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment
.
Multiple Sclerosis and Related Disorders
vol.
50
,
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung H-P, Maniar T, Croze E, Aftab BT et al.
(
2021
)
.
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies (Trends in Molecular Medicine, 26:3 p:296-310, 2020)
.
Trends in Molecular Medicine
vol.
27
,
(
4
)
410
-
411
.
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Pohl D
(
2021
)
.
Air pollution and multiple sclerosis risk
.
Multiple Sclerosis and Related Disorders
vol.
48
,
Kappos L, Cree B, Bar-Or A, Gold R, Vermersch P, Fox R, Benedict R, Arnould S et al.
(
2021
)
.
A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non-active SPMS
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
28
,
174
-
175
.
Kappos L, Cree BAC, Bar-Or A, Gold R, Vermersch P, Fox RJ, Benedict R, Arnould S et al.
(
2021
)
.
A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non-active Secondary Progressive Multiple Sclerosis
.
NEUROLOGY
.
vol.
96
,
Ziemssen T, Alvarez E, Bhan V, Burton J, Hoffmann O, Oreja-Guevara C, Robles-Cedeno R, Trojano M et al.
(
2021
)
.
A Patient-based Digital Tool to Detect Early Signs of Changes in MS Symptoms and Progression: Your MS Questionnaire
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
28
,
730
-
730
.
Stennett A, Allen-Philbey K, Begum T, Johnson A, Dobson R, Giovannoni G, Gnanapavan S, Marta M et al.
(
2021
)
.
An evaluation of remote monitoring in people with MS during the COVID-19 pandemic
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
268
-
269
.
Coyle PK, Giovannoni G, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C et al.
(
2021
)
.
Analysis of Infection in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets who had Grade ≥3 Lymphopenia
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
48
-
48
.
Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C et al.
(
2021
)
.
Analysis of Lymphocyte Subsets in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
44
-
44
.
Vermersch P, Coyle P, Reich D, Giovannoni G, Oreja-Guevara C, Arnold D, Syed S, Matta A et al.
(
2021
)
.
BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
28
,
727
-
727
.
Giovannoni G, Aydemir A, Di Cantogno EV, Leist T
(
2021
)
.
CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis who Received Cladribine Tablets in Phase III Parent Trials
.
NEUROLOGY
.
vol.
96
,
Giovannoni G, Boster AL, Berkovich R, Selmaj KW, Chung L, Shiota D, Afsar S
(
2021
)
.
Cases of COVID-19 in Alemtuzumab-Treated Patients With MS: Pharmacovigilance Report (2059)
.
NEUROLOGY
.
vol.
96
,
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
90
-
91
.
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up
.
NEUROLOGY
.
vol.
96
,
Ziemssen T, Alvarez E, Bhan V, Burton J, Hoffmann O, Oreja-Guevara C, Robles-Cedeno R, Trojano M et al.
(
2021
)
.
Development and Usability Testing of a Patient-based Digital Tool to Understand Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire
.
NEUROLOGY
.
vol.
96
,
Giovannoni G, Alvarez E, Hoffmann O, Oreja-Guevara C, Vermersch P, Khwaja M, Stadler B, Vandercappellen J et al.
(
2021
)
.
Development of Your MS Questionnaire: a patient completed-digital tool to monitor multiple sclerosis disease symptoms and their impact on people's life
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
211
-
212
.
Giovannoni G
(
2021
)
.
Disease-modifying treatment - if and when to stop in progressive MS?
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
43
-
43
.
Giovannoni G, Pozzilli C, LaGanke C, Fox E, Freedman MS, Eichau Madueno S, Ziemssen T, Shiota D et al.
(
2021
)
.
Early treatment with alemtuzumab maintains its efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 10 years in RRMS patients: CARE-MS II follow-up (TOPAZ Study)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
605
-
606
.
Hobart J, Piani-Meier D, Cree B, Giovannoni G, Kappos L, Fox RJ, Bar-Or A, Maca J et al.
(
2021
)
.
Effect of Siponimod on the MSWS-12 and MSIS-29 in Patients With SPMS From the EXPAND Study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
28
,
359
-
359
.
Calabresi PA, Giovannoni G, Hartung H-P, Naismith RT, Fox R, Sormani M-P, Arnold DL, Valis M et al.
(
2021
)
.
Efficacy and safety of opicinumab in participants with relapsing multiple sclerosis: a randomized, placebo-controlled, Phase 2 trial (AFFINITY Part 1)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
90
-
91
.
Simonet C, Gill A, Bestwick J, Lees A, Giovannoni G, Schrag A, Noyce A
(
2021
)
.
Emerging parkinsonism in the PREDICT-PD cohort after 6-years of follow-up
.
MOVEMENT DISORDERS
.
vol.
36
,
S78
-
S79
.
Cree BA, Rouyrre N, Fox RJ, Vermersch P, Giovannoni G, Bar-Or A, Gold R, Maca J et al.
(
2021
)
.
Estimating long-term effect of siponimod on disability progression versus virtual placebo in SPMS using RPSFT model: EXPAND data up to 7 years
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
624
-
625
.
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al.
(
2021
)
.
Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
514
-
515
.
Fox RJ, Kappos L, Cree BAC, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Dahlke F et al.
(
2021
)
.
Gray Matter Volume and Myelination Assessed by Magnetization Transfer Ratio Predict Disease Progression in Secondary Progressive Multiple Sclerosis: Exploratory Analyses from the EXPAND Study
.
NEUROLOGY
.
vol.
96
,
Lee J-M, Nicholas J, Hersh C, Jones E, Pike J, Dominguez-Castro P, Bezlyak V, Lines C et al.
(
2021
)
.
High prevalence of intolerability with interferon beta and glatiramer acetate in patients with MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
697
-
697
.
Arnold DL, Kappos L, Vermersch P, Gold R, Bar-Or A, Giovannoni G, Cree BAC, Meier DP et al.
(
2021
)
.
Long-term Effect of Siponimod on MRI Outcomes in SPMS: Analyses from the EXPAND Study up to 5 Years
.
NEUROLOGY
.
vol.
96
,
Giovannoni G, Leist T, Aydemir A, Di Cantogno EV
(
2021
)
.
Long-term efficacy for patients receiving cladribine tablets in CLARITY/CLARITY extension: Primary results from 9-15 years of follow-up in the CLASSIC-MS study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
792
-
793
.
Giovannoni G, Kappos L, de Seze J, Hauser SL, Bonati U, Overell J, Hahn M, Prajapati K et al.
(
2021
)
.
Long-term reduction of relapse rate and confirmed disability progression after 7.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis in the OPERA OLE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
606
-
607
.
Giovannoni G, Houchen E, Sobisek L, Karu H, Ryan S, Jones E, Castro PD, Bezlyak V et al.
(
2021
)
.
MRI activity versus relapses as markers of disease activity in SPMS: Data from real world and pivotal clinical studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
134
-
134
.
Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D
(
2021
)
.
Post-approval safety of cladribine tablets with particular reference to COVID-19 outcomes: an update
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
638
-
639
.
Foley J, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G et al.
(
2021
)
.
Primary results of NOVA: a randomized controlled study of the efficacy of 6-week dosing of natalizumab versus continued 4-week treatment for multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
789
-
790
.
Vickaryous N, Asardag AN, Chance R, Jones M, Bestwick J, Shah SN, George K, Schmierer K et al.
(
2021
)
.
Seroconversion following vaccination against SARS-CoV-2 in people with MS: impact of disease modifying therapy
.
MULTIPLE SCLEROSIS JOURNAL
vol.
27
,
(
2_SUPPL
)
775
-
776
.
Vermersch P, Gold R, Bar-Or A, Cree BA, Fox RJ, Giovannoni G, Li B, Maca J et al.
(
2021
)
.
Siponimod preserves retinal thickness, a marker of neurodegeneration, in patients with SPMS: Findings from the EXPAND OCT substudy
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
488
-
489
.
Oh J, Cohen S, Isenberg D, Maurer M, Galanter J, Chu T, Teterina A, Goodyear A et al.
(
2021
)
.
The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)
.
NEUROLOGY
.
vol.
96
,
Hobart J, Butzkueven H, Haartsen J, Ziemssen T, Lane T, Giovannoni G
(
2021
)
.
Timely Intervention, Monitoring and Education MATTERS in MS (TIME MATTERS in MS): global applicability of the MS Brain Health quality improvement tool
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
270
-
270
.
Smets I, Holden D, Bianchi L, Ammoscato F, Turner B, Marta M, Schmierer K, Giovannoni G et al.
(
2021
)
.
Treatment-Induced Reductions in Cerebrospinal Fluid Neurofilament Light Levels are Age-Dependent in Multiple Sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
27
-
28
.
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2021
)
.
Up to 6 years follow-up of people with MS (n=250) receiving cladribine
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
546
-
547
.
Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D
(
2021
)
.
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections and COVID-19
.
NEUROLOGY
.
vol.
96
,
Vickaryous N, Jitlal M, Jacobs BM, Middleton R, Chandran S, MacDougall NJJ, Giovannoni G, Dobson R
(
2020
)
.
Remote testing of vitamin D levels across the UK MS population—A case control study
.
PLOS ONE
vol.
15
,
(
12
)
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Pohl D
(
2020
)
.
Is multiple sclerosis overdiagnosed?
.
Multiple Sclerosis and Related Disorders
vol.
47
,
Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P et al.
(
2020
)
.
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses
.
Neurology
vol.
96
,
(
3
)
e376
-
e386
.
Jacobs BM, Smets I, Giovannoni G, Noyce A, Jokubaitis V, Dobson R
(
2020
)
.
Regarding: Nicotinic acetylcholine receptors α7 and α9 modify tobacco smoke risk for multiple sclerosis
.
Multiple Sclerosis Journal
vol.
27
,
(
8
)
1311
-
1312
.
Chun J, Giovannoni G, Hunter SF
(
2020
)
.
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
.
Drugs
vol.
81
,
(
2
)
207
-
231
.
Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R et al.
(
2020
)
.
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
.
Multiple Sclerosis Journal
vol.
27
,
(
10
)
1564
-
1576
.
Thomson A, Dobson R, Baker D, Giovannoni G
(
2020
)
.
Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families
.
Multiple Sclerosis and Related Disorders
vol.
47
,
Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, Camilleri P, Craner M et al.
(
2020
)
.
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis
.
Journal of Neurology, Neurosurgery and Psychiatry
Raftopoulos R, Kuhle J, Grant D, Hickman SJ, Altmann DR, Leppert D, Blennow K, Zetterberg H et al.
(
2021
)
.
Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis
.
European Journal of Neurology
.
vol.
28
,
587
-
594
.
Lechner-Scott J, Hawkes CH, Giovannoni G, Levy M, Maltby V
(
2020
)
.
Why should Neurologists get involved in family planning?
.
Multiple Sclerosis and Related Disorders
vol.
46
,
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung H-P, Arnold D et al.
(
2020
)
.
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
.
The Lancet Neurology
vol.
19
,
(
12
)
988
-
997
.
Mateo-Casas M, Reyes S, De Trane S, Edwards F, Espasandin M, Anjorin G, Baker D, Schmierer K et al.
(
2020
)
.
Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
.
eNeurologicalSci
vol.
21
,
Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S et al.
(
2020
)
.
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
46
,
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M
(
2020
)
.
Is the incidence of multiple sclerosis really increasing?
.
Multiple Sclerosis and Related Disorders
vol.
45
,
Giovannoni G, Lang S, Wolff R, Duffy S, Hyde R, Kinter E, Wakeford C, Sormani MP et al.
(
2020
)
.
A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis
.
Neurology and Therapy
vol.
9
,
(
2
)
359
-
374
.
Pia Sormani M, Wolff R, Lang S, Duffy S, Hyde R, Kinter E, Wakeford C, Giovannoni G et al.
(
2020
)
.
Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis
.
Neurology and Therapy
vol.
9
,
(
2
)
335
-
358
.
Aarum J, Cabrera CP, Jones TA, Rajendran S, Adiutori R, Giovannoni G, Barnes MR, Malaspina A et al.
(
2020
)
.
Enzymatic degradation of RNA causes widespread
protein aggregation in cell and tissue lysates
.
EMBO Reports
vol.
21
,
(
10
)
Article
ARTN e49585
,
Aarum J, Cabrera CP, Jones TA, Rajendran S, Adiutori R, Giovannoni G, Barnes MR, Malaspina A et al.
(
2020
)
.
Enzymatic degradation of RNA causes widespread protein aggregation in cell and tissue lysates
.
EMBO Reports
vol.
21
,
(
10
)
Jacobs B, Belete D, Bestwick J, Blauwendraat C, Bandres-Ciga S, Heilbron K, Dobson R, International Parkinson’s Disease Genomics Consortium (IPDGC) et al.
(
2020
)
.
Parkinson’s disease determinants, prediction and gene-environment interactions in the UK Biobank
.
Journal of Neurology, Neurosurgery and Psychiatry
vol.
91
,
1046
-
1054
.
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H et al.
(
2020
)
.
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
.
JAMA Neurology
vol.
77
,
(
9
)
1132
-
1140
.
Vermersch P, Giovannoni G, Soelberg-Sorensen P, Rammohan K, Cook S, Keller B, Roy S
(
2020
)
.
Réduction du risque de progression en sclérose en plaques secondairement progressive au cours des deux années de traitement par cladribine voie orale : analyse de l’étude CLARITY
.
Revue Neurologique
vol.
176
,
s78
-
s79
.
De Sèze J, Giovannoni G, Kappos L, Hauser SL, Köndgen H, Prajapati K, Wolinsky JS
(
2020
)
.
Réduction à long-terme du taux de poussées et de progression du handicap après 6 ans de traitement par ocrelizumab (OCR) chez des patients atteints de sclérose en plaques récurrente (SEP-R)
.
Revue Neurologique
vol.
176
,
s83
-
s84
.
Gold R, Giovannoni G, Phillips T, Bar-Or A, Fox RJ, Chen C, Miller C, Branco F
(
2020
)
.
Sécurité d’emploi et efficacité globales après 10 ans de traitement par diméthyl fumarate à libération prolongée chez des patients atteints de sclérose en plaques rémittente-récurrente
.
Revue Neurologique
vol.
176
,
s126
-
s127
.
Smets I, Reyes S, Giovannoni G
(
2020
)
.
Distinguishing physiological versus pathological serum NfL levels in multiple sclerosis will require serial measurements
.
Multiple Sclerosis and Related Disorders
vol.
46
,
Dobson R, Giovannoni G, Cuzick J
(
2020
)
.
Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment
.
International Journal of Epidemiology
Levy M, Lechner-Scott J, Hawkes C, Giovannoni G
(
2020
)
.
“Rocking the boat” with a new drug for neuromyelitis optica spectrum disorder
.
Multiple Sclerosis and Related Disorders
vol.
44
,
Schmierer K, Gnanapavan S, Giovannoni G, Ammoscato F, Holden D, Carrillo-Loza K, Christmas T, Bianchi L et al.
(
2020
)
.
CSF neurofilament light chain testing as an aid
to determine treatment strategies in MS
.
Neurology, Neuroimmunology and Neuroinflammation
vol.
7
,
(
6
)
Reyes S, Smets I, Holden D, Carrillo-Loza K, Christmas T, Bianchi L, Ammoscato F, Turner B et al.
(
2020
)
.
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
.
Neurology Neuroimmunology & Neuroinflammation
vol.
7
,
(
6
)
Jacobs B, Taylor T, Awad A, Baker D, Giovannoni G, Noyce A, Dobson R
(
2020
)
.
Summary-data-based mendelian randomisation prioritises potential druggable targets for Multiple Sclerosis
.
Brain Communications
Anderson V, Bentley E, Loveless S, Bianchi L, Harding KE, Wynford-Thomas RA, Joseph F, Giovannoni G et al.
(
2020
)
.
Serum neurofilament-light concentration and real-world outcome in MS
.
Journal of the Neurological Sciences
vol.
417
,
Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G et al.
(
2020
)
.
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
.
Clinical and Experimental Immunology
vol.
202
,
(
2
)
149
-
161
.
Giovannoni G, Knappertz V, Steinerman JR, Tansy AP, Li T, Krieger S, Uccelli A, Uitdehaag BMJ et al.
(
2020
)
.
A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis
.
Neurology
Chitnis T, Banwell B, Krupp L, Arnold DL, Bar-Or A, Brück W, Giovannoni G, Greenberg B et al.
(
2020
)
.
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study
.
Multiple Sclerosis Journal
vol.
27
,
(
6
)
922
-
932
.
Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Mathews J, Lambourne J et al.
(
2020
)
.
Protecting people with multiple sclerosis through vaccination
.
Practical Neurology
Lombardi V, Carassiti D, Giovannoni G, Lu C-H, Adiutori R, Malaspina A
(
2020
)
.
Author Correction: The potential of neurofilaments analysis using dry-blood and plasma spots
.
Scientific Reports
vol.
10
,
(
1
)
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Waubant E
(
2020
)
.
Dare we mention the C-word?
.
Multiple Sclerosis and Related Disorders
vol.
43
,
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, Wiendl H, Yamout B et al.
(
2020
)
.
Expert opinion on the use of cladribine tablets in clinical practice
.
Therapeutic Advances in Neurological Disorders
vol.
13
,
Kuri A, Jacobs BM, Vickaryous N, Pakpoor J, Middeldorp J, Giovannoni G, Dobson R
(
2020
)
.
Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom
.
BMC Public Health
vol.
20
,
(
1
)
Saxena G, Moore JM, Jones M, Pryce G, Ali L, Leisegang GR, Vijay V, Loveless S et al.
(
2020
)
.
Detecting and predicting neutralization of alemtuzumab responses in MS
.
Neurology Neuroimmunology & Neuroinflammation
vol.
7
,
(
4
)
Salama S, Giovannoni G, Hawkes CH, Lechner-Scott J, Waubant E, Levy M
(
2020
)
.
Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
42
,
Dobson R, Jokubaitis V, Giovannoni G
(
2020
)
.
Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis
.
Multiple Sclerosis and Related Disorders
Gold R, Radue E-W, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T et al.
(
2020
)
.
Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
.
Journal of Neurology
vol.
267
,
(
10
)
2851
-
2864
.
Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F et al.
(
2020
)
.
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
.
Drug Safety
vol.
43
,
(
7
)
635
-
643
.
Taylor TR, Jacobs BM, Giovannoni G, Petrushkin H, Dobson R
(
2020
)
.
Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study
.
Multiple Sclerosis and Related Disorders
vol.
43
,
Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G
(
2020
)
.
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
.
Multiple Sclerosis and Related Disorders
vol.
43
,
Lechner-Scott J, Waubant E, Levy M, Hawkes C, Giovannoni G
(
2020
)
.
Is multiple sclerosis a risk factor for infections?
.
Multiple Sclerosis and Related Disorders
vol.
41
,
Hobart J, Giovannoni G
(
2020
)
.
Cognition and its relation to brain health in patients with MS: Response to letter
.
Multiple Sclerosis Journal
vol.
26
,
(
12
)
1613
-
1614
.
De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D et al.
(
2020
)
.
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT
.
Efficacy and Mechanism Evaluation
vol.
7
,
(
3
)
1
-
72
.
Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al.
(
2020
)
.
Severe skin reactions associated with cladribine in people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
.
vol.
43
,
Giovannoni G
(
2020
)
.
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
.
Multiple Sclerosis and Related Disorders
vol.
41
,
Cook S, Giovannoni G, Leist T, Comi G, Nolting A, Sylvester E, Jack D, Damian D et al.
(
2020
)
.
An analysis of the relationship between cladribine dose and risk of malignancies in patients with multiple sclerosis (1928)
.
Neurology
.
vol.
94
,
Leddy S, Jacobs B, Giovannoni G, Dobson R
(
2020
)
.
Bone health, fracture risk, and Multiple Sclerosis: a UK Biobank study (3946)
.
Neurology
vol.
94
,
(
15_supplement
)
Benedict RHB, Arnold DL, Rose J, Cohan S, Lynch S, Kappos L, Havrdova EK, Khatri B et al.
(
2020
)
.
Change in cognitive processing speed is associated with cortical grey matter and thalamic volume loss in patients with relapsing-remitting multiple sclerosis (1905)
.
Neurology
.
vol.
94
,
Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, de Moor C et al.
(
2020
)
.
Disease Control Beyond NEDA: The Value of Non-clinical Disease Activity Measures to Determine Treatment Response to Natalizumab (1194)
.
Neurology
.
vol.
94
,
Jacobs B, Giovannoni G, Dobson R
(
2020
)
.
Environmental exposures associated with Multiple Sclerosis: a UK Biobank study (474)
.
Neurology
vol.
94
,
(
15_supplement
)
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, Wiendl H, Yamout B et al.
(
2020
)
.
Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis (1482)
.
Neurology
vol.
94
,
(
15_supplement
)
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Vermersch P, Dangond F, Keller B, Jack D
(
2020
)
.
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets (1942)
.
Neurology
vol.
94
,
(
15_supplement
)
Kappos L, Giovannoni G, Gold R, Fox RJ, Vermersch P, Benedict RHB, Bar-Or A, Rouyrre N et al.
(
2020
)
.
Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128)
.
Neurology
vol.
94
,
(
15_supplement
)
Giovannoni G, Kappos L, de Seze J, Hauser S, Overell J, Koendgen H, Prajapati K, Manfrini M et al.
(
2020
)
.
Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847)
.
Neurology
.
vol.
94
,
Arnold DL, Cree BAC, Bar-Or A, Giovannoni G, Gold R, Vermersch P, Meier DP, Arnould S et al.
(
2020
)
.
Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study (4037)
.
Neurology
vol.
94
,
(
15_supplement
)
Gold R, Giovannoni G, Phillips JT, Bar-Or A, Fox RJ, Chen C, Parks B, Kapadia S
(
2020
)
.
Overall Safety and Efficacy Through 10 Years of Treatment with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis (1345)
.
Neurology
.
vol.
94
,
Christmas T, Reyes S, Singh N, Allen-Philbey K, Giovannoni G
(
2020
)
.
Postprandial Somnolence in People with Multiple Sclerosis (4393)
.
Neurology
vol.
94
,
(
15_supplement
)
Vermersch P, Giovannoni G, Soelberg-S⊘rensen P, Rammohan K, Cook S, Keller B, Roy S
(
2020
)
.
Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets (1961)
.
Neurology
.
vol.
94
,
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung H-P, Sedel F et al.
(
2020
)
.
Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS (680)
.
Neurology
vol.
94
,
(
15_supplement
)
Kalatskaya I, Giovannoni G, Leist T, Sorensen PS, Boschert U, Demartino J, Rolfe A
(
2020
)
.
Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine Treated Patients at the 96 Week Timepoint (CLARITY) Using Deconvolution Algorithms (1520)
.
Neurology
vol.
94
,
(
15_supplement
)
Fox R, Arnold D, Giovannoni G, Cree B, Vermersch P, Bar-Or A, Gold R, Benedict R et al.
(
2020
)
.
Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130)
.
Neurology
vol.
94
,
(
15_supplement
)
Giovannoni G, Kappos L, Berger J, Cutter G, Fox R, Wiendl H, Chang I, Englishby R et al.
(
2020
)
.
Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time (2815)
.
Neurology
vol.
94
,
(
15_supplement
)
Cook S, Giovannoni G, Leist T, Comi G, Syed S, Nolting A, Damian D, Schick R
(
2020
)
.
Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data (1656)
.
Neurology
.
vol.
94
,
Reyes S, Suarez S, Allen‐Philbey K, Thomson A, Giovannoni G
(
2020
)
.
The impact of social capital on patients with multiple sclerosis
.
Acta Neurologica Scandinavica
vol.
142
,
(
1
)
58
-
65
.
Waubant E, Pröbstel A-K, Levy M, Hawkes CH, Giovannoni G, Lechner-Scott J, Tremlett H
(
2020
)
.
The future of microbiome research in neuroinflammatory disorders
.
Multiple Sclerosis and Related Disorders
vol.
40
,
Giovannoni G, Institute BATLSOMADB
(
2020
)
.
CLINICAL VIEWPOINT: Immunosuppression and COVID-19
.
Advances in Clinical Neuroscience & Rehabilitation
vol.
19
,
(
3
)
8
-
9
.
Hawkes CH, Giovannoni G, Levy M, Lechner-Scott J, Waubant E
(
2020
)
.
Big pharma and social responsibility
.
Multiple Sclerosis and Related Disorders
vol.
39
,
Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J
(
2020
)
.
The COVID-19 pandemic and the use of MS disease-modifying therapies
.
Multiple Sclerosis and Related Disorders
vol.
39
,
Bestwick JP, Auger SD, Simonet C, Rees RN, Rack D, Jitlal M, Giovannoni G, Lees AJ et al.
(
2020
)
.
Improving estimation of Parkinson’s disease risk - The enhanced PREDICT-PD algorithm
.
Dobson R, Jacobs B, Giovannoni G, Cuzick J
(
2020
)
.
Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors
.
Multiple Sclerosis Journal
Bestwick JP, Auger SD, Schrag AE, Grosset DG, Kanavou S, Giovannoni G, Lees AJ, Cuzick J et al.
(
2020
)
.
Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson’s disease
.
Arnold DL, Banwell B, Bar-Or A, Ghezzi A, Greenberg BM, Waubant E, Giovannoni G, Wolinsky JS et al.
(
2020
)
.
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
91
,
Laurson-Doube J, Rijke N, Costello K, McDonell J, Giovannoni G, Banwell B, Baneke P
(
2020
)
.
Health-care disparities for people with multiple sclerosis
.
The Lancet Neurology
vol.
19
,
(
3
)
207
-
208
.
Ali L, SAXENA G, Jones M, Leisegang G, Gammon L, Gnanapavan S, Giovannoni G, Schmierer K et al.
(
2020
)
.
A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
.
BioTechniques: the journal of laboratory technology for bioresearch
Reyes S, Suarez S, Allen-Philbey K, Yildiz Ö, Mathews J, Anjorin G, Edwards F, Jain C et al.
(
2020
)
.
Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
41
,
Baker D, Ali L, SAXENA G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S et al.
(
2020
)
.
The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies
.
Frontiers in Immunology
vol.
11
,
(
124
)
Dobson R, Jitlal M, Marshall CR, Noyce AJ, Robson J, Cuzick J, Giovannoni G
(
2020
)
.
Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk
.
Annals of Neurology
vol.
87
,
(
4
)
599
-
608
.
Saxena GK, Theocharopoulos I, Aziz NT, Jones M, Gnanapavan S, Giovannoni G, Schmierer K, Garnett JA et al.
(
2020
)
.
GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains
.
Scientific Reports
vol.
10
,
(
1
)
Article
1860
,
Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Waubant E
(
2020
)
.
Ageing and multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
38
,
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J et al.
(
2020
)
.
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
.
The Lancet Neurology
vol.
19
,
(
3
)
214
-
225
.
McDonell J, Costello K, Laurson-Doube J, Rijke N, Giovannoni G, Banwell B, Baneke P
(
2020
)
.
World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application
.
Multiple Sclerosis Journal
vol.
26
,
(
2
)
153
-
158
.
Dobson R, Noyce A, Giovannoni G, jacobs B
(
2020
)
.
BMI and low serum vitamin D are causal risk factors for Multiple Sclerosis: a Mendelian Randomisation study
.
Neurology, Neuroimmunology and Neuroinflammation
Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A
(
2020
)
.
The potential of neurofilaments analysis using dry-blood and plasma spots
.
Scientific Reports
vol.
10
,
(
1
)
Freedman M, Pardo G, De Stefano N, Aldridge J, Hyvert Y, Galazka A, Lemieux C, Giovannoni G et al.
(
2020
)
.
Age-related efficacy of cladribine tablets in patients with relapsing-remitting ms in the clarity extension study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
257
-
258
.
Cook S, Giovannoni G, Leist T, Comi G, Nolting A, Sylvester E, Jack D, Damian D et al.
(
2020
)
.
An analysis of the relationship between cladribine dose and risk of malignancies in patients with multiple sclerosis
.
NEUROLOGY
.
vol.
94
,
Kalatskaya I, Giovannoni G, Leist T, Sorensen PS, Boschert U, Demartino J, Rolfe A
(
2020
)
.
Assessing the immune cell subtype reconstitution profile using deconvolution algorithms in patients treated with cladribine in the CLARITY study: findings at the 96-week timepoint
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
26
-
26
.
Goodwin G, Li H, Ismail A, Azevedo H, Giovannoni G, Schrag A, Lees A, Cuzick J et al.
(
2020
)
.
Assessing the screening performance of three abbreviated smell tests in Parkinson's disease
.
MOVEMENT DISORDERS
.
vol.
35
,
S652
-
S652
.
Narayanan S, Cutter G, Wolinsky J, Freedman MS, Comi G, Giovannoni G, Hartung H, Sedel F et al.
(
2020
)
.
Axonal Integrity by MRS at Baseline in the SPI2 Ph3 Trial of MD1003 (hdPB): Effect of Sex, Disease Burden, and Progressive MS Type
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
84
-
84
.
Foley J, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G et al.
(
2020
)
.
Baseline characteristics of multiple sclerosis patients enrolled in NOVA, a multicentre, randomised trial to assess the efficacy of natalizumab every-6-weeks dosing
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
212
-
212
.
Leddy S, Jacobs B, Giovannoni G, Dobson R
(
2020
)
.
Bone health, fracture risk, and Multiple Sclerosis: a UK Biobank study
.
NEUROLOGY
.
vol.
94
,
Smets I, Reyes S, Carrillo-Loza K, Mateo-Casas M, Bianchi L, Holden D, Ammoscato F, Turner B et al.
(
2020
)
.
CSF Neurofilament Light Chain for guiding individual treatment decisions in multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
475
-
476
.
Benedict RHB, Arnold DL, Rose J, Cohan S, Lynch S, Kappos L, Havrdova EK, Khatri B et al.
(
2020
)
.
Change in cognitive processing speed is associated with cortical grey matter and thalamic volume loss in patients with relapsing-remitting multiple sclerosis
.
NEUROLOGY
.
vol.
94
,
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2020
)
.
Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
522
-
523
.
Lieberman D, Mangat H, Allen-Philbey K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J et al.
(
2020
)
.
Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
212
-
213
.
Giovannoni G, Leist T, Aydemir A, Di Cantogno EV
(
2020
)
.
Classic-ms: long-term efficacy and real-world treatment patterns for patients receiving cladribine tablets - interim data with 8-14 years follow-up
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
90
-
90
.
Sormani MP, Giovannoni G, Signori A, Alexandri N
(
2020
)
.
Disability improvement in relapsing-remitting multiple sclerosis patients receiving cladribine tablets, evaluated by expanded disability status scale
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
215
-
215
.
Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, Kieseier B, de Moor C et al.
(
2020
)
.
Disease Control Beyond NEDA: The Value of Non-clinical Disease Activity Measures to Determine Treatment Response to Natalizumab
.
NEUROLOGY
.
vol.
94
,
Giovannoni G, Rammohan K, Leist T, Coyle P, Keller B, Jack D, Alexandri N
(
2020
)
.
Durable efficacy of cladribine tablets: cumulative relapse incidence over 5 years in clarity and clarity extension
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
215
-
216
.
Vennersch P, Fox RJ, Arnold DL, Giovannoni G, Cree BAC, Bar-Or A, Golds R, Benedict RHB et al.
(
2020
)
.
Effect of Siponimod on Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
478
-
478
.
Penner I-K, Giovannoni G, Cree BAC, Fox R, Bar-Or A, Gold R, Vermersch P, Hach T et al.
(
2020
)
.
Effect of siponimod on cognitive processing speed in spms patients with active and non-active disease
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
502
-
502
.
Comi G, Soelberg-Sorensen P, Rammohan K, Giovannoni G, Damian D, Jack D, Dangond F, Galazka A et al.
(
2020
)
.
Efficacy Outcomes In Cladribine Tablets-treated Patients In CLARITY Were Similar Between Patients Who Did Vs. Did Not Enter CLARITY Extension
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
43
-
43
.
Comi G, Sorensen PS, Rammohan K, Giovannoni G, Damian D, Jack D, Dangond F, Galazka A et al.
(
2020
)
.
Efficacy outcomes in cladribine tablets-treated patients in CLARITY were similar between patients who did vs. did not enter CLARITY extension
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
1136
-
1136
.
Jacobs B, Giovannoni G, Dobson R
(
2020
)
.
Environmental exposures associated with Multiple Sclerosis: a UK Biobank study
.
NEUROLOGY
.
vol.
94
,
Sormani MP, Signori A, Giovannoni G, Alexandri N
(
2020
)
.
Evaluation of Disability Improvement in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Cladribine Tablets as Measured by the Expanded Disability Status Scale Score
.
NEUROLOGY
.
vol.
94
,
Arnold DL, Vermersch P, Cree BAC, Bar-or A, Giovannoni G, Gold R, Piani-Meier D, Arnould S et al.
(
2020
)
.
Evidence for Improved Myelination in Patients Treated with Siponimod: Results from the Phase 3 EXPAND MRI Substudy
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
194
-
195
.
Hauser S, Bar-Or A, Francis G, Giovannoni G, Kappos L, Nicholas J, Oh J, Sormani MP et al.
(
2020
)
.
Examination of fenebrutinib, a highly selective btki, on disease progression of multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
220
-
220
.
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, Wiendl H, Yamout B et al.
(
2020
)
.
Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
37
,
Sorensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, Wiendl H, Yamout B et al.
(
2020
)
.
Expert opinion consensus on recommendations for treating relapsing multiple sclerosis with cladribine tablets in daily clinical practice
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
945
-
946
.
Jacobs B, Noyce A, Bestwick J, Belete D, Giovannoni G, Dobson R
(
2020
)
.
Gene-environment interactions in multiple sclerosis: a uk biobank study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
367
-
367
.
Arnold DL, Bar-Or A, Cree BAC, Giovannoni G, Gold R, Vermersch P, Piani-Meier D, Hach T et al.
(
2020
)
.
Impact of siponimod on myelination as assessed by mtr across spms subgroups: post-hoc analysis from the expand mri substudy
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
398
-
399
.
Giovannoni G, Leist T, Sorensen PS, Kalatskaya I, Boschert U, DeMartino J, Rolfe A, Jack D
(
2020
)
.
Increase of Naive B Cells M2 Macrophages and Reduction of Memory B/T Cells During Immune Repopulation at 96 Weeks in CLARITY Assessed by Immune Cell Deconvolution
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
NP41
-
NP41
.
Giovannoni G, Leist TP, Soelberg-Sorensen P, Kalatskaya I, Shafaatian UB, DeMartino J, Rolfe A
(
2020
)
.
Increased Naive B Cells, M2 Macrophages, And Decreased Memory B And T Cells During Immune Repopulation In CLARITY Assessed By Immune Cell Deconvolution
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
65
-
66
.
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Vermersch P, Dangond F, Keller B, Jack D
(
2020
)
.
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets
.
NEUROLOGY
.
vol.
94
,
Parratt J, Hauser SL, Kappos L, Montalban X, Bar-Or A, Giovannoni G, Model F, Prajapati K et al.
(
2020
)
.
Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis [Encore]
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
NP66
-
NP67
.
Gouider R, Giovannoni G, Kappos L, Hauser SL, Montalban X, Koendgen H, Prajapati K, Manfrini M et al.
(
2020
)
.
Long-Term Reduction of Relapse Rate and Confirmed Disability Progression After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
.
Multiple Sclerosis and Related Disorders
.
vol.
37
,
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Vermersch P, Dangond F, Keller B, Jack D
(
2020
)
.
Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
468
-
468
.
Kappos L, Giovannoni G, Gold R, Fox RJ, Vermersch P, Benedict RHB, Bar-Or A, Rouyrre N et al.
(
2020
)
.
Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years
.
NEUROLOGY
.
vol.
94
,
Kappos L, Giovannoni G, Gold R, Fox RJ, Vermersch P, Benedict RHB, Bar-or A, Rouyrres N et al.
(
2020
)
.
Long-term Efficacy of Siponimod Treatment for up to 5 Years in Patients with Secondary Progressive Multiple Sclerosis: Analysis of the EXPAND Extension Study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
337
-
337
.
Hauser SL, Kappos L, Giovannoni G, Montalban X, Koendgen H, Wang Q, Manfrini M, Wolinsky J
(
2020
)
.
Long-term Reduction Of Relapse Rate And Confirmed Disability Progression After 6 Years Of Ocrelizumab Treatment In Patients With Relapsing MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
45
-
46
.
Giovannoni G, Kappos L, de Seze J, Hauser S, Overell J, Koendgen H, Prajapati K, Manfrini M et al.
(
2020
)
.
Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
.
NEUROLOGY
.
vol.
94
,
Giovannoni G, Kappos L, De Seze J, Hauser S, Overell J, Koendgen H, Schneble H-M, Prajapati K et al.
(
2020
)
.
Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 Years of ocrelizumab treatment in patients with rms
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
222
-
223
.
Arnold DL, Cree BAC, Bar-Or A, Giovannoni G, Gold R, Vermersch P, Meier DP, Arnould S et al.
(
2020
)
.
Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study
.
NEUROLOGY
.
vol.
94
,
Rouyrre N, Cree BAC, Fox R, Vermersch P, Giovannoni G, Bar-Or A, Gold R, Piani-Meier D et al.
(
2020
)
.
Modeling a long-term virtual placebo arm for spms population in the expand study: comparing different statistical methods
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
123
-
123
.
Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeno R et al.
(
2020
)
.
Msprodiscuss™ is a useful tool to aid discussion of multiple sclerosis disease progression: results from a large, real-world qualitative survey
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
539
-
539
.
Gudesblatt M, Srinivasan J, Bumstead B, Zarif M, Giovannoni G
(
2020
)
.
Multiple Sclerosis Management And EDSS: A Great Start, But A Reason For Change Was Never So Apparent And Needed
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
33
-
33
.
Gold R, Giovannoni G, Phillips JT, Bar-Or A, Fox RJ, Chen C, Parks B, Kapadia S
(
2020
)
.
Overall Safety and Efficacy Through 10 Years of Treatment with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis
.
NEUROLOGY
.
vol.
94
,
Belete D, Jacobs B, Bestwick J, Blauwendraat C, Bandres-Ciga S, Heilbron K, Dobson R, Nalls M et al.
(
2020
)
.
Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank
.
MOVEMENT DISORDERS
.
vol.
35
,
S74
-
S74
.
Christmas T, Reyes S, Singh N, Allen-Philbey K, Giovannoni G
(
2020
)
.
Postprandial Somnolence in People with Multiple Sclerosis
.
NEUROLOGY
.
vol.
94
,
Christmas T, Ardissino M, Singh N, Allen-Philbey K, Giovannoni G, Reyes S
(
2020
)
.
Postprandial somnolence in multiple sclerosis: the invisible is real
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
641
-
641
.
Yamout B, Giovannoni G, Magyari M, Vermersch P, Merino-Plazas E, Alexandri N, Keller B
(
2020
)
.
Preservation of relapse-free status in Year 2 of treatment with cladribine tablets by relapse-free status in Year 1
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
482
-
482
.
Hauser S, Bar-Or A, Francis G, Kappos L, Nicholas J, Oh J, Sormani MP, Stoll S et al.
(
2020
)
.
Rationale and design of two phase iiib studies of ocrelizumab at higher than the approved dose in patients with rms and ppms
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
230
-
231
.
Boyko AN, Correale JD, Edan G, Freedman M, Giovannoni G, Montalban X, Rammohan K, Leist T et al.
(
2020
)
.
Rationale, design and feasibility assessment of the Phase IV CLASSIC-MS study evaluating long-term efficacy for patients with multiple sclerosis treated with cladribine tablets
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
200
-
200
.
Vermersch P, Giovannoni G, Soelberg-Sorensen P, Rammohan K, Cook S, Keller B, Roy S
(
2020
)
.
Reduction Of Risk Of Secondary Progressive Multiple Sclerosis Within Two Years Of Treatment With Cladribine Tablets: An Analysis Of The CLARITY Study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
67
-
68
.
Taylor B, Wolinsky JS, Kappos L, Montalban X, Model F, Mehta L, Hubeaux S, Giovannoni G
(
2020
)
.
Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis [Encore]
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
NP37
-
NP37
.
Vermersch P, Giovannoni G, Sørensen PS, Rammohan K, Cook S, Keller B, Roy S
(
2020
)
.
Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study
.
Multiple Sclerosis and Related Disorders
vol.
37
,
Kalatskaya I, Giovannoni G, Leist T, Sorensen PS, Boschert U, Demartino J, Rolfe A
(
2020
)
.
Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine Treated Patients at the 96 Week Timepoint (CLARITY) Using Deconvolution Algorithms
.
NEUROLOGY
.
vol.
94
,
Gold R, Giovannoni G, Phillips JT, Bar-Or A, Fox R, Mokliatchouk O, Parks B, Miller C et al.
(
2020
)
.
Safety and efficacy in patients treated with dimethyl fumarate and followed for 13 years: final results of endorse
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
6
-
6
.
Coles AJ, Bass AD, Comi G, Fernandez O, Giovannoni G, Jones J, Kappos L, Havrdova EK et al.
(
2020
)
.
Safety of Alemtuzumab Over 9 Years in Patients With Non-MS Autoimmunity
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
681
-
681
.
Vennersch P, Bass AD, Boster A, Chan A, Coles AJ, Comic G, Giovannoni G, Junes J et al.
(
2020
)
.
Safety of Alemtuzumab in RRMS Patients During the Peri-infusion Period: Clinical Trial and Postmarketing Experience
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
477
-
477
.
Struga G, Bianchi L, Ammoscato F, Bestwick J, Giovannoni G, Gnanapavan S
(
2020
)
.
Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
1143
-
1143
.
Coles A, Bass A, Comi G, Fernandez O, Giovannoni G, Jones J, Havrdova EK, Montalban X et al.
(
2020
)
.
Safety of alemtuzumab over 9 years in patients with non-MS autoimmunity
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
3
-
4
.
Fox R, Arnold D, Giovannoni G, Cree B, Vermersch P, Bar-Or A, Gold R, Benedict R et al.
(
2020
)
.
Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study
.
NEUROLOGY
.
vol.
94
,
Gold R, Kappos L, Benedict RHB, Bar-or A, Vermersch P, Giovannoni G, Fox RJ, Hach T et al.
(
2020
)
.
Siponimod Slows Physical Disability Progression and Decline in Cognitive Processing Speed in SPMS Patients with Active Disease: A Post Hoc Analysis of the EXPAND Study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
328
-
329
.
Giovannoni G, Kappos L, Fox R, Vermersch P, Cree BAC, Benedict R, Bar-Or A, Rouyrre N et al.
(
2020
)
.
Sustained reduction of disability and cognitive decline with long-term siponimod treatment in patients with active spms: expand data up to 5 years
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
235
-
235
.
Greenberg B, Rammohan K, Aldridge J, Lebson LA, Dangond F, Giovannoni G
(
2020
)
.
The effect of cladribine tablets in patients with relapsing-remitting multiple sclerosis who had evidence of disease activity in CLARITY
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
916
-
917
.
Giovannoni G, Pardo G, Ben-Zacharia A, Harty G, Hayward B, Harty G, Jones DL, Rammohan K
(
2020
)
.
Time To First Relapse Over The Duration Of Clarity And Clarity Extension In Patients Treated With Cladribine Tablets 3.5 Mg/kg Over Two Years
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
50
-
51
.
Noyce A, Giovannoni G, Scheltens P, Berg D, Brown L, Dierickx K, Frisoni G, Georges J et al.
(
2020
)
.
Time matters in brain health: how can health systems respond to the growing demand for genetic testing?
.
MOVEMENT DISORDERS
.
vol.
35
,
S71
-
S71
.
Noyce A, Giovannoni G, Scheltens P, Berg D, Brown L, Dierickx K, Frisoni GB, Georges J et al.
(
2020
)
.
Time matters in brain health: how should society prepare for a growing population at risk of neurodegenerative diseases?
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
143
-
143
.
Hobart J, Butzkueven H, Haartsen J, Vollmer T, Ziemssen T, Lane T, Giovannoni G
(
2020
)
.
Timely intervention, monitoring and education matters in ms (time matters in ms): global piloting of the ms brain health quality improvement tool
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
643
-
643
.
Leddy S, Jacobs BM, Giovannoni G, Dobson R
(
2020
)
.
To examine the impact of Multiple Sclerosis on bone health and explore mechanisms for this association
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
981
-
981
.
Giovannoni G, Kappos L, Berger J, Cutter G, Fox R, Wiendl H, Chang I, Englishby R et al.
(
2020
)
.
Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time
.
NEUROLOGY
.
vol.
94
,
Cook S, Giovannoni G, Leist TP, Comi G, Syed S, Nolting A, Damian D, Schick R
(
2020
)
.
Updated Safety Of Cladribine Tablets In The Treatment Of Patients With Multiple Sclerosis: Integrated Safety Analysis And Post-approval Data
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
52
-
52
.
Cook S, Giovannoni G, Leist T, Comi G, Syed S, Noltine A, Damian D, Schick R
(
2020
)
.
Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-Approval Data
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
327
-
328
.
Giovannoni G, Berger J, Leist T, Jack D, Galazka A, Nolting A, Damian D
(
2020
)
.
Updated post-approval safety of cladribine tablets in the treatment of multiple sclerosis, with particular reference to respiratory viral infections
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
318
-
318
.
Vickaryous N, Garjani A, Jacobs B, Jitlal M, Middleton R, Das Nair R, Tuite-Dalton K, Hunter R et al.
(
2020
)
.
Vitamin D levels in the UK MS population and COVID-19 susceptibility
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
26
,
55
-
55
.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung H-P, Maniar T, Croze E, Aftab BT et al.
(
2019
)
.
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
.
Trends in Molecular Medicine
vol.
26
,
(
3
)
296
-
310
.
Giovannoni G, Brex P, Dhiraj D, Fullarton J, Freddi M, Rodgers-Gray B, Schmierer K
(
2019
)
.
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme
.
Multiple Sclerosis Journal - Experimental Translational and Clinical
vol.
5
,
(
4
)
Levy M, Waubant E, Hawkes C, Giovannoni G, Lechner-Scott J
(
2019
)
.
“Is this new medicine going to help me walk again?”
.
Multiple Sclerosis and Related Disorders
vol.
37
,
Giovannoni G, White S, Mistry N, Calhoun S, Young C, Coutts M, Roberts M, Anderson P et al.
(
2019
)
.
163 Development of clinical and patient-reported quality metrics for multiple sclerosis: a UK pilot study report
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
90
,
Giovannoni G, Hauser SL, Brochet B, Montalban X, Naismith RT, Wolinsky JS, Hubeaux S, Mehta L et al.
(
2019
)
.
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
90
,
Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al.
(
2019
)
.
192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis?
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
90
,
Giovannoni G, Kappos L, Berger J, Cutter G, Fox R, Wiendl H, Chang I, Kasliwal R et al.
(
2019
)
.
199 Changes in natalizumab exposure and PML incidence over time
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
90
,
Allen-Philbey K, Silveira F, Turner B, Giovannoni G, Schmierer K
(
2019
)
.
212 Is there an ethnicity bias of access to MS services? The barts health experience revisited
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
90
,
Lombardi V, Carassiti D, Giovannoni G, Lu C-H, Adiutori R, Malaspina A
(
2019
)
.
Theme 7 Pre-clinical therapeutic strategies
.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
vol.
20
,
(
sup1
)
217
-
245
.
Baker D, Pryce G, James LK, Schmierer K, Giovannoni G
(
2019
)
.
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis
.
European Journal of Neurology
vol.
27
,
(
2
)
221
-
228
.
Waubant E, Levy M, Lechner-Scott J, Giovannoni G, Hawkes C
(
2019
)
.
Grassroot efforts towards diversity in MS care and research: Win-win for patients and science
.
Multiple Sclerosis and Related Disorders
vol.
35
,
a1
-
a2
.
Giovannoni G, Rammohan K, Cook S, Soelberg-Sorensen P, Vermersch P, Keller B, di Cantogno EV
(
2019
)
.
Efficacy of cladribine tablets 3.5 mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; clarity and clarity extension
.
Journal of the Neurological Sciences
.
vol.
405
,
177
-
178
.
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Vermersch P, Dangond F, Keller B, Jack D
(
2019
)
.
Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the clarity and clarity extension studies
.
Journal of the Neurological Sciences
.
vol.
405
,
Giovannoni G, Kappos L, Hauser SL, Montalban X, Koendgen H, Prajapati K, Manfrini M, Mehta L et al.
(
2019
)
.
Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
.
Journal of the Neurological Sciences
.
vol.
405
,
308
-
309
.
Vermersch P, Giovannoni G, Soelberg-Sorensen P, Rammohan K, Cook S, Keller B, Roy S
(
2019
)
.
Reduction of risk of secondary progressive multiple sclerosis within two years of treatment with cladribine tablets: An analysis of the clarity study
.
Journal of the Neurological Sciences
.
vol.
405
,
Jacobs BM, Giovannoni G, Cuzick J, Dobson R
(
2019
)
.
Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors
.
medRxiv19007450
-
19007450
.
Oreja-Guevara C, Potra S, Bauer B, Centonze D, Giambastiani M-P, Giovannoni G, Kesselring J, Langdon D et al.
(
2019
)
.
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
.
Advances in Therapy
vol.
36
,
(
11
)
3238
-
3252
.
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Waubant E
(
2019
)
.
Multiple sclerosis and migration revisited
.
Multiple Sclerosis and Related Disorders
vol.
34
,
a1
-
a2
.
Giovannoni G
(
2019
)
.
Do we have equipoise when it comes to how we treat active multiple sclerosis?
.
The Lancet Neurology
vol.
18
,
(
10
)
909
-
911
.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung H-P et al.
(
2019
)
.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
.
The Lancet Neurology
vol.
18
,
(
9
)
845
-
856
.
Pardo S, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E, Levy M
(
2019
)
.
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder
.
Multiple Sclerosis and Related Disorders
vol.
33
,
a1
-
a2
.
Baker D, Jacobs BM, Gnanapavan S, Schmierer K, Giovannoni G
(
2019
)
.
Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
35
,
19
-
25
.
Hasan H, Burrows M, Athauda DS, Hellman B, James B, Warner T, Foltynie T, Giovannoni G et al.
(
2019
)
.
The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect
.
Movement Disorders Clinical Practice
vol.
6
,
(
6
)
462
-
469
.
Stuve O, Soerensen PS, Leist T, Giovannoni G, Hyvert Y, Damian D, Dangond F, Boschert U
(
2019
)
.
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
.
Therapeutic Advances in Neurological Disorders
vol.
12
,
Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE et al.
(
2019
)
.
Screening performance of abbreviated versions of the UPSIT smell test
.
Journal of Neurology
vol.
266
,
(
8
)
1897
-
1906
.
Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E
(
2019
)
.
A narrative to explain worsening secondary progressive multiple sclerosis
.
Multiple Sclerosis and Related Disorders
Waubant E, Giovannoni G, Hawkes C, Lechner-Scott J, Levy M
(
2019
)
.
Three suggestions to decrease the financial burden of MS treatments
.
Multiple Sclerosis and Related Disorders
vol.
30
,
Lechner-Scott J, Giovannoni G, Hawkes C, Levy M, Waubant E
(
2019
)
.
One size doesn't fit all
.
Multiple Sclerosis and Related Disorders
vol.
31
,
a1
-
a2
.
Giovannoni G
(
2019
)
.
Survival: the ultimate long-term outcome in multiple sclerosis
.
Brain
vol.
142
,
(
5
)
1166
-
1167
.
Gaiottino J, Giovannoni G, Breuer J, Tang JW
(
2019
)
.
Chronic-relapsing varicella zoster meningitis – Successfully treated with varicella vaccine
.
Journal of Infection
vol.
79
,
(
1
)
61
-
74
.
Kappos L, Vermersch P, Cree B, Benedict R, Giovannoni G, Bar-Or A, Gold R, Arnould S et al.
(
2019
)
.
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006)
.
Neurology
vol.
92
,
(
15_supplement
)
Narayanan S, Cutter G, Wolinsky J, Freedman M, Comi G, Giovannoni G, Hartung H-P, SEDEL F et al.
(
2019
)
.
Axonal Integrity in Primary and Secondary Progressive Multiple Sclerosis: a Baseline Subgroup Analysis of Sex, Age, and Disease Severity from the Phase III SPI2 Study (S12.005)
.
Neurology
vol.
92
,
(
15_supplement
)
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al.
(
2019
)
.
Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients (S26.008)
.
Neurology
vol.
92
,
(
15_supplement
)
Williams M, Langdon D, Giovannoni G, Pontaga M, Alexandri N
(
2019
)
.
Comparing Patient Perceptions on Multiple Sclerosis Management and Care – A Sub-analysis of Geographic Differences (P4.9-076)
.
Neurology
vol.
92
,
(
15_supplement
)
Gold R, Giovannoni G, Phillips JT, Bar-Or A, Fox RJ, Chen C, Miller C
(
2019
)
.
Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis (P3.2-084)
.
Neurology
.
vol.
92
,
Giovannoni G, Keller B, Jack D
(
2019
)
.
Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY Extension (P3.2-100)
.
Neurology
.
vol.
92
,
Benedict R, Fox R, Tomic D, Cree B, Vermersch P, Giovannoni G, Bar-Or A, Gold R et al.
(
2019
)
.
Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis (P3.2-051)
.
Neurology
vol.
92
,
(
15_supplement
)
Campbell N, Cohen J, Wiendl H, Foley J, Butzkueven H, Ryerson LZ, Giovannoni G, Arnold D et al.
(
2019
)
.
Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study (P3.2-095)
.
Neurology
vol.
92
,
(
15_supplement
)
Hauser SL, Kappos L, Montalban X, Bar-Or A, Giovannoni G, Model F, Hubeaux S, Mehta L et al.
(
2019
)
.
Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (P3.2-054)
.
Neurology
.
vol.
92
,
Cook S, Giovannoni G, Vermersch P, Sorensen PS, Keller B, Jack D
(
2019
)
.
Lymphopenia rates in CLARITY/CLARITY Extension are consistent in patients with or without high disease activity at baseline (P3.2-062)
.
Neurology
vol.
92
,
(
15_supplement
)
Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J et al.
(
2019
)
.
Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091)
.
Neurology
.
vol.
92
,
Maeglin J, Finnegan T, Murray C, Giovannoni G
(
2019
)
.
Online Medical Education Improves Knowledge of Immune Mechanisms in the Treatment of MS Among Neurologists (P1.2-100)
.
Neurology
.
vol.
92
,
Zhu B, Calabresi P, Giovannoni G, Kapoor R, Naismith R, Hartung H-P, Arnold D, Wolstencroft P et al.
(
2019
)
.
Phase 2 AFFINITY Trial Evaluates Opicinumab in a Targeted Population of Patients With Relapsing Multiple Sclerosis: Rationale, Design and Baseline Characteristics (P3.2-072)
.
Neurology
.
vol.
92
,
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al.
(
2019
)
.
Real Life Evidence for CSF Neurofilaments Light Chain in Clinical Practice. (P5.2-021)
.
Neurology
vol.
92
,
(
15_supplement
)
Arnold DL, Giovannoni G, Hartung H-P, Hauser SL, Kappos L, Montalban X, Wolinsky JS, Coutant K et al.
(
2019
)
.
Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up (P3.2-042)
.
Neurology
vol.
92
,
(
15_supplement
)
Wolinsky JS, Kappos L, Montalban X, Model F, Mehta L, Hubeaux S, Giovannoni G
(
2019
)
.
Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis (P3.2-031)
.
Neurology
.
vol.
92
,
Mateo-Casas M, Reyes S, De Trane S, Yildiz O, Turner B, Mathews J, Giovannoni G, O’toole E et al.
(
2019
)
.
Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis (P4.2-022)
.
Neurology
vol.
92
,
(
15_supplement
)
Reyes S, Suarez S, Allen-Philbey K, Thomson A, Giovannoni G
(
2019
)
.
The Impact of Social Capital on Patients with Multiple Sclerosis (P4.2-069)
.
Neurology
vol.
92
,
(
15_supplement
)
Cook S, Giovannoni G, Leist T, Syed S, Nolting A, Damian D, Schick R
(
2019
)
.
Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis (P4.2-046)
.
Neurology
.
vol.
92
,
Levy M, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E
(
2019
)
.
Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease
.
Multiple Sclerosis and Related Disorders
vol.
29
,
a1
-
a2
.
Gold R, Giovannoni G, Phillips T, Bar-Or A, Fox RJ, Chen C, Miller C
(
2019
)
.
Delayed-release Dimethyl Fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple Sclerosis
.
Revue Neurologique
.
vol.
175
,
Giovannoni G, Jack D
(
2019
)
.
Durabilité du statut NEDA-3 (No Evidence of Disease Activity) chez les patients atteints d’une forme récurrente de sclérose en plaques (SEP-R) recevant Cladribine Comprimés 3,5mg/kg (CT3,5) : CLARITY Extension
.
Revue Neurologique
vol.
175
,
Giovannoni G, Kappos L, Berger J, Cutter G, Fox RJ, Wiendl H, Chang I, Kasliwal R et al.
(
2019
)
.
Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time
.
Revue Neurologique
vol.
175
,
s96
-
s97
.
DOBSON R
(
2019
)
.
Visibility and representation of women in multiple sclerosis research
.
Neurology
Axelsson M, Dubuisson N, Novakova L, Malmeström C, Giovannoni G, Lycke J, Gnanapavan S
(
2019
)
.
Cerebrospinal fluid NCAM levels are modulated by disease‐modifying therapies
.
Acta Neurologica Scandinavica
vol.
139
,
(
5
)
422
-
427
.
Hawkes C, Giovannoni G, Lechner-Scott J, Levy M, Waubant E
(
2019
)
.
Multiple Sclerosis and Vitamin D – Caviar or a Dog’s Dinner?
.
Multiple Sclerosis and Related Disorders
vol.
28
,
a1
-
a2
.
Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A et al.
(
2019
)
.
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
29
,
168
-
174
.
Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA
(
2019
)
.
UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines
.
Pract Neurol
Kappos L, Vermersch P, Cree B, Benedict R, Giovannoni G, Bar-Or A, Gold R, Arnould S et al.
(
2019
)
.
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis
.
NEUROLOGY
.
vol.
92
,
Giovannoni G, Rammohan K, Cook S, Soelberg-Sorensen P, Vermersch P, King J, Keller B, di Cantogno EV
(
2019
)
.
An Exploratory Analysis of the Efficacy of Cladribine Tablets 3.5 mg/kg in Patients with Relapsing Multiple Sclerosis Stratified According to Age Above and Below 45 Years in the CLARITY Study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
465
-
466
.
Giovannoni G, Rammohan KW, Cook SD, Soelberg-Sorensen P, Vermersch P, Keller B, di Cantogno EV
(
2019
)
.
An Exploratory Analysis of the Efficacy of Cladribine Tablets in Patients with RMS Stratified According to Age Above and below 45 Years in CLARITY
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
45
-
46
.
Cores C, Reyes S, De Trane S, Giovannoni G, Schmierer K, Baker D
(
2019
)
.
Are poor depleters worse off? Variation in total lymphocyte reduction following MS treatment with cladribine
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
745
-
746
.
Kappos L, Vermersch P, Cree B, Benedict R, Giovannoni G, Bar-or A, Gold R, Arnould S et al.
(
2019
)
.
Assessment of disease progression in patients with secondary progressive multiple sclerosis (SPMS) using a novel functional composite endpoint
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
26
,
240
-
241
.
Narayanan S, Cutter G, Wolinsky J, Freedman M, Comi G, Giovannoni G, Hartung H-P, Sedel F et al.
(
2019
)
.
Axonal Integrity in Primary and Secondary Progressive Multiple Sclerosis: a Baseline Subgroup Analysis of Sex, Age, and Disease Severity from the Phase III SPI2 Study
.
NEUROLOGY
.
vol.
92
,
Vermersch P, Giovannoni G, Soelberg-Sorensen P, Keller B, Jack D
(
2019
)
.
CLARITY extension: sustained efficacy in relapsing remitting multiple sclerosis following switch from cladribine tablets to placebo in patients with high disease activity at baseline
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
26
,
867
-
867
.
Schippling S, Sormani MP, De Stefano N, Giovannoni G, Galazka A, Keller B, Alexandri N
(
2019
)
.
CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with RMS Treated with Cladribine Tablets or Placebo
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
46
-
46
.
Schippling S, Sormani MP, De Stefano N, Giovannoni G, King J, Galazka A, Keller B, Alexandri N
(
2019
)
.
CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets or Placebo
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
466
-
467
.
Ammoscato F, De Angelis F, Plantone D, Parker RA, Wheeler-Kingshott CAMG, Pavitt S, Stallard N, Chandran S et al.
(
2019
)
.
CSF neurofilament heavy chain release (NfH) is important in secondary progressive MS (SPMS) - results from the MS-SMART trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
502
-
503
.
De Trane S, Allen-Philbey K, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al.
(
2019
)
.
Cladribine at all stages of MS: two-year follow-up in 154 patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
519
-
520
.
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al.
(
2019
)
.
Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients
.
NEUROLOGY
.
vol.
92
,
Williams M, Langdon D, Giovannoni G, Pontaga M, Alexandri N
(
2019
)
.
Comparing Patient Perceptions on Multiple Sclerosis Management and Care - A Sub-analysis of Geographic Differences
.
NEUROLOGY
.
vol.
92
,
Kappos L, Mcguigan C, Derfuss T, Giovannoni G, Oh J, Ren Z, McCarthy K, Chang I et al.
(
2019
)
.
Determinants of clinical outcomes for patients with Natalizumab-associated progressive multifocal leukoencephalopathy
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
19
-
20
.
Giovannoni G, Keller B, Jack D
(
2019
)
.
Durability of NEDA-3 Status in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: CLARITY Extension
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
467
-
467
.
Giovannoni G, Keller B, Jack D
(
2019
)
.
Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY Extension
.
NEUROLOGY
.
vol.
92
,
Benedict R, Fox R, Tomic D, Cree B, Vermersch P, Giovannoni G, Bar-Or A, Gold R et al.
(
2019
)
.
Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis
.
NEUROLOGY
.
vol.
92
,
Arnold DL, Fox R, Bar-Or A, Cree BAC, Giovannoni G, Gold R, Vermersch P, Meier DP et al.
(
2019
)
.
Effect of siponimod on cortical grey matter and thalamic volume in patients with secondary progressive multiple sclerosis - results of the EXPAND study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
151
-
152
.
Gold R, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox R, Rouyrre N, Karlsson G et al.
(
2019
)
.
Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
380
-
381
.
Giovannoni G, Rammohan K, Cook S, Soelberg-Sorensen P, Vermersch P, Keller B, Di Cantogno EV
(
2019
)
.
Efficacy of cladribine tablets 3.5mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; CLARITY and CLARITY Extension
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
26
,
492
-
492
.
Cohen JA, Campbell N, Wiendl H, Foley J, Butzkueven H, Ryerson LZ, Giovannoni G, Arnold DL et al.
(
2019
)
.
Evaluating the Efficacy and Safety of 6-Week Extended Interval Dosing of Natalizumab Via a Prospective, Controlled, Randomized Phase 3b Study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
48
-
49
.
Campbell N, Cohen J, Wiendl H, Foley J, Butzkueven H, Ryerson LZ, Giovannoni G, Arnold D et al.
(
2019
)
.
Evaluating the efficacy and safety of 6 week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study
.
NEUROLOGY
.
vol.
92
,
Reyes S, Carrillo-Loza K, Mateo M, Bianchi L, Holden D, Ammoscato F, Marta M, Turner B et al.
(
2019
)
.
Evidence of the utility of CSF neurofilament light chain measurements in people with MS in clinical practice
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
854
-
854
.
Skromne E, Hobart J, Bowen A, Eberhard L, Pepper G, Giovannoni G
(
2019
)
.
Expert consensus on standards for multiple sclerosis care: Results from a modified Delphi process
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
169
-
170
.
Giovannoni G, Leist T, Soelberg-Sorensen P, Kalatskaya I, Boschert U, DeMartino J, Rolfe A
(
2019
)
.
Increase of naive B cells, M2 macrophages and reduction of memory B/T cells during immune repopulation at 96 weeks in CLARITY assessed by immune cell deconvolution
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
514
-
515
.
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Vermersch P, Dangond F, Keller B, Jack D
(
2019
)
.
Long-term disease stability assessed by the expanded disability status scale in patients treated with Cladribine tablets in the CLARITY and CLARITY extension studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
873
-
874
.
Kappos L, Vermersche P, Fox R, Bar-Or A, Cree B, Giovannoni G, Gold R, Masior T et al.
(
2019
)
.
Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis from the BOLD and EXPAND Trial and their Extensions
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
460
-
460
.
Cook S, Giovannoni G, Vermersch P, Soelberg-Sorensen P, Keller B, Jack D
(
2019
)
.
Lymphopenia Rates in CLARITY/CLARITY Extension Are Unrelated to Disease Activity at Baseline
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
468
-
468
.
Cook S, Giovannoni G, Vermersch P, Sorensen PS, Keller B, Jack D
(
2019
)
.
Lymphopenia rates in CLARITY/CLARITY Extension are consistent in patients with or without high disease activity at baseline
.
NEUROLOGY
.
vol.
92
,
Gudesblatt M, Srinivasan J, Drost T, Bumstead B, Fafard L, Jaenicke K, Buhse M, Zarif M et al.
(
2019
)
.
Multiple sclerosis management and EDSS: a great start, but a reason for change was never so apparent and needed
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
628
-
629
.
Giovannoni G, Keller B, Jack D
(
2019
)
.
NEDA-3 durability in CLARITY Extension in patients with relapsing multiple sclerosis receiving cladribine tablets
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
26
,
492
-
493
.
Bianchi L, Baker D, Giovannoni G, Marta M
(
2019
)
.
Neurofilament light chain levels in cerebrospinal fluid and serum of a longitudinal cohort of people with multiple sclerosis on disease modifying drugs
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
734
-
735
.
Dobson R, Jitlal M, Marshall C, Noyce A, Giovannoni G
(
2019
)
.
Obesity is not associated with MS in a socially and ethnically diverse population
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
49
-
49
.
Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J et al.
(
2019
)
.
Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design
.
NEUROLOGY
.
vol.
92
,
Maeglin J, Finnegan T, Murray C, Giovannoni G
(
2019
)
.
Online Medical Education Improves Knowledge of Immune Mechanisms in the Treatment of MS Among Neurologists
.
NEUROLOGY
.
vol.
92
,
Marta M, Bianchi L, Lieberman D, Ciccarelli O, Collorone S, Kapoor R, Chataway J, Schmierer K et al.
(
2019
)
.
Oxcarbazepine as a neuroprotective agent in MS: a phase IIa trial (PROXIMUS)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
91
-
91
.
Chitnis T, Banwell B, Krupp L, Arnold DL, Bar-Or A, Brueck W, Giovannoni G, Greenberg B et al.
(
2019
)
.
Paediatric patients with multiple sclerosis: effect of fingolimod on lymphocyte counts and its relationship with infection from the paradigms study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
376
-
377
.
Allen-Philbey K, Miller J, Giovannoni G, Schmierer K, Turner B
(
2019
)
.
Pharmacovigilance of urinary tract infections in Alemtuzumab cohort
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
321
-
322
.
Zhu B, Calabresi P, Giovannoni G, Kapoor R, Naismith R, Hartung H-P, Arnold D, Wolstencroft P et al.
(
2019
)
.
Phase 2 AFFINITY Trial Evaluates Opicinumab in a Targeted Population of Patients With Relapsing Multiple Sclerosis: Rationale, Design and Baseline Characteristics
.
NEUROLOGY
.
vol.
92
,
Kappos L, Meier DP, Tomic T, Haring D, Bakshi R, Meinert R, Giovannoni G, Chitnis T
(
2019
)
.
Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients with Relapsing-Remitting Multiple Sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
447
-
447
.
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al.
(
2019
)
.
Real life Evidence for CSF Neurofilaments Light Chain in Clinical Practice
.
NEUROLOGY
.
vol.
92
,
Arnold DL, Giovannoni G, Hartung H-P, Hauser SL, Kappos L, Montalban X, Wolinsky JS, Coutant K et al.
(
2019
)
.
Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up
.
NEUROLOGY
.
vol.
92
,
Arnold DL, Giovannoni G, Hartung H-P, Hauser SL, Kappos L, Montalban X, Wolinsky JS, Coutant K et al.
(
2019
)
.
Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO Trial
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
26
,
157
-
157
.
Wolinsky JS, Kappos L, Montalban X, Model F, Mehta L, Hubeaux S, Giovannoni G
(
2019
)
.
Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis
.
NEUROLOGY
.
vol.
92
,
Arnold DL, Giovannoni G, Cree BAC, Vermersch P, Bar-Or A, Gold R, Meier DP, Arnould S et al.
(
2019
)
.
Relationship between grey matter atrophy, disability and cognition in patients with secondary progressive multiple sclerosis: analysis from the EXPAND study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
568
-
569
.
Lieberman DR, Giovannoni G, Cafferty F, Bianchi L, Gnanapavan S, Marta M, Altmann DR, Kapoor R
(
2019
)
.
Seamless phase II-III adaptive trial design elements for progressive MS: Neurofilament light chain (phase II/interim endpoint), phase III endpoints and patient populations
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
600
-
600
.
Schippling S, Sormani MP, De Stefano N, Giovannoni G, Dangond F, Galazka A, Keller B, Alexandri N
(
2019
)
.
Severity and frequency of relapses in patients with relapsing-remitting MS treated with cladribine tablets in CLARITY and placebo in CLARITY extension
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
26
,
857
-
858
.
Giovannoni G, Hawkes C, Levy M, Lechner-Scott J, Waubant E
(
2019
)
.
Should our treatment target in MS include the intrathecal plasma cell response?
.
Multiple Sclerosis and Related Disorders
vol.
27
,
a1
-
a2
.
Benedict R, Tomic D, Fox R, Cree B, Vermersch P, Giovannoni G, Bar-Or A, Gold R et al.
(
2019
)
.
Siponimod Improves Cognitive Processing Speed in Patients with Secondary Progressive Multiple Sclerosis: EXPAND Subgroup Analyses
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
NP20
-
NP21
.
Vermersch P, Gold R, Kappos L, Fox R, Bar-Or A, Cree B, Rouyrre N, Arnould S et al.
(
2019
)
.
Siponimod delays the time to wheelchair in patients with SPMS: results from the EXPAND study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
55
-
56
.
Benedict R, Fox R, Tomic D, Cree B, Vermersch P, Giovannoni G, Bar-or A, Gold R et al.
(
2019
)
.
Siponimod improves cognitive processing speed in patients with secondary progressive multiple sclerosis: EXPAND subgroup analyses
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
26
,
868
-
868
.
Vermersch P, Giovannoni G, Soelberg-Sorensen P, Keller B, Jack D
(
2019
)
.
Sustained Efficacy in Relapsing Remitting Multiple Sclerosis Following Switch to Placebo Treatment from Cladribine Tablets in Patients with High Disease Activity (HDA) at Baseline
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
467
-
468
.
Reyes S, Suarez S, Allen-Philbey K, Thomson A, Giovannoni G
(
2019
)
.
The Impact of Social Capital on Patients with Multiple Sclerosis
.
NEUROLOGY
.
vol.
92
,
Cook S, Giovannoni G, Leist T, King J, Syed S, Nolting A, Schick R
(
2019
)
.
Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
469
-
469
.
Vickaryous N, Jitlal M, Middleton R, Giovannoni G, Dobson R
(
2019
)
.
Vitamin D levels in the UK MS population
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
449
-
450
.
Giovannoni G
(
2018
)
.
Is the ‘MS establishment’ biased; the case for addressing gender inequality in the field of MS?
.
Multiple Sclerosis and Related Disorders
vol.
28
,
153
-
154
.
Reyes S, Giovannoni G, Thomson A
(
2018
)
.
Social capital: Implications for neurology
.
Brain and Behavior
vol.
9
,
(
1
)
Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A et al.
(
2018
)
.
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
.
Multiple Sclerosis and Related Disorders
vol.
29
,
157
-
167
.
Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J et al.
(
2018
)
.
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
.
Multiple Sclerosis Journal
vol.
24
,
(
14
)
1862
-
1870
.
Yeandle D, Rieckmann P, Giovannoni G, Alexandri N, Langdon D
(
2018
)
.
Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier
.
Neurology and Therapy
vol.
7
,
(
2
)
179
-
187
.
Giovannoni G
(
2018
)
.
The unintended consequences of NICE
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
90
,
(
3
)
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al.
(
2018
)
.
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies
.
Multiple Sclerosis and Related Disorders
vol.
27
,
247
-
253
.
Vermersch P, Giovannoni G, Soelberg-sorensen P, Keller B, Jack D
(
2018
)
.
Clinical Efficacy Is Sustained in Relapsing Remitting Multiple Sclerosis Following Treatment Switch to Placebo from Cladribine Tablets in Patients with High Disease Activity at Baseline
.
Multiple Sclerosis and Related Disorders
vol.
26
,
Arnold D, Banwell B, Bar-or A, Ghezzi A, Greenberg B, Waubant E, Giovannoni G, Wolinsky J et al.
(
2018
)
.
Effects of Fingolimod on MRI Outcomes in Patients with Pediatric-onset Multiple Sclerosis: Results from the Phase 3 ParadigMS Study
.
Multiple Sclerosis and Related Disorders
vol.
26
,
Schippling S, Sormani MP, De Stefano N, Giovannoni G, Galazka A, Keller B, Alexandri N
(
2018
)
.
In Clarity the Severity and Frequency of Relapses are Lower in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets Versus Placebo
.
Multiple Sclerosis and Related Disorders
vol.
26
,
Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C et al.
(
2018
)
.
International consensus on quality standards for brain health-focused care in multiple sclerosis
.
Multiple Sclerosis Journal
vol.
25
,
(
13
)
1809
-
1818
.
Kappos L, Vermersch P, Fox R, Bar-or A, Cree B, Giovannoni G, Gold R, Masior T et al.
(
2018
)
.
Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions
.
Multiple Sclerosis and Related Disorders
vol.
26
,
255
-
256
.
Cook S, Giovannoni G, Vermersch P, Soelberg-sorensen P, Keller B, Jack D
(
2018
)
.
Lymphopenia Rates in Clarity/clarity Extension Are Unrelated to Disease Activity at Baseline
.
Multiple Sclerosis and Related Disorders
vol.
26
,
Giovannoni G, Keller B, Jack D
(
2018
)
.
No Evidence of Disease Activity-3 Status Is Durable in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: Clarity Extension
.
Multiple Sclerosis and Related Disorders
vol.
26
,
259
-
260
.
Cook S, Giovannoni G, Leist T, Syed S, Nolting A, Schick R
(
2018
)
.
Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
.
Multiple Sclerosis and Related Disorders
.
vol.
26
,
Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K et al.
(
2018
)
.
e-Health and multiple sclerosis: An update
.
Mult Scler
vol.
24
,
(
13
)
1657
-
1664
.
Waubant E, Giovannoni G, Hawkes C, Levy M
(
2018
)
.
Vaccines and disease-modifying treatments
.
Multiple Sclerosis and Related Disorders
vol.
26
,
a1
-
a2
.
Sorensen PS, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G
(
2018
)
.
The Multiple Sclerosis Care Unit
.
Multiple Sclerosis Journal
vol.
25
,
(
5
)
627
-
636
.
Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol‐Bhullar G, Garren H et al.
(
2018
)
.
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
.
Annals of Neurology
.
vol.
84
,
527
-
536
.
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G
(
2018
)
.
Inclusion criteria used in trials of people with progressive multiple sclerosis
.
Mult Scler1352458518803769
-
1352458518803769
.
Sormani MP, De Stefano N, Giovannoni G, Langdon D, Piani-Meier D, Haering DA, Kappos L, Tomic D
(
2018
)
.
Learning ability correlates with brain atrophy and disability progression in RRMS
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
90
,
(
1
)
Dobson R, Giovannoni G
(
2018
)
.
Multiple Sclerosis - a review
.
Eur J Neurol
vol.
26
,
27
-
40
.
Levy M, Giovannoni G, Hawkes C, Waubant E
(
2018
)
.
Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica
.
Multiple Sclerosis and Related Disorders
vol.
25
,
(
JAMA Neurol. 2018
)
a1
-
a2
.
Cook S, Comi G, Giovannoni G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F, Hicking C
(
2018
)
.
THUR 192 Yearly lymphopenia rates in cladribine tablets-treated rms patients
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
a27
-
a28
.
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L et al.
(
2018
)
.
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
.
New England Journal of Medicine
vol.
379
,
(
11
)
1017
-
1027
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
WED 182 Cladribine tablets effects on lymphocytes in ms patients
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2018
)
.
WED 184 Cladribine tablets in clarity patients with high disease activity ms
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
a25
-
a26
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2018
)
.
WED 185 Clarity: mri outcomes in high disease activity relapsing ms
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
a26
-
a26
.
Stuve O, Soelberg-Sorensen P, Giovannoni G, Leist T, Hyvert Y, Damian D, Boschert U
(
2018
)
.
WED 186 Effect of cladribine tablets on immune cells in patients with ms
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K
(
2018
)
.
Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis
.
Brain
Moneim J, Coles A, Giovannoni G, Horne R, Carr O
(
2018
)
.
Women on multiple sclerosis clinical trial steering committees
.
Annals of Neurology
vol.
84
,
(
2
)
329
-
330
.
Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D et al.
(
2018
)
.
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
.
BMJ Open
vol.
8
,
(
8
)
BO XUENONG, GUSHCHINA S, PRYCE G, YIP P, WU D, PALLIER P, GIOVANNONI G, BAKER D
(
2018
)
.
Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss
.
Glia
vol.
66
,
(
10
)
2108
-
2125
.
Casha S, Rice T, Stirling DP, Silva C, Gnanapavan S, Giovannoni G, Hurlbert RJ, Yong VW
(
2018
)
.
Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial
.
Journal of Neurotrauma
vol.
35
,
(
16
)
1918
-
1928
.
Hawkes CH, Giovannoni G, Levy M, Waubant E
(
2018
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
24
,
a1
-
a2
.
Holden DW, Gold J, Hawkes CH, Giovannoni G, Saxton JM, Carter A, Sharrack B
(
2018
)
.
Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts
.
Multiple Sclerosis and Related Disorders
vol.
25
,
197
-
199
.
Giovannoni G
(
2018
)
.
Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein?
.
Brain
vol.
141
,
(
8
)
2235
-
2237
.
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K
(
2018
)
.
Cladribine: mechanisms and mysteries in multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
89
,
(
12
)
Giovannoni G, Hawkes C, Levy M, Waubant E
(
2018
)
.
Is cognitive impairment in multiple sclerosis reversible?
.
Multiple Sclerosis and Related Disorders
vol.
23
,
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al.
(
2018
)
.
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study
.
Multiple Sclerosis and Related Disorders
vol.
24
,
123
-
128
.
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al.
(
2018
)
.
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
vol.
4
,
(
2
)
2055217318783767
-
2055217318783767
.
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al.
(
2018
)
.
Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine
.
Multiple Sclerosis and Related Disorders
vol.
24
,
20
-
27
.
Giovannoni G
(
2018
)
.
Disease-modifying treatments for early and advanced multiple sclerosis
.
Current Opinion in Neurology
vol.
31
,
(
3
)
233
-
243
.
Marshall I, Thrippleton MJ, Bastin ME, Mollison D, Dickie DA, Chappell FM, Semple SIK, Cooper A et al.
(
2018
)
.
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study
.
Journal of Neurology
vol.
265
,
(
8
)
1795
-
1802
.
Fox E, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Han J et al.
(
2018
)
.
033 Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE)
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
Cook S, Comi G, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, Dangond F, King J et al.
(
2018
)
.
039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
Traboulsee A, Arnold D, Klawiter EC, Havrdova E, Fiore D, Zheng R, Julian L, Giovannoni G
(
2018
)
.
060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE)
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Lublin F, Wang Q, Model F, Wei W et al.
(
2018
)
.
061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE)
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
Butzkueven H, Hobart J, Bowen A, Eberhard L, Pepper G, Giovannoni G
(
2018
)
.
064 Expert consensus on standards for multiple sclerosis care: results from a modified delphi process
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
Giovannoni G, Montalban X, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P et al.
(
2018
)
.
067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
89
,
Jacobs BM, Giovannoni G, Schmierer K
(
2018
)
.
No Evident Disease Activity-More Than a Risky Ambition?
.
JAMA Neurol
Giovannoni G, Sorensen PS, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C et al.
(
2018
)
.
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
.
Multiple Sclerosis Journal
vol.
25
,
(
6
)
819
-
827
.
Waubant E, Berkowitz A, Giovannoni G, Hawkes C, Levy M
(
2018
)
.
Diagnosing and caring for MS in Haiti
.
Multiple Sclerosis and Related Disorders
vol.
22
,
a1
-
a2
.
Chitnis T, Giovannoni G, Trojano M
(
2018
)
.
Complexity of MS management in the current treatment era
.
Neurology
vol.
90
,
(
17
)
761
-
762
.
Giovannoni G, Barkhof F, Hartung H-P, Cree B, Krieger S, Montalban X, Sormani MP, Uccelli A et al.
(
2018
)
.
ARPEGGIO: a placebo-controlled trial of oral laquinimod in primary progressive multiple sclerosis (S8.003)
.
Neurology
.
vol.
90
,
Ceronie B, Dubuisson N, Jacobs BM, Mao Z, Ammoscato F, Lock H, Longhurst H, Giovannoni G et al.
(
2018
)
.
Cladribine for the Effective Control of Multiple Sclerosis via Memory B Cell Depletion (S52.007)
.
Neurology
.
vol.
90
,
Gold R, Giovannoni G, Phillips JT, Fox RJ, Yang L, Taylor C
(
2018
)
.
Delayed-release Dimethyl Fumarate Demonstrates Long-term, Sustained Efficacy in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis followed for at least Eight-Years (P6.382)
.
Neurology
.
vol.
90
,
Cook S, Comi G, Giovannoni G, Rieckmann P, Soerensen PS, Vermersch P, Dangond F, Hicking C
(
2018
)
.
Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)
.
Neurology
.
vol.
90
,
Banwell B, Arnold D, Bar-Or A, Ghezzi A, Greenberg B, Waubant E, Giovannoni G, Wolinsky J et al.
(
2018
)
.
Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study (S51.005)
.
Neurology
vol.
90
,
(
15_supplement
)
Benedict RH, Cree B, Tomic D, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P et al.
(
2018
)
.
Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study (S44.004)
.
Neurology
.
vol.
90
,
Soerensen PS, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364)
.
Neurology
.
vol.
90
,
Ceronie B, Dubuisson N, Ammoscato F, Baker D, Giovannoni G, Schmierer K
(
2018
)
.
Memory B Cells: Toward a Unified Therapeutic Target for Effective Immunotherapy in Multiple Sclerosis (P5.365)
.
Neurology
.
vol.
90
,
Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Chai Y, Zhu B, Castrillo-Viguera C et al.
(
2018
)
.
Overall Response Score: A Novel Disability Endpoint That Allows for the Integrated Assessment of Improvement and Worsening over Time in Patients with MS (P4.380)
.
Neurology
.
vol.
90
,
Mao Z, Alvarez-Gonzalez C, Yildiz O, Allen-Philbey K, Turner B, Gnananpavan S, Marta M, Mathews J et al.
(
2018
)
.
Personalised dosing of cladribine for people with multiple sclerosis (P3.400)
.
Neurology
.
vol.
90
,
Tomic D, Kappos L, Meier DP, Häring D, Meinert R, Giovannoni G, Chitnis T
(
2018
)
.
Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients With Relapsing–Remitting Multiple Sclerosis (P2.393)
.
Neurology
.
vol.
90
,
Sheikh S, Calabresi P, Giovannoni G, Kapoor R, Arnold DL, Chai Y, Zhu B, Castrillo-Viguera C et al.
(
2018
)
.
Predictors of an Opicinumab Treatment Effect and Identification of an Efficacy Subpopulation: A Post hoc Analysis of the SYNERGY Study (P3.408)
.
Neurology
.
vol.
90
,
Gold R, Radue E-W, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Stefoski D, Sprenger T et al.
(
2018
)
.
Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390)
.
Neurology
.
vol.
90
,
Stuve O, Soerensen PS, Giovannoni G, Leist T, Hyvert Y, Damian D, Boschert U
(
2018
)
.
Selective and Discontinuous Reduction of B and T Lymphocytes and NK Cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) after Administration of Cladribine Tablets (P5.351)
.
Neurology
.
vol.
90
,
Dubuisson N, Laws M, Paterson A, Turner B, Thomson A, Westcott M, Giovannoni G
(
2018
)
.
Self-monitoring visual function in Neurology (S16.008)
.
Neurology
.
vol.
90
,
Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al.
(
2018
)
.
The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. (P2.346)
.
Neurology
.
vol.
90
,
Cree B, Fox R, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Magnusson B, Rouyrre N et al.
(
2018
)
.
Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study (S8.005)
.
Neurology
.
vol.
90
,
Giovannoni G, Kappos L, Havrdová E, Bourkhis E
(
2018
)
.
Absence de signes d’activité de la maladie avec le traitement par le daclizumab bêta versus l’interféron bêta-1a intramusculaire dans les sous-groupes de patients de l’étude DECIDE
.
Revue Neurologique
vol.
174
,
Levy M, Giovannoni G, Hawkes C, Waubant E
(
2018
)
.
Editors’ Welcome Pregnancy and progressive multifocal leukoencephalopathy
.
Multiple Sclerosis and Related Disorders
vol.
21
,
a1
-
a2
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
Numération des cellules immunitaires innées chez les patients atteints de sclérose en plaques récurrente-rémittente (SEP-RR) traités par cladribine comprimés à la dose de 3,5mg/kg dans les études CLARITY/CLARITY Extension
.
Revue Neurologique
vol.
174
,
Giovannoni G, Vermersch P, Dangond F, Hicking C
(
2018
)
.
Proportions de patients atteints d’une forme très active de SEP récurrente ne présentant aucun signe d’activité de la maladie en réponse au traitement par cladribine comprimés dans l’étude CLARITY
.
Revue Neurologique
vol.
174
,
Giovannoni G, Vermersch P, Dangond F, Hicking C
(
2018
)
.
Résultats radiologiques obtenus avec cladribine comprimés dans des sous-groupes de patients atteints d’une forme active de sclérose en plaques récurrente dans l’étude CLARITY
.
Revue Neurologique
vol.
174
,
Lebrun-Frenay C, Kobelt G, Traboulsee A, Giovannoni G, MS SBHI
(
2018
)
.
Sclérose en plaques : le temps compte. Recommandations d’un consensus international pour faciliter l’accès au diagnostic et aux traitements
.
Revue Neurologique
vol.
174
,
s88
-
s89
.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL et al.
(
2018
)
.
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
.
The Lancet
vol.
391
,
(
10127
)
1263
-
1273
.
Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ et al.
(
2018
)
.
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
.
Journal of Neurology
vol.
265
,
(
5
)
1199
-
1209
.
Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, Giovannoni G, Hartung H-P et al.
(
2018
)
.
Human Endogenous Retroviruses in Neurological Diseases
.
Trends in Molecular Medicine
vol.
24
,
(
4
)
379
-
394
.
Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung H-P, Kappos L, Lublin F, Selmaj K et al.
(
2018
)
.
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
.
Mult Scler J Exp Transl Clin
vol.
4
,
(
1
)
2055217318760642
-
2055217318760642
.
Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V et al.
(
2018
)
.
Corrigendum to ‘Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies [Clinical Therapeutics 36 (2014) 1958–1971]
.
Clinical Therapeutics
vol.
40
,
(
5
)
Keddie S, Adams A, Kelso ARC, Turner B, Schmierer K, Gnanapavan S, Malaspina A, Giovannoni G et al.
(
2018
)
.
No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation
.
Journal of Neurology
vol.
265
,
(
5
)
1089
-
1095
.
Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung H, Havrdova E, Kappos L et al.
(
2018
)
.
Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management
.
European Journal of Neurology
vol.
25
,
(
5
)
739
-
746
.
Giovannoni G, Hawkes C, Levy M, Waubant E
(
2018
)
.
Are the high-costs of MS disease-modifying therapies justified?
.
Multiple Sclerosis and Related Disorders
vol.
20
,
a3
-
a5
.
Hawkes C, Giovannoni G, Levy M, Waubant E
(
2018
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
20
,
(
Mult. Scler. Relat. Disord. 2018
)
a1
-
a2
.
Noyce AJ, Dickson J, Rees RN, Bestwick JP, Isaias IU, Politis M, Giovannoni G, Warner TT et al.
(
2018
)
.
Dopamine reuptake transporter–single‐photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease
.
Movement Disorders
vol.
33
,
(
3
)
478
-
482
.
Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, Dangond F, Giovannoni G
(
2018
)
.
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
.
Ther Adv Neurol Disord
vol.
11
,
1756285617753365
-
1756285617753365
.
Sormani M, Giovannoni G, Wolff R, Duffy S, Kinter E, Wakeford C, Hyde R, Kleijnen J et al.
(
2018
)
.
VP167 Comparison Of Methodology In Mixed Treatment Comparisons Of Treatments For Multiple Sclerosis
.
International Journal of Technology Assessment in Health Care
vol.
33
,
(
S1
)
226
-
226
.
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al.
(
2018
)
.
Alemtuzumab depletion failure can occur in multiple sclerosis
.
Immunology
vol.
154
,
(
2
)
253
-
260
.
John N, Solanky B, DeAngelis F, Stutters J, Prados F, Plantone D, Tur C, Doshi A et al.
(
2018
)
.
A neurometabolic profile of SPMS: the relationship between brain metabolites and clinical disability
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
72
-
72
.
Giovannoni G, Rammohan K, Cook S, Soelberg-Sorensen P, Vermersch P, Keller B, di Cantogno EV
(
2018
)
.
An exploratory analysis of the efficacy of cladribine tablets 3.5mg/kg in patients with relapsing multiple sclerosis stratified according to age above and below 45 years in the CLARITY study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
681
-
682
.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Hicking C et al.
(
2018
)
.
Analysis of Relapse Rates and Relapse-Free Patients in the CLARITY and CLARITY Extension Studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
396
-
396
.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Hicking C et al.
(
2018
)
.
Analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
NP4
-
NP5
.
Schippling S, Sormani MP, De Stefano N, Giovannoni G, Galazka A, Keller B, Alexandri N
(
2018
)
.
CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
258
-
259
.
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al.
(
2018
)
.
Cladribine personalised dosing in people with MS (n>200) - four years experience in clinical care
.
Stuve O, Soelberg-Sorensen P, Giovannoni G, Leist T, Hyvert Y, Damian D, Boschert U
(
2018
)
.
Cladribine tablets produce selective and discontinuous reduction in B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY extension)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
NP6
-
NP6
.
Stuve O, Soelberg-Sorensen P, Giovannoni G, Leist T, Hyvert Y, Damian D, Boschert U
(
2018
)
.
Cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes and natural killer cells in patients with early and relapsing Multiple Sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
527
-
527
.
Giovannoni G, Keller B, Jack D
(
2018
)
.
Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY extension
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
479
-
480
.
Giovannoni G, Hawkes C, Levy M, Lublin F, Waubant E
(
2018
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
19
,
a1
-
a2
.
Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J et al.
(
2018
)
.
Effect of Ocrelizumab on Severe Progression of Upper Extremity Impairment in Patients with Primary Progressive Multiple Sclerosis in ORATORIO
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
33
-
34
.
Cook S, Comi G, Giovannoni G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F, Hicking C
(
2018
)
.
Effectiveness of Lymphocyte-Based Re-Treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia with Cladribine Tablets 3.5 mg/kg
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
49
-
49
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2018
)
.
Efficacy of Cladribine Tablets 3.5 mg/ kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
396
-
397
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2018
)
.
Efficacy of cladribine tablets 3.5 mg/kg in high disease activity (HDA) subgroups of patients with relapsing multiple sclerosis (RMS) in the CLARITY study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
NP6
-
NP6
.
Giovannoni G, Montalban X, Damian D, Dangond F
(
2018
)
.
Efficacy of cladribine tablets 3.5 mg/kg in patients with highly active relapsing multiple sclerosis (RMS): Pooled analysis of the double-blind cohort from CLARITY and ONWARD
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
332
-
332
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2018
)
.
Efficacy of cladribine tablets 3.5 mg/kg in patients ≤50 and >50 years of age with relapsing-remitting multiple sclerosis (RRMS): a post hoc analysis from CLARITY
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
331
-
331
.
Giovannoni G, Comi G, Cook S, Rieckmann P, Rammohan K, Soelberg-Soerensen P, Vermersch P, Martin E et al.
(
2018
)
.
Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
NP6
-
NP7
.
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al.
(
2018
)
.
Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
949
-
949
.
Hobart J, Bowen A, Eberhard L, Pepper G, Giovannoni G
(
2018
)
.
Engaging Multiple Stakeholder Groups in the Development of Standards for Multiple Sclerosis Care: A Modified Delphi Process
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
111
-
112
.
Traboulsee A, Arnold DL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hauser SL, Kappos L et al.
(
2018
)
.
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
17
-
17
.
Montalban X, Wolinsky J, Kappos L, Hauser SL, Giovannoni G, de Seze J, Bar-Or A, Masterman D et al.
(
2018
)
.
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
NP10
-
NP10
.
Jacobs B, Ammoscato F, Ceronie B, Xenakis T, Baker D, Giovannoni G, Schmierer K
(
2018
)
.
Explaining long-term depletion of memory B lymphocytes after cladribine treatment
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
894
-
894
.
Giovannoni G, Brex P, Walters E, Al-Izki S, Dhiraj D, Schmierer K
(
2018
)
.
Glatiramer acetate slows disability progression - final 10-year results from UK Risk Sharing Scheme
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
728
-
729
.
Giovannoni G, Kappos L, Berger J, Cutter G, Fox RJ, Wiendl H, Chang I, Kasliwal R et al.
(
2018
)
.
Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
296
-
296
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
Innate immune cell counts in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) treated with cladribine tablets 3.5mg/kg in CLARITY and CLARITY extension
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
528
-
528
.
Hobart J, Bowen A, Eberhard L, Pepper G, Giovannoni G
(
2018
)
.
International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
430
-
430
.
Kuhle J, Barro C, Hrusovsky K, Chang L, Jeromin A, Bridel C, Bar-Or A, Bittner S et al.
(
2018
)
.
International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
249
-
251
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
Long-Term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets (CT)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
397
-
397
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
Long-Term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 Mg/Kg: Total Lymphocytes, B-, and T-Cell Subsets
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
48
-
49
.
Comi G, Cook S, Rammohan K, Sorensen PS, Vermersch P, Adeniji AK, Dangond F, Giovannoni G
(
2018
)
.
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
vol.
11
,
1
-
11
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
Long-term lymphocyte counts in patients with RRMS treated with cladribine tablets
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
NP4
-
NP4
.
Kappos L, Vermersch P, Fox R, Bar-Or A, Cree B, Giovannoni G, Gold R, Masior T et al.
(
2018
)
.
Longer-term safety with Siponimod treatment in multiple sclerosis: pooled analysis of data from the BOLD and EXPAND trials and their extensions
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
491
-
492
.
Cook S, Giovannoni G, Vermersch P, Soelberg-Sorensen P, Keller B, Jack D
(
2018
)
.
Lymphopenia rates in CLARITY/CLARITY extension are unrelated to disease activity at baseline
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
478
-
479
.
Schippling S, Centonze D, Giovannoni G, di Cantogno EV
(
2018
)
.
MS in the 21st Century mapping study identifying the global educational offerings for multiple sclerosis patients
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
970
-
971
.
Chataway J, De Angelis F, Connick P, Parker R, Plantone D, Doshi A, John N, Stutters J et al.
(
2018
)
.
MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259]
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
986
-
987
.
Thomson A, Aldam R, Giovannoni G, Dobson R
(
2018
)
.
Making science digestible: the development of educational activities for children with a parent with MS, and the need to better engage families
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
972
-
972
.
Doshi A, De Angelis F, Muhlert N, Stutters J, Eshaghi A, Prados F, Plantone D, John N et al.
(
2018
)
.
Multiple Sclerosis Impact Scale and brain volume are independent predictors of cognitive impairment in Secondary Progressive Multiple Sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
69
-
+
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2018
)
.
Neutrophil and Monocyte Cell Numbers Remained Within Normal Limits in Patients with RRMS Treated with Cladribine Tablets 3.5 Mg/Kg (CLARITY/CLARITY EXT.)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
39
-
39
.
Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Chai Y, Zhu B, Castrillo-Viguera C et al.
(
2018
)
.
Overall Response Score: A Novel Disability Endpoint That Allows for the Integrated Assessment of Improvement and Worsening over Time in Patients with MS
.
NEUROLOGY
.
vol.
90
,
Giovannoni G, Montalban X, Hicking C, Dangond F
(
2018
)
.
Pooled analysis of the efficacy of cladribine tablets 3.5 mg/kg in patients with EDSS ≥3.5 or
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
329
-
329
.
Allen-Philbey K, Lee QM, Francis M, Giovannoni G, Schmierer K, Turner B
(
2018
)
.
Real-world experience of the effectiveness, safety and tolerability of dimethyl fumarate in Barts Health MS cohort
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
276
-
277
.
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Manfrini M et al.
(
2018
)
.
Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
256
-
257
.
Chang I, Giovannoni G, Kappos L, Calabresi PA, Zhu B, Sheikh S, Hyde R, Deykin A et al.
(
2018
)
.
Relationship between overall response score of disability in MS with patient-reported outcome SF-36
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
512
-
513
.
Auger S, Rack D, Bestwick J, Giovannoni G, Lees A, Schrag A, Noyce A
(
2018
)
.
Risk estimation in the years preceding diagnosis of Parkinson's disease in the PREDICT-PD cohort
.
MOVEMENT DISORDERS
.
vol.
33
,
S773
-
S774
.
Butzkueven H, Spelman T, Horakova D, Slee M, Hughes S, Solaro C, Izquierdo G, Sola P et al.
(
2018
)
.
Risk of Becoming Wheelchair-Confined in Patients with Primary Progressive Multiple Sclerosis: Data from the ORATORIO Trial and a Long-Term Real-World Cohort from MSBase Registry
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
320
-
321
.
Gold R, Radue E-W, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Stefoski D, Sprenger T et al.
(
2018
)
.
Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study
.
NEUROLOGY
.
vol.
90
,
Stuve O, Soelberg-Sorensen P, Giovannoni G, Leist T, Hyvert Y, Damian D, Boschert U
(
2018
)
.
Selective and Discontinuous Reduction of B and T Lymphocytes and NK Cells by Cladribine Tablets in Patients with Early and Relapsing MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
397
-
398
.
Stuve O, Soelberg-Sorensen P, Giovannoni G, Leist TP, Hyvert Y, Damian D, Boschert U
(
2018
)
.
Selective, Discontinuous Reduction of B and T Lymphocytes and NK Cells in Patients with Early, Relapsing MS after administration
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
38
-
38
.
Cree B, Fox R, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Tomic D, Magnusson B et al.
(
2018
)
.
Siponimod affects disability progression in SPMS patients independent of relapse activity: results from the phase III EXPAND study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
70
-
71
.
Benedict RH, Cree B, Tomic D, Fox R, Giovannoni G, Bar-or A, Gold R, Vermersch P et al.
(
2018
)
.
Siponimod improves cognitive processing speed in patients with SPMS: Results from Phase 3 EXPAND Study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
432
-
432
.
De Angelis F, Stutters J, Eshaghi A, Garcia A, Prados F, Plantone D, Doshi A, John NA et al.
(
2018
)
.
Spinal cord area is a stronger predictor of physical disability than brain volume in secondary progressive Multiple Sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
25
,
23
-
23
.
Vermersch P, Giovannoni G, Soelberg-Sorensen P, Keller B, Jack D
(
2018
)
.
Sustained efficacy in relapsing remitting multiple sclerosis following switch to placebo treatment from cladribine tablets in patients with high disease activity at baseline
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
268
-
269
.
Allen-Philbey K, Yildiz O, Raciborska D, Stennett A, Mathews J, Turner B, Giovannoni G, Schmierer K
(
2018
)
.
Systematic multidimensional clinical point-of-care monitoring of people with multiple sclerosis using 3test
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
569
-
569
.
Chitnis T, Arnold DL, Banwell B, Bruck W, Ghezzi A, Giovannoni G, Greenberg B, Krupp LB et al.
(
2018
)
.
The Paradigms Study: A Randomized Double-Blind Trial of Fingolimod Versus Interferon β-1a in Patients with Multiple Sclerosis Aged 10 to < 18 Years
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
21
-
22
.
Giovannoni G
(
2018
)
.
What are the implications of retrospectively applying the 2017 McDonald MS diagnostic criteria to patients with CIS?
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
24
,
330
-
330
.
Shribman S, Hasan H, Hadavi S, Giovannoni G, Noyce AJ
(
2017
)
.
The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis
.
Journal of Neurology
vol.
265
,
(
2
)
285
-
290
.
Allen-Philbey K, Albor C, Raciborska D, Turner B, Giovannoni G, Schmierer K
(
2017
)
.
PO109 Is there an ethnicity bias of access to multiple services in the nhs? – the barts health experience
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Giovannoni G, Ziemssen T, Ma W, Fam S
(
2017
)
.
PO111 Daclizumab efficacy in highly active rrms: select/decide
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Giovannoni G, Kappos L, Havrdova E, Khatri BO, Gauthier SA, Greenberg SJ, Wang P, Giannattasio G
(
2017
)
.
PO114 Neda achievement by time interval with daclizumab
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Dubuisson N, Bauer A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K et al.
(
2017
)
.
PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Giovannoni G, Arnold DL, Bar-Or A, de Seze J, Hemmer B, Montalban X, Belachew S, Bernasconi C et al.
(
2017
)
.
PO127 Composite confirmed disability progression in oratorio
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
de Seze J, Bar-Or A, Giovannoni G, Hemmer B, Kappos L, Lublin F, Wolinsky J, Li C et al.
(
2017
)
.
PO128 Infusion-related reactions with ocrelizumab in rms and ppms
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Giovannoni G, Arnold DL, Bar-Or A, Havrdová E, Kappos L, Lublin F, Traboulsee A, Belachew S et al.
(
2017
)
.
PO129 Neda analysis by epoch in the opera studies of ocrelizumab
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Gnanapavan S, Marta M, Baker D et al.
(
2017
)
.
PO134 Personalised dosing of cladribine to treat multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2017
)
.
PO135 Cladribine tablets in rrms: lymphocyte counts
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Hicking C et al.
(
2017
)
.
PO136 Durable efficacy of cladribine tablets: clarity+extension
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
a48
-
a48
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
PO137 Efficacy of cladribine tablets in high disease activity rms
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
PO138 High disease activity in relapsing multiple sclerosis (rms)
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Schmierer K, Herrod S, Alvarez-Gonzalez C, Giovannoni G, Baker D
(
2017
)
.
PO149 A new perspective on autoimmunity after alemtuzumab
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Schmierer K, Marta M, Pryce G, Giovannoni G, Baker D
(
2017
)
.
PO150 Memory b cells are key for immunotherapy in multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
a52
-
a52
.
Shafei R, Fourali S, Hateley S, Dubuisson N, Davidson H, Turner B, Gnanapavan S, Giovannoni G et al.
(
2017
)
.
PO151 Infections in patients with multiple sclerosis on alemtuzumab – should antibiotic prophylaxis be standard?
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Group: MOTMITSCS, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G et al.
(
2017
)
.
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group
.
Multiple Sclerosis and Related Disorders
vol.
19
,
153
-
160
.
Giovannoni G
(
2017
)
.
Personalized medicine in multiple sclerosis
.
Neurodegenerative Disease Management
vol.
7
,
(
6s
)
13
-
17
.
Waubant E, Giovannoni G, Hawkes C, Lublin F
(
2017
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
18
,
a1
-
a2
.
Baker D, Giovannoni G, Schmierer K
(
2017
)
.
Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment
.
Multiple Sclerosis and Related Disorders
Cohan S, Kappos L, Giovannoni G, Wiendl H, Selmaj K, Havrdová EK, Rose J, Greenberg S et al.
(
2017
)
.
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
.
Multiple Sclerosis Journal
vol.
24
,
(
14
)
1883
-
1891
.
Giovannoni G
(
2017
)
.
Cladribine to Treat Relapsing Forms of Multiple Sclerosis
.
Neurotherapeutics
vol.
14
,
(
4
)
874
-
887
.
Lublin F, Giovannoni G, Hawkes C, Waubant E
(
2017
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
17
,
a1
-
a2
.
Dubuisson N, Paterson A, Turner B, Westcott M, Thomson A, Giovannoni G
(
2017
)
.
Self-monitoring visual function via a smartphone application
.
Journal of the Neurological Sciences
.
vol.
381
,
Dobson R, Cock HR, Brex P, Giovannoni G
(
2017
)
.
Vitamin D supplementation
.
Practical Neurology
vol.
18
,
(
1
)
Giovannoni G, Wiendl H, Turner B, Umans K, Mokliatchouk O, Castro-Borrero W, Greenberg SJ, McCroskery P et al.
(
2017
)
.
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta
.
Multiple Sclerosis Journal
vol.
24
,
(
13
)
1725
-
1736
.
Giovannoni G, Sorensen PS, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK et al.
(
2017
)
.
Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
.
Multiple Sclerosis Journal
vol.
24
,
(
12
)
1594
-
1604
.
Havrdova E, Arnold DL, Cohen JA, Hartung H-P, Fox EJ, Giovannoni G, Schippling S, Selmaj KW et al.
(
2017
)
.
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
.
Neurology
vol.
89
,
(
11
)
1107
-
1116
.
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung H-P, Havrdova E, Schippling S, Selmaj KW et al.
(
2017
)
.
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
.
Neurology
vol.
89
,
(
11
)
1117
-
1126
.
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al.
(
2017
)
.
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test
.
Multiple Sclerosis and Related Disorders
vol.
17
,
172
-
176
.
Hawkes C, Giovannoni G, Lublin F, Waubant E
(
2017
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
16
,
a1
-
a2
.
Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K
(
2017
)
.
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
.
JAMA Neurol
vol.
74
,
(
8
)
961
-
969
.
Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL
(
2017
)
.
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM
.
Clinical Therapeutics
vol.
39
,
(
8
)
1671
-
1679
.
Giovannoni G, Bermel R, Phillips T, Rudick R
(
2017
)
.
A brief history of NEDA
.
Multiple Sclerosis and Related Disorders
vol.
20
,
228
-
230
.
Kobelt G, Giovannoni G
(
2017
)
.
Tackling comorbidity in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
17
,
144
-
145
.
BAKER D
(
2017
)
.
Big conductance calcium-activated potassium channel openers control spasticity without sedation
.
British Journal of Pharmcology
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre MJ
(
2017
)
.
Psychiatric disorders in children with demyelinating diseases of the central nervous system
.
Multiple Sclerosis Journal
vol.
24
,
(
9
)
1243
-
1250
.
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K
(
2017
)
.
Disease modification in advanced MS: Focus on upper limb function
.
Multiple Sclerosis Journal
vol.
23
,
(
14
)
1956
-
1957
.
Giovannoni G, Hawkes C, Waubant E, Lublin F
(
2017
)
.
The ‘Field Hypothesis’: rebound activity after stopping disease-modifying therapies
.
Multiple Sclerosis and Related Disorders
vol.
15
,
a1
-
a2
.
Lee PR, Johnson TP, Gnanapavan S, Giovannoni G, Wang T, Steiner JP, Medynets M, Vaal MJ et al.
(
2017
)
.
Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β
.
J Neuroinflammation
vol.
14
,
(
1
)
131
-
131
.
Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J et al.
(
2017
)
.
Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
17
,
32
-
40
.
Giovannoni G
(
2017
)
.
The neurodegenerative prodrome in multiple sclerosis
.
The Lancet Neurology
vol.
16
,
(
6
)
413
-
414
.
Dubuisson N, Puentes F, Giovannoni G, Gnanapavan S
(
2017
)
.
Science is 1% inspiration and 99% biomarkers
.
Multiple Sclerosis
vol.
23
,
(
11
)
1442
-
1452
.
Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K
(
2017
)
.
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
.
Annals of Clinical and Translational Neurology
Giovannoni G
(
2017
)
.
Can we afford not to prevent MS-related disability?
.
Multiple Sclerosis Journal
vol.
23
,
(
8
)
1048
-
1049
.
Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V
(
2017
)
.
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set
.
Neurol Neuroimmunol Neuroinflamm
vol.
4
,
(
4
)
e358
-
e358
.
Wolinsky J, Montalban X, Kappos L, Hauser S, Giovannoni G, de Seze J, Bar-Or A, Masterman D et al.
(
2017
)
.
Evaluation of no evidence of progression or active disease (nepad) in patients with primary progressive multiple sclerosis in the oratorio trial
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
88
,
Absoud M, Brex P, Ciccarelli O, Diribe O, Giovannoni G, Hellier J, Howe R, Holland R et al.
(
2017
)
.
A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)
.
Health Technology Assessment
vol.
21
,
(
31
)
1
-
50
.
BAKER D, Giovannoni G, Sefia E, Pryce G, Meier U
(
2017
)
.
Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis
.
Multiple Sclerosis and Related Disorders
Waubant E, Giovannoni G, Hawkes C, Lublin F
(
2017
)
.
Editors' welcome
.
Multiple Sclerosis and Related Disorders
vol.
14
,
a1
-
a2
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2017
)
.
Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension (P5.379)
.
Neurology
.
vol.
88
,
Schippling S, Traboulsee A, Barnett M, Comi G, De Sèze J, Giovannoni G, Pelletier D, Rovira A et al.
(
2017
)
.
Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II (P5.339)
.
Neurology
.
vol.
88
,
Chitnis T, Arnold D, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L et al.
(
2017
)
.
Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-β-1a (P1.347)
.
Neurology
.
vol.
88
,
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351)
.
Neurology
.
vol.
88
,
Steinerman JR, Davis MD, Knappertz V, Giovannoni G, Wolinsky JS
(
2017
)
.
Disability Progression and Cerebrospinal Fluid Status in PPMS: Re-Analysis of the ProMiSe Clinical Trial Data Set (P2.354)
.
Neurology
.
vol.
88
,
Arnold DL, Barnett M, Comi G, Giovannoni G, Pelletier D, Rovira A, Schippling S, Van Wijmeersch B et al.
(
2017
)
.
Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study (S10.002)
.
Neurology
.
vol.
88
,
Soelberg-Sorensen P, Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Vermersch P, Hicking C et al.
(
2017
)
.
Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies (P6.353)
.
Neurology
.
vol.
88
,
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study (P6.360)
.
Neurology
.
vol.
88
,
Gold R, Giovannoni G, Phillips JT, Fox RJ, Xiao J, Taylor C
(
2017
)
.
Efficacy of Delayed-release Dimethyl Fumarate at Seven-Year Follow-up in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM and ENDORSE (P6.352)
.
Neurology
.
vol.
88
,
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Arnould S et al.
(
2017
)
.
Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study (CT.002)
.
Neurology
.
vol.
88
,
Wolinsky J, Montalban X, Kappos L, Hauser S, Giovannoni G, de Seze J, Bar-Or A, Masterman D et al.
(
2017
)
.
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial (P4.384)
.
Neurology
.
vol.
88
,
Kobelt G, Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Ziemssen T
(
2017
)
.
Maximizing brain health in multiple sclerosis: a quality improvement framework (P3.371)
.
Neurology
.
vol.
88
,
Giovannoni G, Miravalle A, Cohan S, Umans K, Fam S
(
2017
)
.
Return of MS Disease Activity after Daclizumab Discontinuation Did Not Exceed Baseline Levels in SELECT/SELECTION Studies (P2.400)
.
Neurology
.
vol.
88
,
Fox R, Kappos L, Bar-Or A, Cree B, Giovannoni G, Gold R, Vermersch P, Pohlmann H et al.
(
2017
)
.
Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis (S33.007)
.
Neurology
.
vol.
88
,
Giovannoni G, Steiner D, Sellebjerg F, Cohan S, Jeffery D, Rog D, Chen Y, Dong Q et al.
(
2017
)
.
Sustained Disability Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from ASCEND (P5.359)
.
Neurology
.
vol.
88
,
Thomson A, Raciborska D, Baker D, Giovannoni G
(
2017
)
.
How to start a blog
.
Pract Neurol
vol.
17
,
(
3
)
224
-
228
.
Giovannoni G, Tomic D, Bright JR, Havrdová E
(
2017
)
.
"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis
.
Multiple Sclerosis
vol.
23
,
(
9
)
1179
-
1187
.
Lublin F, Giovannoni G, Hawkes C, Waubant E
(
2017
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
13
,
Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL
(
2017
)
.
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
.
Eur J Neurol
vol.
24
,
(
5
)
726
-
733
.
Giovannoni G, Kappos L, Havrdová E, Greenberg S, Wang P, Giannattasio G, Bourkhis E
(
2017
)
.
Absence de signes d’activité de la maladie selon la période avec un traitement par daclizumab versus interféron bêta-1a dans l’étude DECIDE
.
Revue Neurologique
vol.
173
,
Vermesch P, Giovannoni G, Havrdová E, Kappos L, Belachew S, Han J, Hauser SL
(
2017
)
.
Analyse de l’absence d’activité clinique et IRM (NEDA) par périodes chez les patients atteints de SEP-R traités par ocrelizumab. Résultats des études de phase III : OPERA I et OPERA II
.
Revue Neurologique
vol.
173
,
s117
-
s118
.
Giovannoni G, Vermersch P, Martin E, Dangond F, EXTENSION GDCC
(
2017
)
.
Efficacité clinique de Cladribine comprimés (CC) chez les patients atteints de récurrente-rémittente (SEP-RR) : résultats finaux de l’étude d’extension de Phase IIIb à 120 semaines de l’étude CLARITY
.
Revue Neurologique
vol.
173
,
Noyce AJ, Schrag A, Masters JM, Bestwick JP, Giovannoni G, Lees AJ
(
2017
)
.
Subtle motor disturbances in PREDICT-PD participants
.
J Neurol Neurosurg Psychiatry
vol.
88
,
(
3
)
212
-
217
.
Giovannoni G, Vermersch P, Hicking C, Adeniji A, Dangond F, group CCES
(
2017
)
.
Éfficacité durable de Cladribine comprimés chez les patients atteints de (SEP) : analyse des taux de poussées et des patients sans poussées dans les études CLARITY et CLARITY Extension
.
Revue Neurologique
vol.
173
,
Dobson R, Kuhle J, Middeldorp J, Giovannoni G
(
2017
)
.
Epstein-Barr-negative MS: a true phenomenon?
.
Neurol Neuroimmunol Neuroinflamm
vol.
4
,
(
2
)
e318
-
e318
.
Hawkes C, Giovannoni G, Lublin F, Waubant E
(
2017
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
12
,
a1
-
a2
.
Noyce AJ, R'Bibo L, Peress L, Bestwick JP, Adams-Carr KL, Mencacci NE, Hawkes CH, Masters JM et al.
(
2017
)
.
PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease
.
Mov Disord
vol.
32
,
(
2
)
219
-
226
.
GIOVANNONI G
(
2017
)
.
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
.
Neurology
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K
(
2017
)
.
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
.
EBioMedicine
vol.
16
,
41
-
50
.
De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP
(
2017
)
.
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
.
Multiple Sclerosis1352458517690269
-
1352458517690269
.
Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D et al.
(
2017
)
.
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses
.
Multiple Sclerosis and Related Disorders
vol.
12
,
70
-
78
.
Giovannoni G
(
2017
)
.
Should we rebrand multiple sclerosis a dementia?
.
Multiple Sclerosis and Related Disorders
vol.
12
,
79
-
81
.
von Kutzleben S, Pryce G, Giovannoni G, Baker D
(
2017
)
.
Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
.
Immunology
vol.
150
,
(
4
)
444
-
455
.
Middleton RM, Rodgers WJ, Giovannoni G, Schmierer K, Dobson R, Allen-Philbey K, Patterson A, Akbari A et al.
(
2017
)
.
A Comparison of participant supplied EDSS scores and clinically submitted data via the UK MS Register
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
153
-
154
.
Baker D, Kang AS, Gnanapavan S, Giovannoni G, Schmierer K
(
2017
)
.
A central role of B cells in MS control and causing autoimmunity after alemtuzumab
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
336
-
336
.
Kolodny S, Giovannoni G, Grinspan A, Hartung H-P, Cree BAC, Barkhof F, Uccelli A, Sormani MP et al.
(
2017
)
.
ARPEGGIO: Design of a Randomized, Placebo-Controlled Study to Evaluate Oral Laquinimod in Patients with Primary Progressive Multiple Sclerosis (PPMS)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
335
-
336
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2017
)
.
Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
NP12
-
NP12
.
Giovannoni G, Kappos L, Havrdova E, Khatri B, Chiodo L, Mokliatchouk O, Riester K, Giannattasio G
(
2017
)
.
Achievement of no evidence of disease activity with daclizumab beta versus intramuscular interferon beta-1a treatment across patient subgroups in DECIDE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
338
-
339
.
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung H-P, Havrdova E, Schippling S, Selmaj KW et al.
(
2017
)
.
Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings
.
NEUROLOGY
vol.
89
,
(
11
)
1117
-
1126
.
Schippling S, Traboulsee A, Barnett M, Comi G, De Seze J, Giovannoni G, Pelletier D, Rovira A et al.
(
2017
)
.
Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II
.
NEUROLOGY
.
vol.
88
,
Giovannoni G, de Seze J, Kappos L, Montalban X, Hauser SL, Belachew S, Bernasconi C, Buffels R et al.
(
2017
)
.
An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
494
-
494
.
Traboulsee A, Arnold DL, Klawiter EC, Havrdova E, Fiore D, Zheng H, Julian L, Giovannoni G
(
2017
)
.
Association of brain volume loss and NEDA outcomes in patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
389
-
390
.
Noyce A, Dickson J, Bestwick J, Isaias I, Politis M, Giovannoni G, Warner T, Lees A et al.
(
2017
)
.
Associations of DAT SPECT and TCS with prodromal features of Parkinson's disease: Results in PREDICT-PD participants
.
MOVEMENT DISORDERS
.
vol.
32
,
Puentes F, Giovannoni G, Kuhle J
(
2017
)
.
Autoantibodies to neurofilament light protein as a potential biomarker of treatment response and disease progression in multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
291
-
291
.
Dubuisson N, Lycke J, Axelsson M, Giovannoni G, Gnanapavan S
(
2017
)
.
CSF NCAM levels are modulated by highly-active DMTs
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
596
-
596
.
Metcalfe SM, Giovannoni G, Pan W, Banks WA
(
2017
)
.
Can the BBB be targeted for treatment of MS? Evidence that IL-6 is actively transported across the BBB in vivo by an IL-6 specific transporter reveals a novel target linked to inflammatory immunity
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
995
-
995
.
Ceronie B, Zhifeng M, Ammoscato F, Lock H, Longhurst HJ, Giovannoni G, Baker D, Schmierer K
(
2017
)
.
Cladribine controls multiple sclerosis via memory B cell depletion
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
1011
-
1012
.
Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Turner B, Gnanapavan S, Marta M, Mathews J, Giovannoni G et al.
(
2017
)
.
Cladribine personalised dosing to treat multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
609
-
609
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
Cladribine tablets in high disease activity (HDA) subgroups from the CLARITY study of patients with relapsing multiple sclerosis (RMS)
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
203
-
204
.
Stuve O, Soelberg-Sorensen P, Giovannoni G, Leist T, Hyvert Y, Damian D, Boschert U
(
2017
)
.
Cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
335
-
336
.
Nagy A, Hardaker E, Bestwick J, Giovannoni G, Warner T, Lees A, Schrag A, Noyce A
(
2017
)
.
Cognition in the PREDICT-PD Cohort
.
MOVEMENT DISORDERS
.
vol.
32
,
Ziemssen T, Giovannoni G, Wiendl H, Greenberg S, Wang P, Aquino P, Giannattasio G
(
2017
)
.
Consistent effects of daclizumab in disease-modifying therapy (DMT)-naive relapsing-remitting multiple sclerosis (RRMS) patients in DECIDE
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
657
-
658
.
Giovannoni G, Ziemssen T, Ma W, Fam S
(
2017
)
.
Daclizumab HYP efficacy on disease outcome measures using an expanded definition of highly active relapsing-remitting multiple sclerosis: Results from SELECT and DECIDE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
154
-
155
.
Soelberg-Sorensen P, Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Vermersch P, Hicking C et al.
(
2017
)
.
Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies
.
NEUROLOGY
.
vol.
88
,
Giovannoni G, Hawkes C, Lublin F, Waubant E
(
2017
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
11
,
a1
-
a2
.
Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Han J et al.
(
2017
)
.
Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
658
-
659
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
Effects of cladribine tablets on radiological outcomes in high disease activity (HDA) subgroups of patients with relapsing multiple sclerosis (RMS) in the CLARITY
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
613
-
614
.
Fox R, Arnold DL, Bar-Or A, Cree B, Giovannoni G, Gold R, Vermersch P, Pohlmann H et al.
(
2017
)
.
Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
34
-
35
.
Giovannoni G, Bhan V, Centonze D, Cohan S, Ziemssen T, Easter J, Chiodo L, Jiang X et al.
(
2017
)
.
Efficacy and safety of daclizumab beta in patients with relapsing-remitting MS switching from natalizumab: rationale and study design of the phase 3b SUSTAIN study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
867
-
868
.
Phillips JT, Bar-Or A, Gold R, Giovannoni G, Fox RJ, Potts J, Soman T, Marantz J
(
2017
)
.
Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis using a composite measure of disability: Integrated analysis of the Phase 3 defines and confirms studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
155
-
156
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Yang L, Taylor C
(
2017
)
.
Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: eight-year follow-up of an integrated analysis of DEFINE, CONFIRM, and ENDORSE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
313
-
314
.
Kappos L, Vermersch P, Bar-Or A, Gold R, Fox R, Cree B, Magnusson B, Rouyrre N et al.
(
2017
)
.
Efficacy of siponimod on disability progression in SPMS patients with and without on-study relapses
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
397
-
398
.
Wolinsky J, Montalban X, Kappos L, Hauser S, Giovannoni G, de Seze J, Bar-Or A, Masterman D et al.
(
2017
)
.
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial
.
NEUROLOGY
.
vol.
88
,
Havrdova E, Arnold DL, Bar-or A, Comi G, Giovannoni G, Hartung H-P, Hauser SL, Kappos L et al.
(
2017
)
.
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
497
-
497
.
De Angelis F, Gomez AG, Parker R, Plantone D, Doshi A, Barkhof F, Stutters J, Miller DH et al.
(
2017
)
.
Examining cross-sectional relationships of optical coherence tomography, cervical cord MRI and disability in secondary progressive MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
275
-
276
.
Hobart J, Bowen A, Eberhard L, Pepper G, Giovannoni G
(
2017
)
.
Expert consensus on standards for multiple sclerosis care: results from a modified Delphi process
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
469
-
470
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
High Disease Activity (HDA) definitions in patients with Relapsing Multiple Sclerosis (RMS) receiving placebo in the CLARITY Study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
202
-
203
.
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G
(
2017
)
.
Identification of main inclusion criteria of chronic progressive multiple sclerosis clinical trials: a review
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
939
-
940
.
Kappos L, Giovannoni G, de Seze J, Montalban X, Wolinsky J, Belachew S, Deol-Bhullar G, Han J et al.
(
2017
)
.
Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
44
-
44
.
Gold R, Giovannoni G, Cree B, Vermersch P, Fox R, Bar-Or A, Magnusson B, Rouyrre N et al.
(
2017
)
.
Impact of primary endpoint definitions and patient baseline characteristics on study outcomes in progressive multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
660
-
661
.
Rammohan KW, Hartung H-P, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hauser SL et al.
(
2017
)
.
Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
31
-
32
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2017
)
.
Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
598
-
599
.
Soelberg-Sorensen P, Dangond F, Hicking C, Giovannoni G
(
2017
)
.
Long-term lymphocyte counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg: total lymphocytes, B and T cell subsets
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
310
-
310
.
Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G, Ziemssen T
(
2017
)
.
Maximizing Brain Health in Multiple Sclerosis: A Quality Improvement Framework
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
94
-
95
.
Traboulsee A, Giovannoni G, Bar-Or A, Comi G, Hartung H-P, Havrdova E, Kappos L, Lublin F et al.
(
2017
)
.
NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
18
-
19
.
Giovannoni G, Freedman MS, Hartung H-P, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F et al.
(
2017
)
.
Natalizumab improves walking and upper-limb disability compared with placebo in patients with secondary progressive multiple sclerosis: an integrated, post hoc area under the outcome-time curve analysis from the ASCEND trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
36
-
37
.
Comi G, Cristiano E, Dhib-Jalbut S, Edan G, Giovannoni G, Le Page E, Lublin F, Miller A et al.
(
2017
)
.
Neurologists' understanding of advances in multiple sclerosis (MS) across Europe, South America, and the United States
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
662
-
663
.
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Lublin F, Wang Q, Model F, Wei W et al.
(
2017
)
.
Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
309
-
310
.
Sheikh S, Calabresi PA, Giovannoni G, Kapoor R, Arnold DL, Chai Y, Zhu B, Castrillo-Viguera C et al.
(
2017
)
.
P718 Predictors of an opicinumab treatment effect and identification of an efficacy subpopulation: a post hoc analysis of the SYNERGY study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
352
-
352
.
Chitnis T, Arnold DL, Banwell B, Brueck W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L et al.
(
2017
)
.
PARADIGMS: a randomised double-blind study of fingolimod versus interferon β-1a in paediatric multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
977
-
+
.
Giovannoni G, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F et al.
(
2017
)
.
Proportions of patients with highly active RMS achieving no evidence of disease activity (NEDA) in response to cladribine tablets in CLARITY
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
600
-
600
.
Cook S, Comi G, Giovannoni G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F, Hicking C
(
2017
)
.
Rates of lymphopenia year-by-year in patients with relapsing multiple sclerosis treated and retreated with cladribine tablets 3.5mg/kg
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
317
-
318
.
Kappos L, de Seze J, Giovannoni G, Montalban X, Wolinsky J, Belachew S, Bernasconi C, Buffels R et al.
(
2017
)
.
Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: An exploratory analysis of pooled OPERA I and OPERA II studies
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
572
-
572
.
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre M
(
2017
)
.
Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study
.
NEUROLOGY
.
vol.
88
,
Stuve O, Soelberg-Sorensen P, Giovannoni G, Leist T, Hyvert Y, Damian D, Boschert U
(
2017
)
.
Selective and discontinuous reduction of B and T lymphocytes by cladribine tablets in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
413
-
414
.
Dubuisson N, Paterson A, Turner B, Thomson A, Westcott M, Giovannoni G
(
2017
)
.
Self-monitoring visual function via a smartphone application
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
162
-
162
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Taylor C, Marantz J
(
2017
)
.
Seven-year follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: Integrated analysis of DEFINE, CONFIRM, and ENDORSE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
156
-
156
.
Vermersch P, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Arnould S, Wallstroem E et al.
(
2017
)
.
The EXPAND study results: Efficacy of siponimod in secondary progressive multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
44
-
44
.
Giovannoni G, Bar-or A, Cree B, Fox R, Gold R, Vermersch P, Pohlmann H, Wallstrom E et al.
(
2017
)
.
The EXPAND study results: Safety and tolerability of siponimod in patients with secondary progressive multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
495
-
495
.
Carroll W, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C et al.
(
2017
)
.
Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
332
-
332
.
Giovannoni G, Gold R, Kappos L, Greenberg S, Ma W, Giannattasio G, Lima G
(
2017
)
.
Treatment outcomes of daclizumab in patients at high risk of transitioning to secondary progressive multiple sclerosis in DECIDE
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
24
,
60
-
60
.
Cook S, Comi G, Giovannoni G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F, Hicking C
(
2017
)
.
Year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5mg/kg in CLARITY and re-treated in CLARITY Extension
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
23
,
NP11
-
NP11
.
Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P et al.
(
2016
)
.
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study
.
Multiple Sclerosis Journal
vol.
23
,
(
13
)
1736
-
1747
.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X et al.
(
2016
)
.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
.
New England Journal of Medicine
vol.
376
,
(
3
)
221
-
234
.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G et al.
(
2016
)
.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
.
New England Journal of Medicine
vol.
376
,
(
3
)
209
-
220
.
Stavrou M, Smith D, Shaw P, Raciborska D, Silber E, Brex P, Giovannoni G, Schmierer K et al.
(
2016
)
.
REAL WORLD EXPERIENCE OF FINGOLIMOD IN MULTIPLE SCLEROSIS: THE LONDON AUDIT
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
Conference:
ABN
vol.
87
,
Davis A, Turner B, Ramadhan M, Albor C, Schmierer K, Giovannoni G
(
2016
)
.
THE BURDEN OF BLADDER DYSFUNCTION IN MULTIPLE SCLEROSIS: A MULTI-CENTRE AUDIT
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
Conference:
ABN
vol.
87
,
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al.
(
2016
)
.
TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
Conference:
MSLondon (ACTRIMS/ECTRIMS) 2016
vol.
87
,
Williams T, Pryce G, Giovannoni G, Selwood D, Baker D
(
2016
)
.
VSN16R-A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS
.
vol.
87
,
is.
12
,
Abstract:
java.sql.Clob
org.hibernate.engine.jdbc.WrappedClob
java.io.Serializable
,
Arroyo González R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, Giovannoni G, CARE-MS I and II Investigators
(
2016
)
.
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
.
Mult Scler
vol.
23
,
(
10
)
1367
-
1376
.
Giovannoni G, Berkovich R, Fernandez O, Wiendl H, Margolin D, Thangavelu K, LaGanke C, Investigators OBOTC-MIAC-MI
(
2016
)
.
ALEMTUZUMAB IMPROVES EDSS FUNCTIONAL SYSTEMS SCORES IN RRMS
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
87
,
Radue E-W, Giovannoni G, Gold R, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X et al.
(
2016
)
.
DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
87
,
Kappos L, Havrdova E, Giovannoni G, Khatri B, Greenberg S, Wang P, Elkins J, Giannattasio G
(
2016
)
.
DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
87
,
Giovannoni G, Arnold D, Bar-Or A, de Seze J, Hemmer B, Montalban X, Rammohan K, Wolinsky J et al.
(
2016
)
.
OCRELIZUMAB IN PRIMARY PROGRESSIVE MS: THE ORATORIO STUDY
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
87
,
Chataway J, Chandran S, Miller D, Connick P, Giovannoni G, Pavitt S, Stallard N, Hawkins C et al.
(
2016
)
.
RECRUITMENT IN MULTIPLE SCLEROSIS TRIALS: THE MS-SMART EXPERIENCE
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
87
,
Chataway J, Chandran S, Miller D, Connick P, Giovannoni G, Pavitt S, Stallard N, Hawkins C et al.
(
2016
)
.
THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MS – CURRENT UPDATE
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
87
,
Dobson R, Ramagopalan S, Topping J, Smith P, Solanky B, Schmierer K, Chard D, Giovannoni G
(
2016
)
.
A Risk Score for Predicting Multiple Sclerosis
.
PLoS One
vol.
11
,
(
11
)
Article
0164992
,
e0164992
-
e0164992
.
Hawkes C, Lublin F, Giovannoni G, Waubant E
(
2016
)
.
Editors' Welcome
.
Multiple Sclerosis and Related Disorders
vol.
10
,
Pakpoor J, Wotton CJ, Schmierer K, Giovannoni G, Goldacre M
(
2016
)
.
Gender identity disorders and multiple sclerosis risk: A national record-linkage study
.
MULTIPLE SCLEROSIS JOURNAL
vol.
22
,
(
13
)
1759
-
1762
.
Baker D, Anandhakrishnan A, Tuite-Dalton KA, Lockart–Jones H, Middleton RM, Ford DV, Crowe C, Giovannoni G
(
2016
)
.
How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
10
,
127
-
133
.
GIOVANNONI G, Cohen JA, Coles AJ, Hartung H-P, Havrdova E, Selmaj KW, Margolin DH, Lake SL et al.
(
2016
)
.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
.
Neurology
Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung H-P, Havrdova E et al.
(
2016
)
.
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon &bgr;-1a in MS
.
Neurology
vol.
87
,
(
14
)
1464
-
1472
.
Hawkes C, Lublin F, Giovannoni G
(
2016
)
.
Editors' Welcome
.
Multiple Sclerosis and Related Disorders
vol.
9
,
Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K
(
2016
)
.
Importance of upper limb function in advanced multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
Conference:
MSLondon (ACTRIMS/ECTRIMS) 2016
vol.
22
,
676
-
676
.
Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al.
(
2016
)
.
Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results
.
MULTIPLE SCLEROSIS JOURNAL
.
Conference:
MSLondon (ACTRIMS/ECTRIMS) 2016
vol.
22
,
188
-
189
.
Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al.
(
2016
)
.
Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results
.
MULTIPLE SCLEROSIS JOURNAL
.
Conference:
MSLondon (ACTRIMS/ECTRIMS) 2016
vol.
22
,
188
-
188
.
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre M
(
2016
)
.
Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study
.
MULTIPLE SCLEROSIS JOURNAL
.
Conference:
MSLondon (ACTRIMS/ECTRIMS) 2016
vol.
22
,
17
-
17
.
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al.
(
2016
)
.
Treating multiple sclerosis with generic cladribine
.
MULTIPLE SCLEROSIS JOURNAL
.
Conference:
MSLondon (ACTRIMS/ECTRIMS)
vol.
22
,
604
-
605
.
Chitnis T, Ghezzi A, Bajer-Kornek B, Boyko A, Giovannoni G, Pohl D
(
2016
)
.
Pediatric multiple sclerosis
.
Neurology
vol.
87
,
(
9_Supplement_2
)
s103
-
s109
.
Leary S, Giovannoni G, Howard R, Miller D, Thompson A
(
2016
)
.
Multiple Sclerosis and Demyelinating Diseases
.
Neurology
,
Wiley
Gold R, Radue E-W, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X et al.
(
2016
)
.
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
.
BMC Neurology
vol.
16
,
(
1
)
Feys P, Giovannoni G, Dijsselbloem N, Centonze D, Eelen P, Andersen SL
(
2016
)
.
The importance of a multi-disciplinary perspective and patient activation programmes in MS management
.
Multiple Sclerosis Journal
vol.
22
,
(
2_suppl
)
34
-
46
.
Giovannoni G
(
2016
)
.
Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–YES
.
Multiple Sclerosis Journal
vol.
22
,
(
11
)
1397
-
1400
.
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C et al.
(
2016
)
.
Brain health: time matters in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
9
,
s5
-
s48
.
Hawkes C, Lublin F, Giovannoni G
(
2016
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
8
,
a1
-
a2
.
Giovannoni G
(
2016
)
.
Time and brain health both matter in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
9
,
s1
-
s3
.
Rodríguez Cruz PM, Matthews L, Boggild M, Cavey A, Constantinescu CS, Evangelou N, Giovannoni G, Gray O et al.
(
2016
)
.
Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom
.
JAMA Neurology
vol.
73
,
(
8
)
954
-
954
.
Hasan H, Athauda DS, Foltynie T, Giovannoni G, Warner T, Lees AJ, Noyce A
(
2016
)
.
Objective decrement in Parkinson's disease - A new parameter for the BRAIN tap test
.
Movement Disorders
.
Conference:
20th International Congress of Parkinson's Disease and Movement Disorders
(
Berlin, Germany
)
from:
19/06/2016
to:
23/06/2016
,
vol.
31
,
S177
-
S177
.
Giovannoni G
(
2016
)
.
Why do you have to be lucky to get the MS treatment you deserve?
.
Multiple Sclerosis and Related Disorders
vol.
8
,
a3
-
a4
.
Williams T, Marta M, Giovannoni G
(
2016
)
.
IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension
.
Practical Neurology
vol.
16
,
(
3
)
235
-
239
.
Giovannoni G, Kappos L, Gold R, Khatri BO, Selmaj K, Umans K, Greenberg SJ, Sweetser M et al.
(
2016
)
.
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
.
Multiple Sclerosis and Related Disorders
vol.
9
,
36
-
46
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2016
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
7
,
a1
-
a2
.
Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K
(
2016
)
.
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
.
Practical Neurologypractneurol-2015-001
-
practneurol-2015-001
.
Giovannoni G
(
2016
)
.
Gavin Giovannoni on why time matters in multiple sclerosis
.
Neurodegenerative Disease Management
vol.
6
,
(
2
)
77
-
79
.
Nourbakhsh B, Gnanapavan S, Giovannoni G, Julian L, Spain R, Kuhle J, Waubant E
(
2016
)
.
Association of Serum Neurofilament Light Chain with Cognitive and Disability Measures in Patients with Very Early MS: A Longitudinal Study
.
NEUROLOGY
.
vol.
86
,
Nourbakhsh B, Gnanapavan S, Giovannoni G, Julian L, Spain R, Kuhle J, Waubant E
(
2016
)
.
Association of Serum Neurofilament Light Chain with Cognitive and Disability Measures in Patients with Very Early MS: A Longitudinal Study (P1.396)
.
Neurology
.
vol.
86
,
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Bhasin P et al.
(
2016
)
.
Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis (P3.084)
.
Neurology
.
vol.
86
,
Giovannoni G, Comi G, Cook S, Rieckmann P, Rammohan K, Soelberg-Soerensenn P, Vermersch P, Martin E et al.
(
2016
)
.
Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study
.
NEUROLOGY
.
vol.
86
,
Giovannoni G, Comi G, Cook S, Rieckmann P, Rammohan K, Soelberg-Soerensenn P, Vermersch P, Martin E et al.
(
2016
)
.
Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028)
.
Neurology
.
vol.
86
,
Fox E, Arnold D, Cohen J, Giovannoni G, Hartung H-P, Havrdova E, Selmaj K, Limmroth V et al.
(
2016
)
.
Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II
.
NEUROLOGY
.
vol.
86
,
Fox E, Arnold D, Cohen J, Giovannoni G, Hartung H-P, Havrdova E, Selmaj K, Limmroth V et al.
(
2016
)
.
Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II (S51.005)
.
Neurology
.
vol.
86
,
Bennett J, Cree B, Leist T, Moses H, Giovannoni G, Tsao C, Zhao J, Pan Q et al.
(
2016
)
.
Effects of Daclizumab HYP on Accumulation of Disability Exclusive of Acute Relapse in Moderately/Severely Disabled Relapsing-Remitting Multiple Sclerosis Patients: Neurophysical Composite Outcome from the DECIDE Study (P3.085)
.
Neurology
.
vol.
86
,
Montalban X, Hemmer B, Rammohan K, Giovannoni G, De Seze J, Bar-Or A, Arnold D, Sauter A et al.
(
2016
)
.
Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study
.
NEUROLOGY
.
vol.
86
,
Montalban X, Hemmer B, Rammohan K, Giovannoni G, De Seze J, Bar-Or A, Arnold D, Sauter A et al.
(
2016
)
.
Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001)
.
Neurology
.
vol.
86
,
Phillips JT, Bar-Or A, Gold R, Giovannoni G, Fox R, Potts J, Soman T, Marantz J
(
2016
)
.
Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
.
NEUROLOGY
.
vol.
86
,
Phillips JT, Bar-Or A, Gold R, Giovannoni G, Fox R, Potts J, Soman T, Marantz J
(
2016
)
.
Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P2.144)
.
Neurology
.
vol.
86
,
Pakpoor J, Wotton C, Schmierer K, Giovannoni G, Goldacre M
(
2016
)
.
Gender Identity Disorders and Multiple Sclerosis Risk: A National Record Linkage Study
.
NEUROLOGY
.
vol.
86
,
Pakpoor J, Wotton C, Schmierer K, Giovannoni G, Goldacre M
(
2016
)
.
Gender Identity Disorders and Multiple Sclerosis Risk: A National Record-Linkage Study
.
NEUROLOGY
.
vol.
86
,
Pakpoor J, Wotton C, Schmierer K, Giovannoni G, Goldacre M
(
2016
)
.
Gender identity Disorders and Multiple Sclerosis Risk: A National Record-Linkage Study
.
NEUROLOGY
.
vol.
86
,
Giovannoni G, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E, Selmaj K et al.
(
2016
)
.
Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment (P3.054)
.
Neurology
.
vol.
86
,
Gold R, Giovannoni G, Phillips JT, Fox R, Zhang A, Taylor C, Marantz J
(
2016
)
.
Longer-Term Follow-Up of the Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM, and ENDORSE
.
NEUROLOGY
.
vol.
86
,
Gold R, Giovannoni G, Phillips JT, Fox R, Zhang A, Taylor C, Marantz J
(
2016
)
.
Longer-Term Follow-Up of the Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM, and ENDORSE (P3.033)
.
Neurology
.
vol.
86
,
Giancarlo C, Giovannoni G, Cook S, Rammohan K, Soelberg-Soerensenn P, Vermersch P, Martin E, Dangond F et al.
(
2016
)
.
Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study (P2.114)
.
Neurology
.
vol.
86
,
Wiendl H, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E, Selmaj K et al.
(
2016
)
.
No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from the CARE-MS II Study
.
NEUROLOGY
.
vol.
86
,
Wiendl H, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E, Selmaj K et al.
(
2016
)
.
No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from the CARE-MS II Study (P3.059)
.
Neurology
.
vol.
86
,
May Y, Li Y, Raffel J, Craner M, Hemingway C, Giovannoni G, Overell J, Hyde R et al.
(
2016
)
.
OPTIMISE - A Web-Based Solution for Recording and Analyzing Longitudinal Multiple Sclerosis Data (P2.116)
.
Neurology
.
vol.
86
,
Coles A, Arnold D, Cohen J, Fox E, Giovannoni G, Hartung H-P, Havrdova E, Selmaj K et al.
(
2016
)
.
Patients with Active RRMS and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P3.022)
.
Neurology
.
vol.
86
,
LaGanke C, Berkovich R, Fernandez O, Fox E, Wiendl H, Margolin D, Thangavelu K, Giovannoni G
(
2016
)
.
Patients with RRMS Who Had an Inadequate Response to a Prior Therapy Demonstrated Durable Improvement in EDSS Functional Systems Scores Over 5 Years with Alemtuzumab (P6.186)
.
Neurology
.
vol.
86
,
Raftopoulos R, Hickman S, Toosy A, Sharrack B, Mallik S, Paling D, Altmann D, Yiannakas M et al.
(
2016
)
.
Prognostic Factors Associated with Axonal Loss after Optic Neuritis
.
NEUROLOGY
.
Conference:
AAN
vol.
86
,
Cook S, Comi G, Rieckmann P, Rammohan K, Soelberg-Soerensenn P, Vermersch P, Martin E, Dangond F et al.
(
2016
)
.
Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results fro the 120-Week Phase IIIb Extension Trial to the CLARITY Study
.
NEUROLOGY
.
vol.
86
,
Cook S, Comi G, Rieckmann P, Rammohan K, Soelberg-Soerensenn P, Vermersch P, Martin E, Dangond F et al.
(
2016
)
.
Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.095)
.
Neurology
.
vol.
86
,
Cook S, Rammohan K, Rieckmann P, Soelberg-Sørensenn P, Vermersch P, Hicking C, Dangond F, Giovannoni G
(
2016
)
.
Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis (P3.058)
.
Neurology
.
vol.
86
,
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C et al.
(
2016
)
.
Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access
.
NEUROLOGY
.
vol.
86
,
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C et al.
(
2016
)
.
Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access (P1.340)
.
Neurology
.
vol.
86
,
Limmroth V, Giovannoni G, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E et al.
(
2016
)
.
Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study
.
NEUROLOGY
.
vol.
86
,
Limmroth V, Giovannoni G, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E et al.
(
2016
)
.
Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study (S51.004)
.
Neurology
.
vol.
86
,
Limmroth V, Giovannoni G, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E et al.
(
2016
)
.
Treatment-Naive Patients with Active RRMS Demonstrate Durable improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I study
.
NEUROLOGY
.
vol.
86
,
Nissim A
.
COMBINATORIAL ANTIBODY PHAGE DISPLAY LIBRARIES CONSTRUCTED FROM B-CELLS INFILTRATING BRAIN TISSUE OF PEOPLE WITH PROGRESSIVE MULTIPLE SCLEROSIS
.
De Seze J, Arnold D, Giovannoni G, Montalban X, Sauter A, Chin P, Wolinsky J
(
2016
)
.
Efficacité et sécurité de l’ocrelizumab chez les patients atteints de sclérose en plaques primaire progressive : résultats d’ORATORIO, étude de phase III, en double-insu, contrôlée par placebo
.
Revue Neurologique
vol.
172
,
Matthews PM, Roncaroli F, Waldman A, Sormani MP, De Stefano N, Giovannoni G, Reynolds R
(
2016
)
.
A practical review of the neuropathology and neuroimaging of multiple sclerosis
.
Practical Neurology
vol.
16
,
(
4
)
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2016
)
.
Editors' Welcome
.
Multiple Sclerosis and Related Disorders
vol.
6
,
a1
-
a2
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL
(
2016
)
.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
.
Neurology and Therapy
vol.
5
,
(
1
)
45
-
57
.
Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Marantz JL, Yang M, Lee A
(
2016
)
.
Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
.
Multiple Sclerosis Journal - Experimental Translational and Clinical
vol.
2
,
Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Reingold S et al.
(
2016
)
.
The challenge of comorbidity in clinical trials for multiple sclerosis
.
Neurology
vol.
86
,
(
15
)
1437
-
1445
.
Giovannoni G
(
2016
)
.
How long is the presymptomatic phase of multiple sclerosis?
.
Multiple Sclerosis and Related Disorders
vol.
7
,
12
-
13
.
Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Fiest K et al.
(
2016
)
.
Recommendations for observational studies of comorbidity in multiple sclerosis
.
Neurology
vol.
86
,
(
15
)
1446
-
1453
.
Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M et al.
(
2016
)
.
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
.
Neurology Neuroimmunology & Neuroinflammation
vol.
3
,
(
2
)
Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC et al.
(
2016
)
.
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial
.
The Lancet Neurology
vol.
15
,
(
3
)
259
-
269
.
Radue E-W, Sprenger T, Vollmer T, Giovannoni G, Gold R, Havrdova E, Selmaj K, Stefoski D et al.
(
2016
)
.
Daclizumab high‐yield process reduced the evolution of new gadolinium‐enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis
.
European Journal of Neurology
vol.
23
,
(
2
)
412
-
415
.
Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E
(
2016
)
.
The effects of intrathecal rituximab on biomarkers in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
6
,
49
-
53
.
Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Marantz JL, Yang M, Lee A
(
2016
)
.
Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
.
vol.
2
,
Havrdova E, Baum K, Hartung H-P, Giovannoni G, Margolin DH, Thangavelu K, Wiendl H
(
2016
)
.
A Cohort of CARE-MS I patients had no evidence of disease activity over 4 years following 2 courses of alemtuzumab and no further treatment
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
23
,
815
-
815
.
Masters JM, Noyce AJ, Lynham S, Warner TT, Giovannoni G, Proctor GB
(
2016
)
.
A comprehensive characterisation of the salivary proteome of patients with Parkinson's disease
.
MOVEMENT DISORDERS
.
vol.
31
,
S238
-
S239
.
Davis A, Turner B, Ramadhan M, Albor C, Schmierer K, Giovannoni G
(
2016
)
.
A multi-centre audit to describe the burden of bladder dysfunction in multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
23
,
531
-
531
.
Montalban X, Hemmer B, Rammohan KW, Giovannoni G, De Seze J, Bar-Or A, Arnold DL, Sauter A et al.
(
2016
)
.
A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
17
-
17
.
Giovannoni G, Kappos L, Havrdova E, Khatri BO, Gauthier SA, Greenberg SJ, Wang P, Giannattasio G
(
2016
)
.
Achievement of no evidence of disease activity by time interval with daclizumab HYP versus intramuscular interferon beta-1a treatment in DECIDE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
317
-
318
.
Inshasi JS, Al Jumah M, Alroughani R, Compston DAS, Filippi M, Giovannoni G, Havrdova E, Yamout B et al.
(
2016
)
.
Alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis demonstrate durable slowing of brain volume loss over 5 years with most not receiving treatment for 4 years-CARE-MS I and II extension study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
NP7
-
NP7
.
Giovannoni G, Arnold DL, Bar-Or A, De Seze J, Hemmer B, Montalban X, Rammohan KW, Belachew S et al.
(
2016
)
.
An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
371
-
372
.
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Bhasin P et al.
(
2016
)
.
Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis
.
NEUROLOGY
.
vol.
86
,
Giovannoni G, Comi G, Montalban X, Hicking C, Dangond F
(
2016
)
.
Benefits of cladribine tablets on magnetic resonance imaging (MRI) outcomes in patients with multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
304
-
304
.
Giovannoni G, Montalban X, Hicking C, Dangond F
(
2016
)
.
Benefits of cladribine tablets on relapse rates and disability progression in patients with multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
305
-
305
.
Giovannoni G, Montalban X, Hicking C, Dangond F
(
2016
)
.
Benefits of cladribine tablets on the achievement of no evidence of disease activity (NEDA) status in patients with multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
303
-
304
.
Giovannoni G, Comi G, Cook S, Rieckmann P, Rammohan K, Soelberg-Sorensen P, Vermersch P, Adeniji A et al.
(
2016
)
.
Benefits of cladribine tablets on the proportion of patients with multiple sclerosis free from clinical and radiological indicators of disease activity in the CLARITY EXTENSION study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
300
-
301
.
Noyce AJ, Schrag A, Masters J, Bestwick JP, Giovannoni G, Lees AJ
(
2016
)
.
Blinded video assessment of subtle Parkinsonian signs in PREDICT-PD participants
.
MOVEMENT DISORDERS
.
vol.
31
,
S506
-
S506
.
Giovannoni G, Butzkueven H, Costello K, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP et al.
(
2016
)
.
Brain health: time matters in multiple sclerosis - developmental process and objectives of international consensus policy recommendations
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
23
,
669
-
670
.
de Stefano N, Giorgio A, Battaglini M, De Leucio A, Giovannoni G, Hicking C, Dangond F, Sormani MP
(
2016
)
.
Cladribine effect on brain volume loss and its correlation with disability progression in patients with relapsing multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
216
-
217
.
Giovannoni G, Comi G, Cook S, Rieckmann P, Rammohan K, Soelberg-Sorensen P, Vermersch P, Martin E et al.
(
2016
)
.
Clinical efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
.
SWISS MEDICAL WEEKLY
.
vol.
146
,
79S
-
79S
.
Fox E, Arnold D, Cohen J, Giovannoni G, Hartung H-P, Havrdova E, Selmaj K, Limmroth V et al.
(
2016
)
.
Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II
.
NEUROLOGY
.
vol.
86
,
Arnold DL, Barnett M, Comi G, Giovannoni G, Pelletier D, Rovira A, Schippling S, Van Wijmeersch B et al.
(
2016
)
.
Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
329
-
329
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2016
)
.
Editors' Welcome
.
Multiple Sclerosis and Related Disorders
vol.
5
,
de Stefano N, Giorgio A, Battaglini M, Giovannoni G, Hicking C, Dangond F, Sormani MP
(
2016
)
.
Effect of cladribine tablets on brain atrophy rates in patients with relapsing-remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
23
,
532
-
532
.
Bennett J, Cree B, Leist T, Moses H, Giovannoni G, Tsao C, Zhao J, Pan G et al.
(
2016
)
.
Effects of Daclizumab on Accumulation of Disability Exclusive of Acute Relapse in Moderately/Severely Disabled Relapsing-Remitting Multiple Sclerosis Patients: Neurophysical Composite Outcome from the DECIDE Study
.
NEUROLOGY
.
vol.
86
,
Giovannoni G
(
2016
)
.
Efficacy and Safety of Existing and Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
.
European Neurological Review
vol.
11
,
(
2
)
Montalban X, Hemmer B, Rammohan K, Giovannoni G, De Seze J, Bar-Or A, Arnold D, Sauter A et al.
(
2016
)
.
Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study
.
NEUROLOGY
.
vol.
86
,
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Arnould S et al.
(
2016
)
.
Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
828
-
829
.
Phillips JT, Bar-Or A, Gold R, Giovannoni G, Fox R, Potts J, Soman T, Marantz J
(
2016
)
.
Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
.
NEUROLOGY
.
vol.
86
,
Cohan S, Kappos L, Giovannoni G, Wiendl H, Selmaj K, Havrdova E, Rose J, Greenberg SJ et al.
(
2016
)
.
Efficacy of daclizumab HYP vs intramuscular interferon beta-1a on 24-week sustained disability progression using a modified multiple sclerosis functional composite
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
295
-
296
.
Fernandez O, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Marantz JL
(
2016
)
.
Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users with low clinical disease activity-Integrated analysis of the phase 3 define and confirm studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
NP3
-
NP3
.
Phillips JT, Bar-Or A, Gold R, Giovannoni G, Fox RJ, Potts J, Marantz JL
(
2016
)
.
Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing- remitting multiple sclerosis using a composite measure of disability-Integrated analysis of the phase 3 define and confirm studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
NP3
-
NP4
.
Freedman MS, Kappos L, Cree BAC, Radue E-W, Giovannoni G, Ritter S, Meier DP, Tomic D
(
2016
)
.
Efficacy of fingolimod on no evidence of disease activity (NEDA)-4 in pooled FREEDOMS and FREEDOMS II studies by subgroups of baseline characteristics
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
NP21
-
NP21
.
Wolinsky JS, Arnold D, Bar-Or A, de Seze J, Giovannoni G, Hemmer B, Rammohan KW, Sauter A et al.
(
2016
)
.
Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
67
-
68
.
Wolinsky J, Arnold D, Bar-or A, de Seze J, Giovannoni G, Hemmer B, Rammohan K, Sauter A et al.
(
2016
)
.
Efficacy of ocrelizumab in patients with primary progressive MS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
23
,
56
-
56
.
Montalban X, Arnold DL, Bar-Or A, De Seze J, Giovannoni G, Hemmer B, Rammohan K, Masterman D et al.
(
2016
)
.
Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
50
-
51
.
R'Bibo L, Mencacci NE, Schrag A, Bestwick JP, Peress L, Masters J, Giovannoni G, Lees AJ et al.
(
2016
)
.
Exploring association of GBA variants with pre-diagnostic features of PD in the PREDICT-PD cohort: A nested case-control study
.
MOVEMENT DISORDERS
.
vol.
31
,
S125
-
S125
.
Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G, Ziemssen T
(
2016
)
.
Implementing quality recommendations in multiple sclerosis care - a strategic approach to improve brain health
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
638
-
638
.
Arroyo Gonzalez R, Dive D, Dreyer M, Hupperts RMM, LaGanke C, Lycke J, Moreau T, Singer B et al.
(
2016
)
.
Improvements in quality of life over 5 years with alemtuzumab are associated with confirmed disability improvement in patients with active relapsing-remitting multiple sclerosis who had an inadequate response to prior therapy (CARE-MS II)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
382
-
383
.
Hartung H-P, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hauser SL, Hemmer B et al.
(
2016
)
.
Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
658
-
659
.
Montalban X, Arnold D, Bar-or A, de Seze J, Giovannoni G, Hemmer B, Rammohan K, Mairon N et al.
(
2016
)
.
Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS)
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
23
,
410
-
410
.
De Seze J, Arnold DL, Bar-Or A, Giovannoni G, Hartung H-P, Hauser SL, Hemmer B, Kappos L et al.
(
2016
)
.
Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
351
-
352
.
Plantone D, Solanky B, Miller D, Pavitt S, Giovannoni G, Wheeler-Kingshott CG, De Angelis F, Doshi A et al.
(
2016
)
.
Initial cross-sectional MR spectroscopy analysis of a cohort of secondary progressive MS patients enrolled in the MS-SMART trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
512
-
513
.
Giovannoni G
(
2016
)
.
Is multiple sclerosis a length-dependent central axonopathy
.
IRISH JOURNAL OF MEDICAL SCIENCE
vol.
185
,
S176
-
S176
.
Giovannoni G, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E, Selmaj K et al.
(
2016
)
.
Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment
.
NEUROLOGY
.
vol.
86
,
Connick P, Miller D, Pavitt S, Giovannoni G, Wheeler-Kingshott C, Weir C, Stallard N, Hawkins C et al.
(
2016
)
.
MS-SMART trial design and recruitment status: a multi-arm phase IIB randomised double blind placebo-controlled clinical trial comparing the efficacy of three repositioned neuroprotective drugs in secondary progressive multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
630
-
631
.
Comi G, Giovannoni G, Cook S, Rieckmann P, Rammohan K, Soelberg-Sorensen P, Vermersch P, Martin E et al.
(
2016
)
.
Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the 120-week Phase IIIb extension of the CLARITY study
.
SWISS MEDICAL WEEKLY
.
vol.
146
,
77S
-
77S
.
Vermersch P, Gold R, Holloway C, Rovira A, Giovannoni G, Toumi M
(
2016
)
.
Multi-stakeholder Colloquium – Opportunities and Challenges in Multiple Sclerosis Management
.
European Neurological Review
vol.
11
,
(
1
)
Giovannoni G, Craveiro L
(
2016
)
.
Múltipa brain health initiative: Time matters in MS
.
Sinapse
vol.
16
,
(
2
)
5
-
12
.
Kappos L, Stefano ND, Sormani MP, Giovannoni G, Haring D, Tomic D, Meier DP, Chitnis T
(
2016
)
.
NEDA as a predictor of conversion to secondary progressive multiple sclerosis in patients with relapsing-remitting multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
638
-
639
.
Giovannoni G, Arnold DL, Bar-Or A, Comi G, Hartung H-P, Havrdova E, Kappos L, Lublin F et al.
(
2016
)
.
NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from OPERA I and OPERA II, phase III studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
837
-
838
.
May Y, Li Y, Raffel J, Craner M, Hemingway C, Giovannoni G, Overell J, Hyde R et al.
(
2016
)
.
OPTIMISE - A Web-Based Solution for Recording and Analyzing Longitudinal Multiple Sclerosis Data
.
NEUROLOGY
.
vol.
86
,
De Angelis F, Cameron J, Connick P, Miller D, Pavitt S, Giovannoni G, Wheeler-Kingshott CG, Plantone D et al.
(
2016
)
.
Optical coherence tomography in secondary progressive multiple sclerosis: a baseline data report from the MS-SMART trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
250
-
251
.
Chitnis T, Arnold DL, Banwell B, Brueck W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L et al.
(
2016
)
.
PARADIGMS baseline characteristics: a randomised, double-blind study of fingolimod in paediatric patients with multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
102
-
103
.
Osborne CW, Bestwick J, Giovannoni G, Lees AJ, Schrag A, Noyce A
(
2016
)
.
Participant feedback in the PREDICT-PD study
.
MOVEMENT DISORDERS
.
vol.
31
,
S594
-
S594
.
Coles A, Arnold D, Cohen J, Fox E, Giovannoni G, Hartung H-P, Havrdova E, Selmaj K et al.
(
2016
)
.
Patients with Active RRMs and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study
.
NEUROLOGY
.
vol.
86
,
LaGanke C, Berkovich R, Fernandez O, Fox E, Wiendl H, Margolin D, Thangavelu K, Giovannoni G
(
2016
)
.
Patients with RRMS Who Had an Inadequate Response to a Prior Therapy Demonstrated Durable Improvement in EDSS Functional Systems Scores Over 5 Years with Alemtuzumab
.
NEUROLOGY
.
vol.
86
,
Gafson AR, Nicholas R, Giovannoni G, Matthews PM
(
2016
)
.
Plasma cytokine concentration changes in multiple sclerosis patients after treatment with dimethyl fumarate
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
670
-
671
.
Finnegan T, Giovannoni G
(
2016
)
.
Progressive multiple sclerosis: effectiveness of a medical education activity in improving the knowledge of novel approaches to treatment
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
370
-
370
.
Cook S, Comi G, Rieckmann P, Rammohan K, Soelberg-Sorensen P, Vermersch P, Martin E, Dangond F et al.
(
2016
)
.
Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
.
SWISS MEDICAL WEEKLY
.
vol.
146
,
78S
-
78S
.
Nourbakhsh B, Gnanapavan S, Giovannoni G, Julian L, Spain RI, Kuhle J, Waubant E
(
2016
)
.
Serum neurofilament light chain levels are associated with cognitive and disability measures in patients with very early MS: a longitudinal study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
9
-
9
.
Disanto G, Adiutori R, Dobson R, Martinelli V, Costa GD, Runia T, Evdoshenko E, Thouvenot E et al.
(
2016
)
.
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
vol.
87
,
(
2
)
126
-
129
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Xiao J, Taylor C, Marantz JL
(
2016
)
.
Seven-year follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: integrated analysis of DEFINE, CONFIRM, and ENDORSE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
296
-
297
.
Kapoor R, Steiner D, Miller A, Giovannoni G, Cohan S, Gold R, Rog D, Ho P-R et al.
(
2016
)
.
Subgroup analyses of natalizumab treatment response in ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial in patients with secondary progressive multiple sclerosis (SPMS)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
874
-
875
.
Giovannoni G, Steiner D, Sellebjerg F, Cohan S, Jeffery D, Rog D, Chen Y, Dong Q et al.
(
2016
)
.
Sustained disability improvement in patients with secondary progressive multiple sclerosis (SPMS) assessed by a multicomponent endpoint: a post hoc analysis from the ASCEND study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
671
-
672
.
Sormani MP, de Stefano N, Giovannoni G, Langdon DW, Meier DP, Haring DA, Tomic D, Kappos L
(
2016
)
.
The value of PASAT short-term training: Only a, practice effect' or does it tell us more about MS?
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
651
-
652
.
Sormani MP, Giovannoni G
(
2016
)
.
Therapeutic lag: is treatment effect delayed in progressive MS?
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
77
-
77
.
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C et al.
(
2016
)
.
Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access
.
NEUROLOGY
.
vol.
86
,
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Pepper G, Thalheim C et al.
(
2016
)
.
Time matters in multiple sclerosis-International consensus policy recommendations on diagnosis, management, and treatment access
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
NP16
-
NP16
.
Limmroth V, Giovannoni G, Arnold D, Cohen J, Coles A, Fox E, Hartung H-P, Havrdova E et al.
(
2016
)
.
Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study
.
NEUROLOGY
.
vol.
86
,
Schippling S, Rovira A, Giovannoni G, Arnold DL, Traboulsee A, Margolin DH, Thangavelu K, Filippi M
(
2016
)
.
Treatment-naive patients with active relapsing-remitting multiple sclerosis at baseline demonstrate slowing of brain volume loss with alemtuzumab: 5-year outcomes from the CARE-MS I extension study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
23
,
824
-
825
.
Thomson A, Baker D, Giovannoni G
(
2016
)
.
Using social media to communicate with people affected by multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
22
,
691
-
692
.
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S
(
2015
)
.
Optimizing treatment success in multiple sclerosis
.
Journal of Neurology
vol.
263
,
(
6
)
1053
-
1065
.
Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R et al.
(
2015
)
.
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial
.
JAMA Neurology
vol.
72
,
(
12
)
1
-
9
.
Noyce A, Bestwick J, Mencacci N, Hawkes C, Hardy J, Giovannoni G, Lees A, Schrag A
(
2015
)
.
PREDICT-PD: Identifying Risk of Parkinson's disease in the Community
.
MOVEMENT DISORDERS
.
vol.
30
,
1989
-
1989
.
Masters JM, Bestwick J, Warner TT, Giovannoni G, Proctor GB, Noyce AJ
(
2015
)
.
Systematic review and meta‐analysis of salivary protein concentration in Parkinson's disease
.
Movement Disorders
vol.
30
,
(
14
)
1971
-
1972
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2015
)
.
Editors' Welcome
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
6
)
a1
-
a2
.
Bove R, White CC, Giovannoni G, Glanz B, Golubchikov V, Hujol J, Jennings C, Langdon D et al.
(
2015
)
.
Evaluating more naturalistic outcome measures
.
Neurology Neuroimmunology & Neuroinflammation
vol.
2
,
(
6
)
Coles A, Giovannoni G, Moreau T, Havrdova E, Margolin D, Kasten L, Singer B
(
2015
)
.
ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
86
,
Thomson A, Davis A, Paterson A, Giovannoni G, Schmierer K
(
2015
)
.
DESIGNING AN INFORMATION RESOURCE TO EXPLAIN DIAGNOSTIC LUMBAR PUNCTURE AND PROMOTE BEST PRACTICE
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
86
,
Masters J, Noyce A, Giovannoni G, Warner T, Proctor G
(
2015
)
.
ELEVATED SALIVARY DJ-1 IN PARKINSON'S DISEASE IS ASSOCIATED WITH ALTERED SALIVARY SECRETION
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
86
,
Chataway J, Chandran S, Miller D, Giovannoni G, Wheeler-Kingshott C, Pavitt S, Stallard N, Hawkins C et al.
(
2015
)
.
THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A MULTI-ARM, MULTI-CENTRE TRIAL OF NEUROPROTECTION
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
86
,
Davis A, Dobson R, Kaninia S, Giovannoni G, Schmierer K
(
2015
)
.
Atraumatic needles for lumbar puncture: why haven't neurologists changed?
.
Practical Neurology
vol.
16
,
(
1
)
Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, Abourjaily H, Pace A et al.
(
2015
)
.
Clinical Significance of Gastrointestinal and Flushing Events in MS Patients Treated With Delayed-Release Dimethyl Fumarate
.
International Journal of MS Care
vol.
17
,
(
5
)
236
-
243
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2015
)
.
Editors' Welcome
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
5
)
a1
-
a2
.
Masters JM, Noyce AJ, Warner TT, Giovannoni G, Proctor GB
(
2015
)
.
Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity
.
Parkinsonism & Related Disorders
vol.
21
,
(
10
)
1251
-
1255
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2015
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
4
)
a1
-
a3
.
Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D et al.
(
2015
)
.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
.
Practical Neurology
vol.
15
,
(
4
)
Kappos L, Radue E-W, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung H-P et al.
(
2015
)
.
Switching from natalizumab to fingolimod
.
Neurology
vol.
85
,
(
1
)
29
-
39
.
Absoud M, Gadian J, Hellier J, Brex PA, Ciccarelli O, Giovannoni G, Kelly J, McCrone P et al.
(
2015
)
.
Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)
.
BMJ Open
vol.
5
,
(
5
)
Noyce AJ, Mencacci NE, Schrag A, Bestwick JP, Giovannoni G, Lees AJ, Hardy J
(
2015
)
.
Web‐based assessment of Parkinson's prodromal markers identifies GBA variants
.
Movement Disorders
vol.
30
,
(
7
)
1002
-
1003
.
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M
(
2015
)
.
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
4
)
329
-
333
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2015
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
3
)
Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P et al.
(
2015
)
.
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
.
Neurology
vol.
84
,
(
22
)
2247
-
2257
.
Lu C-H, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, Pearce N, Kuhle J et al.
(
2015
)
.
Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
.
J Neurol Neurosurg Psychiatry
vol.
86
,
(
5
)
565
-
573
.
Thomson A, Rivas C, Giovannoni G
(
2015
)
.
Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities
.
BMC Health Services Research
vol.
15
,
(
1
)
McCarthy CL, Giovannoni G, Coles AJ
(
2015
)
.
Timing is everything in the treatment of multiple sclerosis
.
BMJ Case Reports
vol.
2015
,
Brinar V, Giovannoni G, Havrdova E, Twyman C, Sharrack B, Ziemssen T, Baldinetti F, Rizzo M et al.
(
2015
)
.
A Phase 3b/4 Long-Term Study of Alemtuzumab in Patients With Relapsing-Remitting Multiple Sclerosis: TOPAZ Study Design (P7.219)
.
Neurology
vol.
84
,
(
14_supplement
)
Barkhof F, Giovannoni G, Hartung H-P, Cree B, Uccelli A, Sormani MP, Krieger S, Uitdehaag B et al.
(
2015
)
.
ARPEGGIO: A randomized, placebo-controlled study to evaluate oral laquinimod in patients with primary progressive multiple sclerosis (PPMS) (P7.210)
.
Neurology
vol.
84
,
(
14_supplement
)
Montalban X, Hemmer B, Rammohan K, Giovannoni G, De Seze J, Bar-Or A, Arnold D, Sauter A et al.
(
2015
)
.
Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017)
.
Neurology
.
vol.
84
,
Phillips J, Gold R, Giovannoni G, Fox R, Zhang A, Kurukulasuriya N
(
2015
)
.
Clinical Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P7.228)
.
Neurology
vol.
84
,
(
14_supplement
)
Koch M, Steinerman J, Knappertz V, Sasson N, Giovannoni G, Cutter G, Wolinsky J
(
2015
)
.
Comparative utility of different progression metrics in PPMS: re-analysis of the PROMiSe clinical trial dataset (P7.237)
.
Neurology
vol.
84
,
(
14_supplement
)
Havrdova E, Giovannoni G, Arnold D, Coles A, Fox E, Hartung H-P, Selmaj K, Margolin D et al.
(
2015
)
.
Durable Effect of Alemtuzumab on Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-Year Follow-up of CARE-MS II (P7.276)
.
Neurology
vol.
84
,
(
14_supplement
)
Compston A, Giovannoni G, Arnold D, Fox E, Hartung H-P, Havrdova E, Selmaj K, Margolin D et al.
(
2015
)
.
Durable Effect of Alemtuzumab on Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients: Four-Year Follow-up of CARE-MS I (S4.007)
.
Neurology
vol.
84
,
(
14_supplement
)
LaGanke C, Hughes B, Berkovich R, Cohen J, Giovannoni G, Kasten L, Margolin D, Havrdova E
(
2015
)
.
Durable Effect of Alemtuzumab on Disability Improvement in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P3.261)
.
Neurology
vol.
84
,
(
14_supplement
)
Havrdova E, Giovannoni G, Gold R, Fox R, Kappos L, Phillips JT, Zhang A, Kurukulasuriya N
(
2015
)
.
Effect of Delayed-Release Dimethyl Fumarate on No Evident Disease Activity in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P7.247)
.
Neurology
vol.
84
,
(
14_supplement
)
Fernandez O, Giovannoni G, Fox R, Gold R, Phillips JT, Okwuokenye M, Zhang A, Kurukulasuriya N
(
2015
)
.
Efficacy of Delayed-Release Dimethyl Fumarate for RRMS in Prior Interferon Users in the DEFINE and CONFIRM Studies (P7.231)
.
Neurology
.
vol.
84
,
Fox E, Giovannoni G, Arnold D, Coles A, Hartung H-P, Havrdova E, Selmaj K, Margolin D et al.
(
2015
)
.
Improvement in Clinical Outcomes Following Switch From Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study (P7.278)
.
Neurology
vol.
84
,
(
14_supplement
)
Hartung H-P, Giovannoni G, Arnold D, Coles A, Fox E, Havrdova E, Selmaj K, Margolin D et al.
(
2015
)
.
Improvement in Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients Who Switched From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.270)
.
Neurology
vol.
84
,
(
14_supplement
)
Kita M, Cohen J, Moreau T, Havrdova E, Arroyo-Gonzalez R, Herbert J, Kasten L, Margolin D et al.
(
2015
)
.
Improvement in Disability With Alemtuzumab Is Associated With Quality of Life Improvement Over 3 Years in Patients Who Relapsed on Prior Therapy (P3.260)
.
Neurology
vol.
84
,
(
14_supplement
)
Radue E-W, Giovannoni G, Gold R, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X et al.
(
2015
)
.
Long-Term Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis: 3 Year Results from the SELECTED Extension Study (P7.226)
.
Neurology
vol.
84
,
(
14_supplement
)
Gold R, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Radue E-W, Sprenger T, Montalban X et al.
(
2015
)
.
Long-Term Safety of Daclizumab HYP in Patients with Relapsing-Remitting Multiple Sclerosis: 3-4 Year Results from the SELECTED Extension Study (P7.225)
.
Neurology
vol.
84
,
(
14_supplement
)
Bar-Or A, Hutchinson M, Gold R, Fox R, Havrdova E, Giovannoni G, Potts J, Kurukulasuriya N
(
2015
)
.
Long-term Efficacy of Delayed-Release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis According to Prior Therapy: Integrated Analysis of the DEFINE, CONFIRM, and ENDORSE Studies (P7.229)
.
Neurology
vol.
84
,
(
14_supplement
)
Gold R, Giovannoni G, Phillips JT, Fox R, Zhang A, Kurukulasuriya N
(
2015
)
.
Long-term Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with RRMS: An Integrated Analysis of DEFINE, CONFIRM, and ENDORSE (P7.227)
.
Neurology
.
vol.
84
,
Giovannoni G, Havrdova E, Gold R, Fox R, Kappos L, Phillips JT, Zhang A, Kurukulasuriya N
(
2015
)
.
Long-term Follow-up of the Effect of Delayed-Release Dimethyl Fumarate on No Evidence of Disease Activity in Patients with Multiple Sclerosis (P7.280)
.
Neurology
.
vol.
84
,
Giovannoni G, Belachew S, Dong Q, Rudick R, Mikol D, Shang S
(
2015
)
.
Natalizumab Reduces Total Disability Burden Relative to Placebo in Patients with Relapsing-Remitting Multiple Sclerosis Regardless of the Occurrence of Relapses or Confirmed Disability Progression or Improvement over 2 Years in the AFFIRM Study (P7.244)
.
Neurology
vol.
84
,
(
14_supplement
)
Kita M, Kappos L, Fox R, Gold R, Giovannoni G, Phillips JT, Sarda S, Okwuokenye M et al.
(
2015
)
.
Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Delayed-Release Dimethyl Fumarate: A Three-Year Interim Analysis of ENDORSE (P7.236)
.
Neurology
vol.
84
,
(
14_supplement
)
Raftopoulos R, Chen C-L, Hickman S, Toosy A, Wheeler-Kingshott C, Altmann D, Mallik S, Paling D et al.
(
2015
)
.
Swelling of the Outer Retinal Layers in Acute Optic Neuritis (P4.042)
.
Neurology
vol.
84
,
(
14_supplement
)
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre M
(
2015
)
.
Testicular Hypofunction and Multiple Sclerosis Risk: A Record-Linkage Study (P1.101)
.
Neurology
vol.
84
,
(
14_supplement
)
Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, Francis G, Shrinivasan A et al.
(
2015
)
.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
.
Neurology
vol.
84
,
(
16
)
1639
-
1643
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2015
)
.
Editors’ welcome
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
2
)
93
-
94
.
Steele S, Freitag A, McGettigan P, Giovannoni G, Pollock AM
(
2015
)
.
A guide to private prescribing
.
Prescriber
vol.
26
,
(
6
)
19
-
23
.
Marta M, Santos E, Coutinho E, Silva AM, Correia J, Vasconcelos C, Giovannoni G
(
2015
)
.
The role of infections in Behçet disease and neuro-Behçet syndrome
.
Autoimmunity Reviews
vol.
14
,
(
7
)
609
-
615
.
Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J et al.
(
2015
)
.
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
3
)
202
-
218
.
Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, Lu C-H, Dobson R et al.
(
2015
)
.
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
.
J Neurol Neurosurg Psychiatry
vol.
86
,
(
3
)
273
-
279
.
Disanto G, Adiutori R, Dobson R, Martinelli V, Costa GD, Runia T, Evdoshenko E, Thouvenot E et al.
(
2015
)
.
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
87
,
(
2
)
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier U-C et al.
(
2015
)
.
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
.
Multiple Sclerosis Journal
vol.
21
,
(
8
)
1013
-
1024
.
Marques IB, Flanagan S, Noble H, Giovannoni G, Marta M
(
2015
)
.
Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse
.
Neurology Neuroimmunology & Neuroinflammation
vol.
2
,
(
2
)
Biela A, Watkinson M, Meier UC, Baker D, Giovannoni G, Becer CR, Krause S
(
2015
)
.
Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy
.
Biosensors and Bioelectronics
vol.
68
,
660
-
667
.
Giovannoni G
(
2015
)
.
Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis - Yes
.
Multiple Sclerosis Journal
vol.
21
,
(
2
)
134
-
136
.
Elkins J, Sheridan J, Amaravadi L, Riester K, Selmaj K, Bielekova B, Parr E, Giovannoni G
(
2015
)
.
CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS
.
Neurology Neuroimmunology & Neuroinflammation
vol.
2
,
(
2
)
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2015
)
.
Editors׳ welcome
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
1
)
1
-
2
.
Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V et al.
(
2015
)
.
Time course of clinical and neuroradiological effects of delayed‐release dimethyl fumarate in multiple sclerosis
.
European Journal of Neurology
vol.
22
,
(
4
)
664
-
671
.
Arnold DL, Traboulsee A, Cohen JA, Coles AJ, Fox EJ, Giovannoni G, Hartung H-P, Havrdova E et al.
(
2015
)
.
Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS I with the majority of patients treatment-free for 4 years
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
568
-
569
.
Traboulsee A, Cohen JA, Coles AJ, Compston DAS, Fox EJ, Giovannoni G, Hartung H-P, Havrdova E et al.
(
2015
)
.
Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
570
-
571
.
Fernandez Fernandez O, Hartung H-P, LaGanke C, Margolin DH, Kasten L, Moreau T, Giovannoni G
(
2015
)
.
Alemtuzumab has a durable effect on disability improvement in treatment-naive patients with relapsing-remitting multiple sclerosis: a 4-year follow-up of CARE-MS I
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
22
,
824
-
824
.
Montalban X, Giovannoni G, Hartung H-P, Havrdova E, Margolin DH, Kasten L
(
2015
)
.
Alemtuzumab improves disability outcomes versus subcutaneous interferon beta-1a in CARE-MS I and II patients with active relapsing multiple sclerosis using the novel SAD-plus endpoint
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
588
-
588
.
Arroyo Gonzalez R, Moreau T, Cohen JA, Giovannoni G, Margolin DH, Kasten L, Havrdova E
(
2015
)
.
Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
22
,
614
-
614
.
Barkhof F, Cohen JA, Coles AJ, Compston DAS, Filippi M, Fox EJ, Giovannoni G, Hartung H-P et al.
(
2015
)
.
Alemtuzumab slows brain volume loss over 5 years in patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE MS I and II extension study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
44
-
45
.
Havrdova E, Gold R, Fox RJ, Giovannoni G, Xiao J, Edwards MR
(
2015
)
.
Association between no evidence of disease activity (NEDA) and long-term clinical efficacy of delayed-release dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis from the phase 3 study, ENDORSE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
256
-
257
.
Raghupathi K, Pace A, Giovannoni G, Weinstock-Guttman B, Montalban X, Rudick R, Hyde R, Castrillo C et al.
(
2015
)
.
Baseline cognitive function predicts clinical disability progression in an integrated RRMS clinical trial database
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
121
-
122
.
Wiendl H, Havrdova E, Rose J, Giovannoni G, Tsao LC, Zhao J, Pan Q, Elkins J et al.
(
2015
)
.
Daclizumab high-yield process (DAC HYP) vs. intramuscular interferon beta-1a in subgroups predictive of active disease: results from the DECIDE study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
232
-
233
.
Thomson A, Davis A, Paterson A, Giovannoni G, Schmierer K
(
2015
)
.
Designing an information resource to explain diagnostic lumbar puncture and promote best practice
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
22
,
491
-
492
.
Moreau T, Arroyo Gonzalez R, Hartung H-P, Hupperts RMM, Kita M, Margolin DH, Kasten L, Giovannoni G
(
2015
)
.
Disability improvement with alemtuzumab is associated with durable improvement on functional assessment in multiple sclerosis scores over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
564
-
565
.
Wiendl H, Arnold DL, Hupperts RM, Giovannoni G, Margolin DH, Kasten L, Havrdova E
(
2015
)
.
Durable effect of alemtuzumab on disease activity in patients with relapsing-remitting multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
22
,
256
-
256
.
Giovannoni G, Berkovich R, Fernandez O, Fox EJ, Wiendl H, Margolin DH, Kasten L, LaGanke C
(
2015
)
.
Durable improvement in expanded disability status scale functional systems scores over 4 years with alemtuzumab despite a majority of patients not receiving treatment since year 1
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
571
-
572
.
Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg S, Wang P, Elkins J et al.
(
2015
)
.
Effect of daclizumab HYP versus intramuscular interferon beta-1a on no evidence of disease activity in patients with relapsing-remitting multiple sclerosis: analysis of the DECIDE study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
22
-
22
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC
(
2015
)
.
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)
.
Mult Scler
vol.
21
,
(
1
)
57
-
66
.
Montalban X, Hemmer B, Rammohan K, Giovannoni G, de Seze J, Bar-Or A, Arnold DL, Sauter A et al.
(
2015
)
.
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
781
-
782
.
Fernandez O, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL
(
2015
)
.
Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users with low clinical disease activity: integrated analysis of the phase 3 DEFINE and CONFIRM studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
687
-
687
.
Giovannoni G, Gold R, Phillips JT, Fox RJ, Lewin JB, Zhang A, Marantz JL
(
2015
)
.
Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hoc analysis of the phase 3 DEFINE and CONFIRM studies according to baseline cognitive function
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
252
-
253
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Lewin JB, Zhang A, Marantz JL
(
2015
)
.
Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post-hoc analysis of the phase 3 DEFINE and CONFIRM studies according to baseline disability
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
263
-
264
.
Freedman MS, Kappos L, Cree BAC, Radue E-W, Giovannoni G, Ritter S, Meier DP, Tomic D
(
2015
)
.
Efficacy of fingolimod on NEDA-4 in pooled FREEDOMS and FREEDOMS II studies by subgroups of baseline characteristics
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
301
-
302
.
Masters JM, Noyce AJ, Giovannoni G, Warner TT, Proctor GB
(
2015
)
.
Elevated salivary DJ-1 in Parkinson's disease is associated with altered salivary secretion
.
MOVEMENT DISORDERS
.
vol.
30
,
S169
-
S170
.
Giovannoni G, Brex P, Sumra M, Walters E, Schmierer K
(
2015
)
.
Glatiramer acetate slows disability progression - results from a 6-year analysis of the UK Risk Sharing Scheme
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
800
-
801
.
Gold J, Goldacre R, Maruszak H, Giovannoni G, Yeates D, Goldacre M
(
2015
)
.
HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study
.
J Neurol Neurosurg Psychiatry
vol.
86
,
(
1
)
9
-
12
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Kurukulasuriya NC
(
2015
)
.
Long-term efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
22
,
27
-
27
.
Giovannoni G, Havrdova E, Gold R, Fox RJ, Kappos L, Phillips JT, Zhang A, Kurukulasuriya NC
(
2015
)
.
Long-term follow-up of the effect of delayed-release dimethyl fumarate on No Evidence of Disease Activity in patients with multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
22
,
479
-
479
.
Marantz J, Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A
(
2015
)
.
Longer-term follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
263
-
263
.
Wiendl H, Giovannoni G, Greenberg S, Sheridan J, Amaravadi L, McCroskery P, Giannattasio G
(
2015
)
.
Lymphocyte counts in patients receiving daclizumab HYP in DECIDE
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
266
-
267
.
Koch MW, Steinerman JR, Knappertz V, Davis MD, Giovannoni G, Cutter GR, Wolinsky JS
(
2015
)
.
MRI measures and disability progression in PPMS: analysis of the PROMiSe clinical trial dataset
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
46
-
46
.
Raftopoulos R, Hickman S, Toosy A, Sharrack B, Mallik S, Altmann D, Malladi P, Koltzenburg M et al.
(
2015
)
.
Neuroprotection with phenytoin in acute optic neuritis: results of a phase II randomised controlled trial
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
22
,
48
-
48
.
Gold J, Giovannoni G, Marta MC, Meier U, Miller D, Christensen T, Maruszak H, Holden D et al.
(
2015
)
.
Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
162
-
162
.
Vermersch P, Giovannoni G, Cohen JA, Moreau T, Wray S, Margolin DH, Kasten L
(
2015
)
.
Quality of life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
621
-
621
.
Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R et al.
(
2015
)
.
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies
.
CLINICAL THERAPEUTICS
vol.
37
,
(
11
)
2543
-
2551
.
Giovannoni G, Kappos L, Gold R, Khatri B, Selmaj K, Umans K, Greenberg S, Sweetser M et al.
(
2015
)
.
Safety and tolerability of daclizumab HYP in patients with relapsing-remitting multiple sclerosis: an integrated analysis of six clinical studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
254
-
254
.
Gnanapavan S, Grant D, Morant S, Nourbakhsh B, Revirajan N, Azevedo C, Pelletier D, Waubant E et al.
(
2015
)
.
Serum neurofilament light chain levels are associated with brain atrophy in early MS - analysis from the randomized controlled phase II trial of riluzole in early MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
355
-
356
.
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Bhasin P et al.
(
2015
)
.
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
317
-
318
.
Raftopoulos R, Rangarajan A, Chen C-L, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Malik S et al.
(
2015
)
.
Sodium channel blockade with phenytoin has a neuroprotective effect on the ganglion cell complex after acute optic neuritis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
273
-
274
.
Arroyo Gonzalez R, Moreau T, Hartung H-P, Hupperts RM, Kita M, Margolin DH, Kasten L, Giovannoni G
(
2015
)
.
Sustained reduction in disability with alemtuzumab is associated with durable quality-of-life improvement on SF-36 over 4 years in CARE-MS II patients with RRMS though most were treatment-free after year 1
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
600
-
601
.
Giovannoni G, Baker D, Schmierer K
(
2015
)
.
The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
1
)
3
-
5
.
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D
(
2014
)
.
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids
.
Journal of Neuroimmune Pharmacology
vol.
10
,
(
2
)
281
-
292
.
Gnanapavan S, Giovannoni G
(
2014
)
.
Developing Biomarkers for MS
.
Current Topics in Behavioral Neurosciences
vol.
26
,
179
-
194
.
Marques IB, Giovannoni G, Marta M
(
2014
)
.
Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept
.
BMC Neurology
vol.
14
,
(
1
)
Fine D, Dattani A, Moreira I, Giovannoni G, Marta M
(
2014
)
.
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
1
)
88
-
91
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2014
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
6
)
Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G
(
2014
)
.
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
.
Advances in Therapy
vol.
31
,
(
11
)
1134
-
1154
.
Gnanapavan S, Yousaf N, Heywood W, Grant D, Mills K, Chernajovsky Y, Keir G, Giovannoni G
(
2014
)
.
Growth associated protein (GAP-43): cloning and the development of a sensitive ELISA for neurological disorders
.
J Neuroimmunol
vol.
276
,
(
1-2
)
18
-
23
.
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Lam E et al.
(
2014
)
.
P036 Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
6
)
Pakpoor J, Handel AE, Disanto G, Davenport RJ, Giovannoni G, Ramagopalan SV
(
2014
)
.
National survey of UK medical students on the perception of neurology
.
BMC Medical Education
vol.
14
,
(
1
)
Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J et al.
(
2014
)
.
A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe
.
Multiple Sclerosis and Related Disorders
vol.
4
,
(
1
)
83
-
84
.
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre MJ
(
2014
)
.
Reply
.
Annals of Neurology
vol.
76
,
(
5
)
765
-
766
.
Dua P, Jacobson L, Church A, Martino D, Sisay S, Vincent A, Lang B, Giovannoni G et al.
(
2014
)
.
Detection of antibodies against the N-methyl-d-aspartate receptor in a sub-group of patients diagnosed with Tourette's syndrome
.
Journal of Neuroimmunology
.
vol.
275
,
Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R et al.
(
2014
)
.
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
.
Journal of Neurology
vol.
261
,
(
12
)
2429
-
2437
.
Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre MJ
(
2014
)
.
Testicular hypofunction and multiple sclerosis risk: a record-linkage study
.
Ann Neurol
vol.
76
,
(
4
)
625
-
628
.
Sisay S, Rosello A, Henseleit K, Tan M, Marta-caldo M, Dua P, Warnes G, Palace J et al.
(
2014
)
.
Unaltered frequency and functionality of CD56bright and CD56dim natural killer cells in untreated relapsing–remitting multiple sclerosis patients
.
Journal of Neuroimmunology
.
vol.
275
,
Giovannoni G, Baker D, Schmierer K
(
2014
)
.
Simvastatin in patients with progressive multiple sclerosis
.
Lancet
vol.
384
,
(
9947
)
Cooper R, Doshi A, Harris P, Sivagnanasundaram J, Wells G, Barritt A, Aram J, Giovannoni G et al.
(
2014
)
.
IMMUNOCOMPETENT PML—AN IMMUNOLOGICAL SCOTOMA?
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
85
,
e4
-
e4
.
Pakpoor J, Handel A, Disanto G, Davenport R, Giovannoni G, Ramagopalan S
(
2014
)
.
SURVEY OF UK MEDICAL STUDENTS ON THE PERCEPTION OF NEUROLOGY
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
85
,
e4
-
e4
.
Schmierer K, Marta M, Turner B, Giovannoni G
(
2014
)
.
THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
85
,
e4
-
e4
.
Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S
(
2014
)
.
Natalizumab reduces relapse clinical severity and improves relapse recovery in MS
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
6
)
705
-
711
.
Pakpoor J, Goldacre R, Disanto G, Giovannoni G, Goldacre MJ
(
2014
)
.
Alcohol misuse disorders and multiple sclerosis risk
.
JAMA Neurol
vol.
71
,
(
9
)
1188
-
1189
.
Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R et al.
(
2014
)
.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
.
Journal of Neurology
vol.
261
,
(
9
)
1794
-
1802
.
Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G et al.
(
2014
)
.
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis
.
Mult Scler
vol.
20
,
(
10
)
1355
-
1362
.
Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A et al.
(
2014
)
.
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders
.
Neurology
vol.
83
,
(
13
)
1210
-
1216
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2014
)
.
Editors׳ welcome
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
5
)
553
-
554
.
Arnold DL, Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M et al.
(
2014
)
.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
.
Journal of Neurology
Shahim P, Tegner Y, Adiutori R, Ladenson JH, Macy EH, Crimmins D, Mattsson N, Giovannoni G et al.
(
2014
)
.
P3‐078: SERUM NEUROFILAMENT LIGHT PROTEIN AND VISIN‐LIKE PROTEIN‐1 IN CONCUSSED PROFESSIONAL ICE HOCKEY PLAYERS
.
Alzheimer's & Dementia
vol.
10
,
(
4S_Part_18
)
p655
-
p655
.
Shribman S, Torsney KM, Noyce AJ, Giovannoni G, Fearnley J, Dobson R
(
2014
)
.
A service development study of the assessment and management of fracture risk in Parkinson's disease
.
J Neurol
vol.
261
,
(
6
)
1153
-
1159
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2014
)
.
Editors׳ welcome
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
4
)
417
-
418
.
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, McNeill M et al.
(
2014
)
.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
.
Lancet Neurol
vol.
13
,
(
5
)
472
-
481
.
Ramien C, Pachnio A, Sisay S, Begum J, Leese A, Disanto G, Kuhle J, Giovannoni G et al.
(
2014
)
.
Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort
.
Mult Scler
vol.
20
,
(
6
)
751
-
753
.
Hartung H-P, Barkhof F, Fernandez O, Hobart J, Giovannoni G, Sormani MP, Dadon Y, Sasson N et al.
(
2014
)
.
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Laquinimod 0.6mg or 1.2mg QD versus IFNβ-1a in Patients with Relapsing Remitting Multiple Sclerosis (P3.153)
.
Neurology
vol.
82
,
(
10_supplement
)
Dobson R, Topping J, Chard D, Schmierer K, Smith P, Ramagopalan S, Giovannoni G
(
2014
)
.
A Multivariate Risk Calculator for Multiple Sclerosis and Study of an Endophenotype in Siblings of People with Multiple Sclerosis (S34.002)
.
Neurology
vol.
82
,
(
10_supplement
)
Havrdova E, Gold R, Fox R, Kappos L, Phillips JT, Zhang A, Kurukulasuriya N, Sheikh S et al.
(
2014
)
.
Effect of Delayed-Release Dimethyl Fumarate on Freedom from Measured Clinical and Neuroradiological Disease Activity in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: An Integrated Analysis of DEFINE and CONFIRM (P3.159)
.
Neurology
vol.
82
,
(
10_supplement
)
Kappos L, Fox R, Gold R, Kita M, Phillips JT, Sarda S, Zhong L, Niecko T et al.
(
2014
)
.
Effect of Delayed-Release Dimethyl Fumarate on Health-Related Quality of Life in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P3.162)
.
Neurology
vol.
82
,
(
10_supplement
)
Amaravadi L, Mikulskis A, McNeill M, Riester K, Sweetser M, Elkins J, Giovannoni G
(
2014
)
.
Evaluation of Immunogenicity in Multiple Sclerosis Patients Treated with Daclizumab-HYP During the SELECT and SELECTION Clinical Trials (P3.177)
.
Neurology
vol.
82
,
(
10_supplement
)
Giovannoni G, Naismith RT
(
2014
)
.
Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes
.
Neurology
vol.
82
,
(
14
)
1196
-
1197
.
Pakpoor J, Handel A, Disanto G, Davenport R, Giovannoni G, Ramagopalan S
(
2014
)
.
National Survey of UK Medical Students on the Perception of Neurology (P1.331)
.
Neurology
vol.
82
,
(
10_supplement
)
Raftopoulos R, Hickman S, Toosy A, Wheeler-Kingshott C, Altmann D, Mallik S, Paling D, Yiannakas M et al.
(
2014
)
.
OCT, Visual Function and MRI Measures in Acute Optic Neuritis: Baseline Data from a Clinical Trial (P2.255)
.
Neurology
vol.
82
,
(
10_supplement
)
Comi G, Sormani MP, Giovannoni G, Ladkani D, Sasson N, Gorfine T, Knappertz V
(
2014
)
.
Rationale For Advancing Laquinimod For Progressive MS: Evidence From Large Clinical Trials In RRMS (S4.001)
.
Neurology
vol.
82
,
(
10_supplement
)
Giovannoni G, Margolin D, Palmer J, Herbert J
(
2014
)
.
Sustained Improvement in Disability Outcomes with Alemtuzumab in Active Relapsing-Remitting Multiple Sclerosis Patients Who Participated in CARE-MS II: Three-year Follow-up (P3.165)
.
Neurology
vol.
82
,
(
10_supplement
)
Kita M, Fox R, Gold R, Giovannoni G, Phillips JT, Sarda S, Okwuokenye M, Kong J et al.
(
2014
)
.
Two-Year Interim Analysis of Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Delayed-Release Dimethyl Fumarate in the ENDORSE Study (P4.178)
.
Neurology
vol.
82
,
(
10_supplement
)
Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker D, Amor S et al.
(
2014
)
.
Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis
.
J Neurol Neurosurg Psychiatry
vol.
85
,
(
3
)
274
-
278
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2014
)
.
Editors׳ welcome
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
3
)
Davis A, Dobson R, Kaninia S, Espasandin M, Berg A, Giovannoni G, Schmierer K
(
2014
)
.
Change practice now! Using atraumatic needles to prevent post lumbar puncture headache
.
Eur J Neurol
vol.
21
,
(
2
)
305
-
311
.
Giovannoni G, Radue E-W, Havrdova E, Riester K, Greenberg S, Mehta L, Elkins J
(
2014
)
.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
.
J Neurol
vol.
261
,
(
2
)
316
-
323
.
Dua P, Warnes G, Chruch A, Martino D, Baker D, Giovannoni G, Meier UC
(
2014
)
.
Functional effects of anti-neuronal antibodies from patients with Tourette's syndrome and disorders associated with streptococcal infection
.
Neurology Psychiatry and Brain Research
vol.
20
,
(
1
)
17
-
18
.
Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G
(
2014
)
.
Assessing treatment response to interferon-β: is there a role for MRI?
.
Neurology
vol.
82
,
(
3
)
248
-
254
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2014
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
2
)
139
-
140
.
Lim ET, Giovannoni G
(
2014
)
.
Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis
.
Expert Review of Neurotherapeutics
vol.
5
,
(
3
)
379
-
390
.
Pakpoor J, Nyein S, Disanto G, Nwosu A, Baker D, Giovannoni G
(
2014
)
.
A global analysis of the use of social media to discuss multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
334
-
335
.
Shribman SE, Torsney K, Noyce AJ, Giovannoni G, Fearnley J, Dobson R
(
2014
)
.
A service development study of the assessment and management of fracture risk in Parkinson's disease
.
MOVEMENT DISORDERS
.
vol.
29
,
S192
-
S192
.
Pakpoor J, Goldacre R, Disanto G, Giovannoni G, Goldacre MJ
(
2014
)
.
Alcohol Misuse Disorders and Multiple Sclerosis Risk
.
JAMA NEUROLOGY
vol.
71
,
(
9
)
1188
-
U217
.
Pakpoor J, Goldacre R, Disanto G, Giovannoni G, Goldacre M
(
2014
)
.
Alcohol-use disorders and multiple sclerosis risk: a national record-linkage study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
148
-
149
.
Sarda SP, Kita M, Fox RJ, Gold R, Giovannoni G, Phillips T, Okwuokenye M, Kong J et al.
(
2014
)
.
An interim analysis of quality of life in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
413
-
414
.
Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G
(
2014
)
.
Assessing treatment response to interferon-β Is there a role for MRI?
.
NEUROLOGY
vol.
82
,
(
3
)
248
-
254
.
Noyce AJ, Nagy A, Acharya S, Hadavi S, Bestwick JP, Fearnley J, Lees AJ, Giovannoni G
(
2014
)
.
Bradykinesia-akinesia incoordination test: validating an online keyboard test of upper limb function
.
PLoS One
vol.
9
,
(
4
)
Giovannoni G
(
2014
)
.
Cerebrospinal fluid analysis
.
Handb Clin Neurol
vol.
122
,
681
-
702
.
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A et al.
(
2014
)
.
Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists
.
FASEB J
vol.
28
,
(
1
)
117
-
130
.
Disanto G, Sandve GK, Ricigliano VAG, Pakpoor J, Berlanga-Taylor AJ, Handel AE, Kuhle J, Holden L et al.
(
2014
)
.
DNase hypersensitive sites and association with multiple sclerosis
.
HUMAN MOLECULAR GENETICS
vol.
23
,
(
4
)
942
-
948
.
Havrdova E, Gold R, Fox RJ, Kappos L, Phillips JT, Zhang A, Kurukulasuriya NC, Sheikh SI et al.
(
2014
)
.
Delayed-release dimethyl fumarate and freedom from measured clinical and neuroradiologic disease activity in relapsing-remitting multiple sclerosis (RRMS) patients: integrated analysis of DEFINE and CONFIRM
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
21
,
459
-
459
.
Kappos L, Fox RJ, Gold R, Kita M, Phillips JT, Sarda SP, Zhong L, Niecko T et al.
(
2014
)
.
Delayed-release dimethyl fumarate and health-related quality of life (HRQoL) in relapsing-remitting multiple sclerosis (RRMS) patients according to prior therapy: integrated analysis of DEFINE and CONFIRM
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
21
,
462
-
462
.
Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Zhang R, Viglietta V et al.
(
2014
)
.
Delayed-release dimethyl fumarate and relapses requiring intravenous steroid use and MS-related hospitalizations: integrated analysis of the phase 3 DEFINE and CONFIRM studies
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
21
,
457
-
457
.
Havrdova E, Giovannoni G, Stefoski D, Forster S, Umans K, Mehta L, Greenberg S, Elkins J
(
2014
)
.
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study
.
MULTIPLE SCLEROSIS JOURNAL
vol.
20
,
(
4
)
464
-
470
.
Kita M, Fox R, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V et al.
(
2014
)
.
Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
.
CLINICAL THERAPEUTICS
vol.
36
,
(
12
)
1958
-
1971
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Rana J, Zhang A, Meltzer L, Kurukulasuriya NC
(
2014
)
.
Efficacy of Oral BG-12 (Dimethyl Fumarate) in Patients Newly Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Analysis of DEFINE and CONFIRM
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
931
-
932
.
Fernandez O, Giovannoni G, Fox RJ, Gold R, Phillips JT, Yang M, Zhang A, Kurukulasuriya NC
(
2014
)
.
Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders" to prior treatment with interferon beta
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
21
,
25
-
25
.
Fernandez O, Giovannoni G, Fox RJ, Gold R, Phillips JT, Yang M, Zhang A, Kurukulasuriya NC
(
2014
)
.
Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders'' to prior treatment with interferon beta
.
JOURNAL OF NEUROLOGY
.
vol.
261
,
S19
-
S20
.
Noyce AJ, Mencacci N, Schrag A, Giovannoni G, Lees AJ, Hardy J
(
2014
)
.
GBA1 and LRRK2 mutations in higher and lower risk subjects from the PREDICT-PD project
.
MOVEMENT DISORDERS
.
vol.
29
,
S58
-
S59
.
Sadovnick AD, Lee JD, Ramagopalan SV, Dyment DA, Hanwell H, Giovannoni G, Criscuoli M, Yee IM et al.
(
2014
)
.
Genetic and Environmental Risk Factors for Multiple Sclerosis among Iranian Immigrants in Canada
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
909
-
910
.
Disanto G, Dobson R, Pakpoor J, Elangovan RI, Adiutori R, Gobbi C, Kuhle J, Giovannoni G
(
2014
)
.
Genetic predictors of multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
253
-
253
.
Al-Izki S, Pryce G, Hankey DJR, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C et al.
(
2014
)
.
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis
.
Brain
vol.
137
,
(
Pt 1
)
92
-
108
.
Baker D, Pepper G, Yauner F, Giovannoni G
(
2014
)
.
MSer - A new, neutral descriptor for someone with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
1
)
31
-
33
.
Guimond C, Lee JD, Ramagopalan SV, Dyment DA, Hanwell H, Giovannoni G, Criscuoli M, Yee IM et al.
(
2014
)
.
Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors
.
MULTIPLE SCLEROSIS JOURNAL
vol.
20
,
(
9
)
1182
-
1188
.
Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Knowles CH, Hardy J, Giovannoni G, Nageshwaran S et al.
(
2014
)
.
PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
vol.
85
,
(
1
)
31
-
37
.
Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S et al.
(
2014
)
.
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study
.
MULTIPLE SCLEROSIS JOURNAL
vol.
20
,
(
2
)
243
-
252
.
Giovannoni G, Heesen C
(
2014
)
.
Shared decision making in the evolving multiple sclerosis (MS) treatment landscape
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
1015
-
1015
.
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Lam E et al.
(
2014
)
.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
20
,
927
-
928
.
Shribman SE, Noyce AJ, Martin JE, Giovannoni G, Knowles CH
(
2014
)
.
The distribution of α-synuclein in the enteric nervous system: An immunohistochemical study on colonic resections from 24 control and 4 Parkinson's disease patients
.
MOVEMENT DISORDERS
.
vol.
29
,
1839
-
1839
.
Disanto G, Dobson R, Pakpoor J, Elangovan RI, Adiutori R, Kuhle J, Giovannoni G
(
2014
)
.
The refinement of genetic predictors of multiple sclerosis
.
PLoS One
vol.
9
,
(
5
)
Raffel J, Dobson R, Gafson A, Mattoscio M, Muraro P, Giovannoni G
(
2013
)
.
Multiple sclerosis therapy and Epstein–Barr virus antibody titres
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
3
)
372
-
374
.
Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, Baker D, Chandran S
(
2013
)
.
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis
.
Acta Neuropathologica Communications
vol.
1
,
(
1
)
Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G et al.
(
2013
)
.
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors
.
Mult Scler
vol.
19
,
(
14
)
1896
-
1904
.
Kuhle J, Malmeström C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, Giovannoni G, Kappos L et al.
(
2013
)
.
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis
.
Acta Neurol Scand
vol.
128
,
(
6
)
e33
-
e36
.
Hadavi S, Giovannoni G, Dobson R
(
2013
)
.
A service development audit of fampridine use in ms
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
11
)
Shribman S, Davis A, Vella N, Giovannoni G
(
2013
)
.
Heavy metal toxicity: lessons from a case of simultaneous occupational exposure to manganese and mercury
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
11
)
Gafson A, Worthington V, Lakdawala N, Giovannoni G, Farrell R
(
2013
)
.
Neutralising antibodies to interferon-Beta predict conversion to secondary progressive multiple sclerosis in patients with multiple sclerosis
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
11
)
Hadavi S, Shribman S, Nagy A, Acharya S, Fearnley J, Dobson R, Lees A, Giovannoni G et al.
(
2013
)
.
The bradykinesia-akinesia incoordination test: a simple objective test in multiple sclerosis
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
11
)
Dobson R, McMillan A, Kung K, Thom M, Davis A, Simister R, Giovannoni G, Gnanapavan S
(
2013
)
.
Think outside the box, collapse the box, and take a sharp knife to it!
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
11
)
Dobson R, Topping J, Ramagopalan S, Giovannoni G
(
2013
)
.
Towards an endophenotype in multiple sclerosis
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
11
)
Gafson AR, Giovannoni G
(
2013
)
.
CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
2
)
143
-
146
.
Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A et al.
(
2013
)
.
A comparative study of CSF neurofilament light and heavy chain protein in MS
.
Mult Scler
vol.
19
,
(
12
)
1597
-
1603
.
Lycke J, Arnold DL, Cohen JA, Coles AJ, Confavreux C, Fox EJ, Hartung H-P, Havrdova E et al.
(
2013
)
.
Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study)
.
Journal of the Neurological Sciences
vol.
333
,
e374
-
e375
.
Balcer LJ, Arnold DL, Cohen JA, Coles AJ, Confavreux C, Fox EJ, Hartung H-P, Havrdova E et al.
(
2013
)
.
Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study
.
Journal of the Neurological Sciences
vol.
333
,
Margolin DH, Rizzo MA, Smith G, Arnold DL, Cohen JA, Coles AJ, Confavreux C, Fox EJ et al.
(
2013
)
.
Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy
.
Journal of the Neurological Sciences
vol.
333
,
e375
-
e376
.
Maruszak H, Gold J, Giovannoni G
(
2013
)
.
Antiretroviral treatment in patient with secondary progressive multiple sclerosis — /INS;Impact on disease progression and safety
.
Journal of the Neurological Sciences
vol.
333
,
Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Kurukulasuriya NC et al.
(
2013
)
.
BG-12 effects on quality of life in relapsing–/INS;remitting ms patients: Integrated analysis of the Phase 3 DEFINE and CONFIRM studies
.
Journal of the Neurological Sciences
vol.
333
,
Vecchio D, Albor C, Richards OJ, Turner BP, Giovannoni G, Schmierer K
(
2013
)
.
Do disease modifying treatments improve outcome? First results from the London MS Database
.
Journal of the Neurological Sciences
vol.
333
,
Havrdova E, Phillips JT, Selmaj K, Gold R, Fox RJ, Giovannoni G, Pace A, Novas M et al.
(
2013
)
.
Gastrointestinal tolerability events in relapsing–/INS;remitting multiple sclerosis patients treated with BG-12 (dimethyl fumarate): Integrated analysis of DEFINE and CONFIRM
.
Journal of the Neurological Sciences
vol.
333
,
e368
-
e369
.
James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV
(
2013
)
.
The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis
.
Mult Scler
vol.
19
,
(
12
)
1571
-
1579
.
Leddy S, Hadavi S, McCarren A, Giovannoni G, Dobson R
(
2013
)
.
Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis
.
J Neurol
vol.
260
,
(
10
)
2505
-
2510
.
Disanto G, Handel AE, Damoiseaux J, Hupperts R, Giovannoni G, Smolders J, Ramagopalan SV
(
2013
)
.
Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients
.
Mult Scler
vol.
19
,
(
12
)
1679
-
1680
.
Dobson R, Giovannoni G
(
2013
)
.
Bone health in multiple sclerosis: should we be doing more?
.
Neurodegenerative Disease Management
vol.
3
,
(
5
)
401
-
403
.
Disanto G, Hall C, Lucas R, Ponsonby A-L, Berlanga-Taylor AJ, Giovannoni G, Ramagopalan SV, Ausimmune Investigator Group
(
2013
)
.
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis
.
Mult Scler
vol.
19
,
(
10
)
1355
-
1358
.
(
2013
)
.
Editors' welcome
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
1
)
1
-
2
.
Dobson R, Ramagopalan S, Davis A, Giovannoni G
(
2013
)
.
Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
8
)
909
-
914
.
Ramagopalan SV, Goldacre R, Disanto G, Giovannoni G, Goldacre MJ
(
2013
)
.
Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies
.
BMC Med
vol.
11
,
Baker D, Pepper G, Yauner F, Giovannoni G
(
2013
)
.
MSer – A new, neutral descriptor for someone with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
3
,
(
1
)
31
-
33
.
Handel AE, Sandve GK, Disanto G, Berlanga-Taylor AJ, Gallone G, Hanwell H, Drabløs F, Giovannoni G et al.
(
2013
)
.
Vitamin D receptor ChIP-seq in primary CD4+ cells: Relationship to serum 25-hydroxyvitamin D levels and autoimmune disease
.
BMC Medicine
vol.
11
,
(
1
)
Bolton C, Gates J, Giovannoni G
(
2013
)
.
Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE)
.
Inflamm Res
vol.
62
,
(
7
)
659
-
667
.
Banwell B, Giovannoni G, Hawkes CH, Lublin F
(
2013
)
.
Promoting regeneration and repair in Multiple Sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
2
,
(
4
)
261
-
262
.
Pakpoor J, Pakpoor J, Disanto G, Giovannoni G, Ramagopalan SV
(
2013
)
.
Cytomegalovirus and multiple sclerosis risk
.
Journal of Neurology
vol.
260
,
(
6
)
1658
-
1660
.
Pakpoor J, Pakpoor J, Disanto G, Giovannoni G, Ramagopalan SV
(
2013
)
.
Cytomegalovirus and multiple sclerosis risk
.
J Neurol
vol.
260
,
(
6
)
1658
-
1660
.
Gnanapavan S, Ho P, Heywood W, Jackson S, Grant D, Rantell K, Keir G, Mills K et al.
(
2013
)
.
Progression in multiple sclerosis is associated with low endogenous NCAM
.
J Neurochem
vol.
125
,
(
5
)
766
-
773
.
Gemma C, Ramagopalan SV, Down TA, Beyan H, Hawa MI, Holland ML, Hurd PJ, Giovannoni G et al.
(
2013
)
.
Inactive or moderately active human promoters are enriched for inter-individual epialleles
.
Genome Biol
vol.
14
,
(
5
)
Giovannoni G, Gold R, Fox RJ, Kita M, Yang M, Zhang R, Dawson KT, Viglietta V et al.
(
2013
)
.
An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies
.
Value Health
vol.
16
,
(
3
)
A101
-
A102
.
Dobson R, Giovannoni G
(
2013
)
.
Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis
.
J Neurol
vol.
260
,
(
5
)
1272
-
1285
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2013
)
.
Editorial
.
Multiple Sclerosis and Related Disorders
vol.
2
,
(
3
)
Dobson R, Yarnall A, Noyce AJ, Giovannoni G
(
2013
)
.
Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes
.
Pract Neurol
vol.
13
,
(
2
)
70
-
79
.
Pakpoor J, Handel AE, Giovannoni G, Dobson R, Ramagopalan SV
(
2013
)
.
Correction: Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine
.
PLOS ONE
vol.
8
,
(
4
)
Disanto G, Watson CT, Meier UC, Ebers GC, Giovannoni G, Ramagopalan SV
(
2013
)
.
Month of birth and thymic output
.
JAMA Neurol
vol.
70
,
(
4
)
527
-
528
.
Dobson R, Giovannoni G, Ramagopalan S
(
2013
)
.
The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude
.
J Neurol Neurosurg Psychiatry
vol.
84
,
(
4
)
427
-
432
.
Dobson R, Leddy SG, Gangadharan S, Giovannoni G
(
2013
)
.
Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems
.
BMJ Open
vol.
3
,
(
3
)
Pakpoor J, Giovannoni G, Ramagopalan SV
(
2013
)
.
Epstein-Barr virus and multiple sclerosis: association or causation?
.
Expert Rev Neurother
vol.
13
,
(
3
)
287
-
297
.
Disanto G, Pakpoor J, Morahan JM, Hall C, Meier UC, Giovannoni G, Ramagopalan SV
(
2013
)
.
Epstein-Barr virus, latitude and multiple sclerosis
.
Mult Scler
vol.
19
,
(
3
)
362
-
365
.
Dobson R, Ramagopalan SV, Giovannoni G
(
2013
)
.
Genome-wide association studies: will we ever predict susceptibility to multiple sclerosis through genetics?
.
Expert Rev Neurother
vol.
13
,
(
3
)
235
-
237
.
Giovannoni G, Bell J, Feldmann M, Thompson EJ
(
2013
)
.
Increased Urinary Neopterin Excretion in Vaccinated Adults
.
Pteridines
vol.
7
,
(
3
)
82
-
86
.
Ramagopalan SV, Giovannoni G, Yeates DG, Seagroatt V, Goldacre MJ
(
2013
)
.
Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis
.
Mult Scler
vol.
19
,
(
3
)
359
-
361
.
Kita M, Fox R, Gold R, Giovannoni G, Phillips JT, Sarda S, Kong J, Viglietta V et al.
(
2013
)
.
Effects of BG-12 (Dimethyl Fumarate) on Quality of Life in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.092)
.
Neurology
vol.
80
,
(
7_supplement
)
Giovannoni G, Gold R, Fox R, Kappos L, Kita M, Yang M, Zhang R, Dawson K et al.
(
2013
)
.
Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies (P07.121)
.
Neurology
vol.
80
,
(
7_supplement
)
Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, Giovannoni G, Ramagopalan SV
(
2013
)
.
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis
.
Mult Scler
vol.
19
,
(
2
)
162
-
166
.
Giovannoni G
(
2013
)
.
ECTRIMS 2012: Treatment highlights
.
Multiple Sclerosis and Related Disorders
vol.
2
,
(
2
)
68
-
72
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2013
)
.
Editors' welcome and a working definition for a multiple sclerosis cure
.
Multiple Sclerosis and Related Disorders
vol.
2
,
(
2
)
65
-
67
.
Leddy S, Hadavi S, McCarren A, Giovannoni G, Dobson R
(
2013
)
.
A novel internet-based method of capturing outcomes in multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
357
-
358
.
Baker D, Lidster K, Al-Izki S, Pryce G, Giovannoni G
(
2013
)
.
Animal models of progressive disability in MS
.
IRISH JOURNAL OF MEDICAL SCIENCE
vol.
182
,
S5
-
S6
.
Havrdova E, Gold R, Fox R, Kappos L, Phillips JT, Zhang A, Kurukulasuriya N, Sheikh S et al.
(
2013
)
.
BG-12 (Dimethyl Fumarate) Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies
.
NEUROLOGY
.
vol.
80
,
Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M et al.
(
2013
)
.
Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS - Neurofilament as a Surrogate of Disease Progression
.
PLOS ONE
vol.
8
,
(
8
)
Article
ARTN e70019
,
Nagy A, Acharya S, Hadavi S, Bestwick JP, Fearnley J, Lees AJ, Giovannoni G, Noyce AJ
(
2013
)
.
Bradykinesia-akinesia incoordination test: Validating an online keyboard test of upper limb function
.
MOVEMENT DISORDERS
.
vol.
28
,
S114
-
S114
.
Kuhle J, Stites T, Chen Y, Dahlke F, Francis G, Sfikas N, Radue E-W, Giovannoni G et al.
(
2013
)
.
CSF neurofilament light chain levels are markedly reduced by fingolimod in relapsing multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
559
-
560
.
Dobson R, Topping J, Davis A, Thompson E, Giovannoni G
(
2013
)
.
Cerebrospinal fluid and urinary biomarkers in multiple sclerosis
.
ACTA NEUROLOGICA SCANDINAVICA
vol.
128
,
(
5
)
321
-
327
.
Dobson R, Ramagopalan S, Davis A, Giovannoni G
(
2013
)
.
Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: A meta-analysis of prevalence, prognosis and effect of latitude
.
Journal of Neurology, Neurosurgery and Psychiatry
vol.
84
,
(
8
)
909
-
914
.
Hutchinson M, Gold R, Fox R, Havrdova E, Giovannoni G, Zhang A, Hotermans C, Stephan M et al.
(
2013
)
.
Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
.
NEUROLOGY
.
vol.
80
,
Hutchinson M, Gold R, Fox RJ, Havrdova E, Giovannoni G, Zhang A, Hotermans C, Stephan M et al.
(
2013
)
.
Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing remitting multiple sclerosis according to prior therapy: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
235
-
235
.
Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O'Gorman J, Stephan M et al.
(
2013
)
.
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study
.
JOURNAL OF NEUROLOGY
vol.
260
,
(
9
)
2297
-
2305
.
Dobson R, Topping J, Giovannoni G
(
2013
)
.
Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers
.
J Med Virol
vol.
85
,
(
1
)
128
-
131
.
Maggiore C, Giovannoni G, Martin J, Nissim A
(
2013
)
.
Construction of an antibody phage display library from B-cells infiltrating brain tissue of people with progressive multiple sclerosis
.
JOURNAL OF NEUROLOGY
vol.
260
,
S39
-
S39
.
Pakpoor J, Pakpoor J, Disanto G, Giovannoni G, Ramagopalan SV
(
2013
)
.
Cyt.lovirus and multiple sclerosis risk: a systematic review and meta-analysis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
154
-
155
.
Radue E-W, Gold R, Giovannoni G, Stefoski D, Selmaj K, You X, Elkins J
(
2013
)
.
Daclizumab HYP Reduces the Evolution of New Gadolinium-Enhancing Lesions to T1-Black Holes: Results from the SELECT Study
.
NEUROLOGY
.
vol.
80
,
Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, Robinson R et al.
(
2013
)
.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
.
LANCET
vol.
381
,
(
9884
)
2167
-
2175
.
Giovannoni G, Arnold D, Cohen J, Coles A, Confavreux C, Fox E, Hartung H, Havrdova E et al.
(
2013
)
.
Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II)
.
NEUROLOGY
.
vol.
80
,
Kappos L, Radue E-W, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Naegelin Y et al.
(
2013
)
.
Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
50
-
51
.
Miao T, Raymond M, Bhullar P, Ghaffari E, Symonds ALJ, Meier UC, Giovannoni G, Li S et al.
(
2013
)
.
Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf
.
J Immunol
vol.
190
,
(
1
)
58
-
65
.
Hutchinson M, Bar-Or A, Fox RJ, Gold R, Giovannoni G, Kita M, O'Gorman J, Yang M et al.
(
2013
)
.
Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
682
-
683
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC
(
2013
)
.
Effect of BG-12 (dimethyl fumarate) in newly diagnosed patients with relapsing-remitting multiple sclerosis from the DEFINE and CONFIRM studies
.
JOURNAL OF NEUROLOGY
vol.
260
,
S51
-
S51
.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NC
(
2013
)
.
Effect of BG-12 (dimethyl fumarate) in newly diagnosed relapsing remitting multiple sclerosis (RRMS) patients from the DEFINE and CONFIRM studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
453
-
454
.
Havrdova E, Gold R, Fox RJ, Kappos L, Phillips JT, Zhang A, Kurukulasuriya NC, Sheikh SI et al.
(
2013
)
.
Effect of BG-12 (dimethyl fumarate) on freedom from measured clinical and neuroradiological disease activity over time in patients with relapsing remitting multiple sclerosis: results from the phase 3 studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
211
-
212
.
Kita M, Fox R, Gold R, Giovannoni G, Phillips JT, Sarda S, Kong J, Viglietta V et al.
(
2013
)
.
Effects of BG-12 (Dimethyl Fumarate) on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
.
NEUROLOGY
.
vol.
80
,
Havrdova E, Bates D, Galetta S, Giovannoni G, Hutchinson M, Lublin F, O'Connor P, Pellegrini F et al.
(
2013
)
.
Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
209
-
210
.
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, McNeill M et al.
(
2013
)
.
Efficacy and safety of daclizumab high-yield process (DAC HYP) treatment in relapsing-remitting multiple sclerosis: results from the SELECTION extension study
.
JOURNAL OF NEUROLOGY
vol.
260
,
S50
-
S51
.
Mehta L, Giovannoni G, Radue E-W, Havrdova E, Riester K, Greenberg S, Elkins J
(
2013
)
.
Efficacy of Daclizumab HYP Treatment in Patients with Highly Active Relapsing-Remitting Multiple Sclerosis: Results from the SELECT Study
.
NEUROLOGY
.
vol.
80
,
Bergvall N, Nixon R, Tomic D, Sfikas N, Cutter G, Giovannoni G
(
2013
)
.
Efficacy of oral fingolimod versus dimethyl fumarate on measures of freedom from disease activity in patients with multiple sclerosis, based on indirect comparisons of phase 3 trials
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
519
-
519
.
Giovannoni G, Mikulskis A, McNeil M, Riester K, Sweetser M, Elkins J, Amaravadi L
(
2013
)
.
Evaluation of immunogenicity in multiple sclerosis patients continuously treated with daclizumab-HYP during the SELECT and SELECTION clinical trials
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
390
-
390
.
Gafson A, Worthington V, Calado-Marta M, Lakdawala N, Giovannoni G, Farrell R
(
2013
)
.
Evaluation of the humoral response to Epstein-Barr virus as a predictor of conversion to secondary progressive multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
543
-
544
.
Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, Pace A, Novas M, Meltzer L et al.
(
2013
)
.
Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate) in the phase 3 DEFINE and CONFIRM trials
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
221
-
221
.
Meltzer L, Selmaj K, Gold R, Fox R, Havrdova E, Giovannoni G, Pace A, Novas M et al.
(
2013
)
.
Gastrointestinal Tolerability Events in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM
.
NEUROLOGY
.
vol.
80
,
Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G et al.
(
2013
)
.
Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis
.
PLoS One
vol.
8
,
(
10
)
Christensen T, Giovannoni G
(
2013
)
.
HERVs: have we been here before? (vol 18, pg 1670, 2012)
.
MULTIPLE SCLEROSIS JOURNAL
vol.
19
,
(
6
)
827
-
829
.
Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick JP, Monsch AU et al.
(
2013
)
.
Increased neurofilament light chain blood levels in neurodegenerative neurological diseases
.
PLoS One
vol.
8
,
(
9
)
Handel AE, Sandve GK, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV
(
2013
)
.
Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression
.
BMC MEDICAL GENOMICS
vol.
6
,
Article
ARTN 45
,
Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Zhang R et al.
(
2013
)
.
Interim analysis of quality of life in patients with relapsing remitting multiple sclerosis treated with BG-12 (dimethyl fumarate) in the ENDORSE study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
530
-
530
.
Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Hamlett AC et al.
(
2013
)
.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
.
JOURNAL OF NEUROLOGY
vol.
260
,
(
4
)
1136
-
1146
.
Kuhle J, Dobson R, Bestwick JP, Topping J, Dalla Costa G, Khademi M, Sombekke M, Killestein J et al.
(
2013
)
.
Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
33
-
34
.
Lublin F, Cutter G, Giovannoni G, Polman C, Paes D, Patel R, Sun J, Belachew S
(
2013
)
.
Natalizumab reduces the disabling amplitude of multiple sclerosis relapses and improves post-relapse residual disability
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
213
-
214
.
Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P, Giovannoni G, Baker MD, Baker D
(
2013
)
.
Neuroprotection in a novel mouse model of multiple sclerosis
.
PLoS One
vol.
8
,
(
11
)
Raftopoulos RE, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Malik S, Paling D, Yiannakas M et al.
(
2013
)
.
Optical coherence tomography (OCT), visual function and MRI measures in acute optic neuritis: baseline data from a clinical trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
8
-
9
.
Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Knowles C, Hardy J, Giovannoni G, Nageshwaran S et al.
(
2013
)
.
PREDICT-PD study: Online screening algorithm identifying Parkinson's disease risk
.
MOVEMENT DISORDERS
.
vol.
28
,
S389
-
S389
.
Bergvall N, Nixon R, Tomic D, Sfikas N, Cutter G, Giovannoni G
(
2013
)
.
Predicting the efficacy of fingolimod versus dimethyl fumarate in patients with multiple sclerosis using a statistical modelling approach
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
519
-
520
.
Havrdova E, Giovannoni G, Stefoski D, Umans K, Greenberg S, Mehta L, Elkins J
(
2013
)
.
Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study
.
NEUROLOGY
.
vol.
80
,
Giovannoni G, Gold R, Fox R, Kappos L, Kita M, Yang M, Zhang R, Dawson K et al.
(
2013
)
.
Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies
.
NEUROLOGY
.
vol.
80
,
Thompson AJ, Giovannoni G
(
2013
)
.
Removal of access to alemtuzumab for patients with aggressive multiple sclerosis
.
BMJ-BRITISH MEDICAL JOURNAL
vol.
346
,
Article
ARTN f275
,
Mehta D, Amaravadi L, Gold R, Sheridan J, Riester K, Selmaj K, Giovannoni G, Elkins J
(
2013
)
.
Reversal of the Pharmacodynamic Effects of Daclizumab HYP Following Treatment Washout: Results from the SELECTION Study
.
NEUROLOGY
.
vol.
80
,
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Hamlett A et al.
(
2013
)
.
Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study
.
NEUROLOGY
.
vol.
80
,
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Lam E et al.
(
2013
)
.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
.
NEUROLOGY
.
vol.
80
,
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, McNeill M et al.
(
2013
)
.
The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results
.
NEUROLOGY
.
vol.
80
,
Dobson R, Giovannoni G, Ramagopalan S
(
2013
)
.
The month of birth effect in multiple sclerosis: Systematic review, meta-analysis and effect of latitude
.
Journal of Neurology, Neurosurgery and Psychiatry
vol.
84
,
(
4
)
427
-
432
.
Kappos L, Giovannoni G, Gold R, Fox R, Phillips JT, Hotermans C, Zhang A, Viglietta V et al.
(
2013
)
.
Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis
.
NEUROLOGY
.
vol.
80
,
Gold J, Christensen T, Maruszak H, Giovannoni G
(
2013
)
.
Triggering role of viruses in multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
32
-
32
.
Orchard A, Giovannoni G, Langdon D
(
2013
)
.
UK validation of the brief international assessment for multiple sclerosis (BICAMS)
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
19
,
203
-
203
.
Giovannoni G, Foley JF, Brandes DW
(
2012
)
.
Hidden disabilities in multiple sclerosis - The impact of multiple sclerosis on patients and their caregivers
.
European Neurological Review
vol.
7
,
(
SUPPL. 2
)
2
-
9
.
Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A
(
2012
)
.
Meta-analysis of early nonmotor features and risk factors for Parkinson disease
.
Ann Neurol
vol.
72
,
(
6
)
893
-
901
.
Dobson R, Ramagopalan S, Giovannoni G
(
2012
)
.
Bone health and multiple sclerosis
.
Mult Scler
vol.
18
,
(
11
)
1522
-
1528
.
Beyan H, Down TA, Ramagopalan SV, Uvebrant K, Nilsson A, Holland ML, Gemma C, Giovannoni G et al.
(
2012
)
.
Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans
.
Genome Res
vol.
22
,
(
11
)
2138
-
2145
.
Dobson R, Ramagopalan S, Giovannoni G, Bazelier MT, de Vries F
(
2012
)
.
Risk of fractures in patients with multiple sclerosis
.
Neurology
vol.
79
,
(
18
)
1934
-
1935
.
Jaber A, Driebergen R, Giovannoni G, Schellekens H, Simsarian J, Antonelli M
(
2012
)
.
The Rebif® New Formulation Story
.
Drugs in R&D
vol.
8
,
(
6
)
335
-
348
.
Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV
(
2012
)
.
Breastfeeding and multiple sclerosis relapses: A meta-analysis
.
Journal of Neurology
vol.
259
,
(
10
)
2246
-
2248
.
Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV
(
2012
)
.
Breastfeeding and multiple sclerosis relapses: a meta-analysis
.
J Neurol
vol.
259
,
(
10
)
2246
-
2248
.
Sato DK, Nakashima I, Fukazawa T, Shimizu Y, Tomizawa Y, Yokoyama K, Misu T, Creeke PI et al.
(
2012
)
.
Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients
.
Tohoku J Exp Med
vol.
228
,
(
2
)
85
-
92
.
Gafson AR, Giovannoni G
(
2012
)
.
Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis
.
Mult Scler
vol.
18
,
(
10
)
1509
-
1511
.
(
2012
)
.
Editors’ welcome
.
Multiple Sclerosis and Related Disorders
vol.
2
,
(
1
)
Gnanapavan S, Giovannoni G
(
2012
)
.
Neural cell adhesion molecules in brain plasticity and disease
.
Multiple Sclerosis and Related Disorders
vol.
2
,
(
1
)
13
-
20
.
Pakpoor J, Handel AE, Giovannoni G, Dobson R, Ramagopalan SV
(
2012
)
.
Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine
.
PLoS ONE
vol.
7
,
(
9
)
CALADO MARTA MS, giovannoni
(
2012
)
.
‘What does it mean to have MS? - chapter
.
Multiple Sclerosis
,
Oxford University Press
(
United Kingdom
),
Disanto G, Sandve GK, Berlanga-Taylor AJ, Ragnedda G, Morahan JM, Watson CT, Giovannoni G, Ebers GC et al.
(
2012
)
.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis
.
Hum Mol Genet
vol.
21
,
(
16
)
3575
-
3586
.
Hilliard A, Stott C, Wright S, Guy G, Pryce G, Al-Izki S, Bolton C, Giovannoni G
(
2012
)
.
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
.
International Scholarly Research Notices
vol.
2012
,
(
1
)
Raffel JB, Hunt D, Topping J, Bremner J, Brown KE, Giovannoni G
(
2012
)
.
Assay selection affects John Cunningham virus serostatus classification in multiple sclerosis
.
Ann Neurol
vol.
72
,
(
2
)
295
-
296
.
Marta M, Giovannoni G
(
2012
)
.
Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon
.
CNS Neurol Disord Drug Targets
vol.
11
,
(
5
)
610
-
623
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2012
)
.
Editors' welcome
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
4
)
Jia Y, Wu T, Jelinek CA, Bielekova B, Chang L, Newsome S, Gnanapavan S, Giovannoni G et al.
(
2012
)
.
Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
.
Clinical Proteomics
vol.
9
,
(
1
)
Disanto G, Chaplin G, Morahan JM, Giovannoni G, Hyppönen E, Ebers GC, Ramagopalan SV
(
2012
)
.
Month of birth, vitamin D and risk of immune-mediated disease: a case control study
.
BMC Med
vol.
10
,
Giovannoni G, Southam E, Waubant E
(
2012
)
.
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence
.
Mult Scler
vol.
18
,
(
7
)
932
-
946
.
Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G
(
2012
)
.
Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis
.
Autoimmunity
vol.
45
,
(
4
)
298
-
303
.
Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, Melamud L, Marta M et al.
(
2012
)
.
Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients
.
Neurology
vol.
78
,
(
20
)
1601
-
1607
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2012
)
.
Editors’ Welcome
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
3
)
Dobson R, Ramagopalan S, Giovannoni G
(
2012
)
.
The effect of gender in clinically isolated syndrome (CIS): a meta-analysis
.
Mult Scler
vol.
18
,
(
5
)
600
-
604
.
Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI
(
2012
)
.
Development of resistance to biologic therapies with reference to IFN-β
.
Rheumatology (Oxford)
vol.
51
,
(
4
)
590
-
599
.
Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV
(
2012
)
.
The evidence for a role of B cells in multiple sclerosis
.
Neurology
vol.
78
,
(
11
)
823
-
832
.
Dua P, Meier UC, Baker D, Giovannoni G
(
2012
)
.
Functional effects of anti-neuronal antibodies in patients with encephalitis lethargica and other related disorders associated with streptococcal infection
.
Neurology Psychiatry and Brain Research
vol.
18
,
(
2
)
Giovannoni G
(
2012
)
.
Emerging disease modifying treatments—A therapeutics update from ECTRIMS/ACTRIMS, Amsterdam, 2011
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
2
)
56
-
58
.
Brothwell M, Giovannoni G, Spink J
(
2012
)
.
127 Attitudes towards end of life issues among people with MS: a 360 survey
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
83
,
(
3
)
Giovannoni G, Rhoades RW
(
2012
)
.
Individualizing treatment goals and interventions for people with MS
.
Curr Opin Neurol
vol.
25 Suppl
,
S20
-
S27
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2012
)
.
Editors' welcome
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
2
)
Hunt D, Giovannoni G
(
2012
)
.
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
.
Practical Neurology
vol.
12
,
(
1
)
Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G
(
2012
)
.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
2
)
64
-
75
.
Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, Meager A, Elia A et al.
(
2012
)
.
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions
.
Neurology
vol.
78
,
(
1
)
15
-
23
.
Furby J, Giovannoni G, Page R
(
2012
)
.
A CASE OF UNIHEMISPHERIC PROGRESSIVE MULTIPLE SCLEROSIS
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Noyce A, Silveira-Moriyama L, Lees AJ, Schrag A, Bestwick J, Hawkes CH, Giovannoni G, Hardy J et al.
(
2012
)
.
A PILOT STUDY OF AN ALGORITHM DESIGNED TO IDENTIFY PARKINSON'S DISEASE IN THE EARLY, NON-MOTOR PHASE
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, Robinson R et al.
(
2012
)
.
A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial
.
NEUROLOGY
.
vol.
78
,
Raftopoulos RE, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Schmierer K, Sharrack B, Sheridan R et al.
(
2012
)
.
A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
442
-
443
.
Noyce A, Bestwick J, Hawkes CH, Knowles CH, Hardy J, Lees AJ, Silveira-Moriyama L, Giovannoni G et al.
(
2012
)
.
AN ALGORITHM TO IDENTIFY INDIVIDUALS AT HIGH-RISK OF PARKINSON'S DISEASE IN THE COMMUNITY
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT et al.
(
2012
)
.
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS
.
JOURNAL OF NEUROLOGY
vol.
259
,
(
5
)
898
-
905
.
Watson CT, Disanto G, Sandve GK, Breden F, Giovannoni G, Ramagopalan SV
(
2012
)
.
Age-associated hyper-methylated regions in the human brain overlap with bivalent chromatin domains
.
PLoS One
vol.
7
,
(
9
)
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW et al.
(
2012
)
.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
.
LANCET
vol.
380
,
(
9856
)
1819
-
1828
.
Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Selmaj K, Zhang A, Sheikh SI et al.
(
2012
)
.
Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with BG-12: findings from the DEFINE study
.
JOURNAL OF NEUROLOGY
.
vol.
259
,
S106
-
S106
.
Tzartos J, Khan G, Cruz-Sadaba M, Vossenkamper A, Lonardi S, Sefia E, Meager A, Farrell PJ et al.
(
2012
)
.
Association of innate immune activation with latent Epstein - Barr virus infection in active multiple sclerosis lesions
.
IMMUNOLOGY
.
vol.
137
,
51
-
51
.
Giovannoni G, Gold R, Kappos L, Arnold D, Bar-Or A, Selmaj K, Zhang A, Sheikh S et al.
(
2012
)
.
BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
.
NEUROLOGY
.
vol.
78
,
Dobson R, Rudick RA, Giovannoni G
(
2012
)
.
CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON β: A SYSTEMATIC REVIEW AND META-ANALYSIS
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Raffel J, Hunt D, Topping J, Bremner J, Giovannoni G
(
2012
)
.
CLASSIFICATION OF JC VIRUS SEROSTATUS DEPENDS UPON ASSAY SELECTION: A COMPARISON OF BIOGEN AND HPA ASSAYS
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Davis A, Dobson R, Espasandin M, Giovannoni G, Schmierer K
(
2012
)
.
Cerebrospinal fluid biomarkers as outcome measures in clinical trials of MS: The significance of post lumbar puncture headaches
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
237
-
238
.
Bar-Or A, Fox RJ, Gold R, Giovannoni G, Kita M, O'Gorman J, Yang M, Sheikh SI et al.
(
2012
)
.
Clinical effects of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
191
-
191
.
Dobson R, Meier UC, Schmierer K, Giovannoni G
(
2012
)
.
DO SIBLINGS OF PEOPLE WITH MULTIPLE SCLEROSIS (MS) HAVE MARKERS OF MS RISK?
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Radue EW, Gold R, Giovannoni G, Stefoski D, Mueller-Lenke N, Glyman S, Riester K, Elkins J
(
2012
)
.
Daclizumab HYP monotherapy reduces black holes and T2 burden of disease in relapsing-remitting multiple sclerosis: results of the SELECT trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
193
-
194
.
Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S et al.
(
2012
)
.
EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: FINDINGS FROM THE PHASE 3 DEFINE STUDY
.
VALUE IN HEALTH
vol.
15
,
(
7
)
A557
-
A557
.
Arnold D, Brinar V, Cohen J, Coles A, Confavreux C, Fisher E, Fox E, Giovannoni G et al.
(
2012
)
.
Effect of Alemtuzumab vs. Rebif® on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study
.
NEUROLOGY
.
vol.
78
,
Bar-Or A, Gold R, Kappos L, Arnold D, Giovannoni G, Selmaj K, O'Gorman J, Stephan M et al.
(
2012
)
.
Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
.
NEUROLOGY
.
vol.
78
,
Arnold D, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Zhang R, Stephan M et al.
(
2012
)
.
Effect of BG-12 on Brain Atrophy and Lesions Volume: MRI Results from the DEFINE Study during First and Second Year of Treatment
.
NEUROLOGY
.
vol.
78
,
Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O'Gorman J, Stephan M et al.
(
2012
)
.
Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the DEFINE study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
19
,
356
-
356
.
Giovannoni G, Radue EW, Havrdova E, Riester K, Greenberg S, Glyman S, Elkins J
(
2012
)
.
Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
189
-
189
.
Arnold D, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Stephan M et al.
(
2012
)
.
Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study
.
NEUROLOGY
.
vol.
78
,
agarwal S, Kappos L, Gold R, Arnold D, Bar-Or A, Giovannoni G, Selmaj K, Kong J et al.
(
2012
)
.
Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
.
NEUROLOGY
.
vol.
78
,
Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R et al.
(
2012
)
.
Effects of BG-12 on magnetic resonance imaging and magnetisation transfer ratio outcomes in relapsing-remitting multiple sclerosis: findings from the phase 3 DEFINE study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
214
-
215
.
Coles A, Brinar V, Arnold D, Cohen J, Confavreux C, Fox E, Hartung H, Havrdova E et al.
(
2012
)
.
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naive Patients
.
NEUROLOGY
.
vol.
78
,
Stubinski B, Rocak S, Giovannoni G
(
2012
)
.
Efficacy, Tolerability and Immunogenicity of the Serum-Free Formulation of Subcutaneous Interferon Beta-1a: Findings of Clinical Trials in Patients with Multiple Sclerosis or with a First Clinical Demyelinating Event
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
536
-
536
.
Pakpoor J, Disanto G, Meier UC, Giovannoni G, Ramagopalan SV
(
2012
)
.
Epstein-Barr virus seroprevalence in multiple sclerosis patients: a systematic review and meta-analysis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
368
-
369
.
Watson CT, Disanto G, Breden F, Giovannoni G, Ramagopalan SV
(
2012
)
.
Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs
.
Sci Rep
vol.
2
,
Disanto G, Sandve GK, Berlanga-Taylor AJ, Morahan JM, Dobson R, Giovannoni G, Ramagopalan SV
(
2012
)
.
Genomic Regions Associated with Multiple Sclerosis Are Active in B Cells
.
PLOS ONE
vol.
7
,
(
3
)
Article
ARTN e32281
,
Christensen T, Giovannoni G
(
2012
)
.
HERVs: have we been here before?
.
MULTIPLE SCLEROSIS JOURNAL
vol.
18
,
(
12
)
1670
-
1672
.
Selmaj K, Arnold D, Brinar V, Cohen J, Coles A, Confavreux C, Fox E, Giovannoni G et al.
(
2012
)
.
Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif® in Multiple Sclerosis I (CARE-MS I)
.
NEUROLOGY
.
vol.
78
,
Giovannoni G, Stefoski D, Umans K, Greenberg S, Glyman S, Elkins J
(
2012
)
.
Increase in proportion of patients free from disease activity following 1 year of treatment with daclizumab high-yield process in relapsing-remitting multiple sclerosis: results from the SELECT study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
419
-
419
.
Havrdova E, Arnold D, Cohen J, Coles A, Confavreux C, Fox E, Hartung H, Selmaj K et al.
(
2012
)
.
Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I)
.
NEUROLOGY
.
vol.
78
,
Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G et al.
(
2012
)
.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
vol.
83
,
(
3
)
298
-
304
.
Lycke J, Arnold D, Cohen J, Coles AJ, Confavreux C, Fox EJ, Hartung H-P, Havrdova E et al.
(
2012
)
.
Lymphocyte subset dynamics following alemtuzumab administration in the CARE-MS I trial
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
19
,
89
-
89
.
Tzartos JS, Khan G, Middeldorp J, Giovannoni G
(
2012
)
.
Neuropathological study of Epstein Barr-virus infection in the MS brain
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
140
-
140
.
Giovannoni G, Chamoun V, Scadding J, Thompson E
(
2012
)
.
Neurosarcoidosis
.
Sarcoidosis
,
Dobson R, Ramagopalan S, Giovannoni G
(
2012
)
.
Osteoporosis and fracture risk in multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
243
-
244
.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT et al.
(
2012
)
.
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
.
NEW ENGLAND JOURNAL OF MEDICINE
vol.
367
,
(
12
)
1098
-
1107
.
Nicholson TRJ, Ferdinando S, Krishnaiah RB, Anhoury S, Lennox BR, Mataix-Cols D, Cleare A, Veale DM et al.
(
2012
)
.
Prevalence of anti-basal ganglia antibodies in adult obsessive compulsive disorder: cross-sectional study
.
BRITISH JOURNAL OF PSYCHIATRY
vol.
200
,
(
5
)
381
-
386
.
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue E-W, Stefoski D, McNeill M et al.
(
2012
)
.
Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
514
-
514
.
Ragnedda G, Disanto G, Giovannoni G, Ebers GC, Sotgiu S, Ramagopalan SV
(
2012
)
.
Protein-protein interaction analysis highlights additional loci of interest for multiple sclerosis
.
PLoS One
vol.
7
,
(
10
)
Havrdova E, Gold R, Fox RJ, Kappos L, Kita M, Sarda SP, Yang M, Zhang R et al.
(
2012
)
.
RELAPSES REQUIRING INTRAVENOUS STEROIDS AND MULTIPLE SCLEROSIS-RELATED HOSPITALIZATIONS: FINDINGS FROM THE PHASE 3 DEFINE AND CONFIRM STUDIES
.
VALUE IN HEALTH
vol.
15
,
(
7
)
A546
-
A546
.
Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS et al.
(
2012
)
.
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study
.
Clin Drug Investig
vol.
32
,
(
1
)
15
-
27
.
Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS et al.
(
2012
)
.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study
.
Clin Drug Investig
vol.
32
,
(
1
)
15
-
27
.
Fox E, Arnold D, Brinar V, Cohen J, Coles A, Confavreux C, Giovannoni G, Hartung H et al.
(
2012
)
.
Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naive Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints
.
NEUROLOGY
.
vol.
78
,
Havrdova E, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Zhang R, Dawson KT et al.
(
2012
)
.
Relapses requiring intravenous steroid use and MS-related hospitalisations: findings from the phase 3 DEFINE and CONFIRM studies
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
204
-
205
.
Noyce AJ, Bestwick J, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A
(
2012
)
.
Risk factors and early non-motor features for Parkinson's disease: A systematic review and meta-analysis
.
MOVEMENT DISORDERS
.
vol.
27
,
S4
-
S4
.
Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC et al.
(
2012
)
.
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
.
MULTIPLE SCLEROSIS JOURNAL
vol.
18
,
(
2
)
143
-
152
.
Disanto G, Morahan JM, Lacey MV, DeLuca GC, Giovannoni G, Ebers GC, Ramagopalan SV
(
2012
)
.
Seasonal distribution of psychiatric births in England
.
PLoS One
vol.
7
,
(
4
)
Raffel J, Dobson R, Giovannoni G
(
2012
)
.
THE EFFECT OF NATALIZUMAB AND INTERFERON-β ON URINARY FREE LIGHT CHAINS AND ANTI-EBV NUCLEAR ANTIGEN-1 ANTIBODIES IN RELAPSING REMITTING MULTIPLE SCLEROSIS
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Noyce A, Treacy C, Budu C, Fearnley J, Lees AJ, Giovannoni G
(
2012
)
.
THE NEW BRADYKINESIA AKINESIA INCOORDINATION (BRAIN) TEST: AN ONLINE TEST OF UPPER LIMB MOVEMENT
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Giovannoni G
(
2012
)
.
The REFLEX study: a missed opportunity?
.
Lancet Neurol
vol.
11
,
(
1
)
22
-
24
.
Havrdova E, Gold R, Giovannoni G, Umans K, Glyman S, Elkins J
(
2012
)
.
The effect of daclizumab HYP on sustained disability progression in the SELECT trial
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
435
-
436
.
Topping J, Evdoshenko E, Dobson R, Lapin S, Maslyanskiy A, Giovannoni G
(
2012
)
.
The effects of intrathecal rituximab on biomarkers in MS
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
268
-
268
.
Noyce AJ, Treacy C, Budu C, Fearnley J, Lees AJ, Giovannoni G
(
2012
)
.
The new Bradykinesia Akinesia Incoordination (BRAIN) test: preliminary data from an online test of upper limb movement
.
Mov Disord
vol.
27
,
(
1
)
157
-
158
.
Acharya S, Nagy A, Budu C, Treacy C, Fearnley J, Lees AJ, Giovannoni G, Noyce AJ
(
2012
)
.
The new bradykinesia akinesia incoordination (BRAIN) test: People with Parkinson's disease versus healthy controls
.
MOVEMENT DISORDERS
.
vol.
27
,
S102
-
S102
.
Meier UC, Giovannoni G, Tzartos J, Khan G
(
2012
)
.
Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?
.
Clin. Exp. Immunol
vol.
167
,
(
1
)
1
-
6
.
Dobson R, Topping J, Davis A, Giovannoni G
(
2012
)
.
Urinary and CSF biomarkers in multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
18
,
502
-
503
.
Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J, Harris C et al.
(
2012
)
.
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010
.
Int J MS Care
vol.
14
,
(
3
)
105
-
114
.
Dobson R, Giovannoni G
(
2012
)
.
WHY CAN'T I WIN ANY MORE?
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
83
,
Giovannoni G, Cook SD
(
2011
)
.
Cladribine to treat multiple sclerosis
.
Multiple Sclerosis Therapeutics
,
Cambridge University Press (CUP)
Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, Meager A, Elia A et al.
(
2011
)
.
Association of innate immune activation with latent Epstein Barr virus in active MS lesions
.
Neurology
vol.
78
,
(
1
)
15
-
23
.
Gnanapavan S, Giovannoni G
(
2011
)
.
Why all the interest in NCAM?
.
Alzheimer's Disease Research Journal
vol.
4
,
(
3
)
301
-
314
.
Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G
(
2011
)
.
Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice
.
Mult Scler
vol.
17
,
(
11
)
1333
-
1340
.
Disanto G, Handel AE, Morahan JM, Deluca GC, Kimball SM, Hypponen E, Giovannoni G, Ebers GC et al.
(
2011
)
.
Vitamin D and multiple sclerosis hospital admissions in Scotland
.
QJM
vol.
104
,
(
11
)
1001
-
1003
.
Hadavi S, Noyce AJ, Leslie RD, Giovannoni G
(
2011
)
.
Stiff person syndrome
.
Pract Neurol
vol.
11
,
(
5
)
272
-
282
.
Gnanapavan S, Vincent A, Giovannoni G
(
2011
)
.
Surviving stiff-person syndrome: a case report
.
J NEUROL
vol.
258
,
(
10
)
1898
-
1900
.
Deisenhammer F, Egg R, Giovannoni G, Hemmer B, Petzold A, Sellebjerg F, Teunissen C, Tumani H
(
2011
)
.
Disease‐Specific Cerebrospinal Fluid Investigations
.
European Handbook of Neurological Management
,
Wiley
Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A et al.
(
2011
)
.
Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
1
)
49
-
54
.
Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D
(
2011
)
.
Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
1
)
29
-
38
.
Gafson A, Giovannoni G, Hawkes CH
(
2011
)
.
The diagnostic criteria for multiple sclerosis: From Charcot to McDonald
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
1
)
9
-
14
.
Maruszak H, Brew BJ, Giovannoni G, Gold J
(
2011
)
.
Could antiretroviral drugs be effective in multiple sclerosis? A case report
.
Eur J Neurol
vol.
18
,
(
9
)
e110
-
e111
.
Tumani H, Deisenhammer F, Giovannoni G, Gold R, Hartung HP, Hemmer B, Hohlfeld R, Otto M et al.
(
2011
)
.
Revised McDonald Criteria: The Persisting Importance of Cerebrospinal Fluid Analysis
.
ANN NEUROL
vol.
70
,
(
3
)
520
-
520
.
Disanto G, Meier U, Giovannoni G, Ramagopalan SV
(
2011
)
.
Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development?
.
EXPERT REV NEUROTHER
vol.
11
,
(
9
)
1221
-
1224
.
Banwell B, Giovannoni G, Hawkes C, Lublin F
(
2011
)
.
Editor's Welcome
.
Multiple Sclerosis and Related Disorders
vol.
1
,
(
1
)
1
-
2
.
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D
(
2011
)
.
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis
.
Mult Scler
vol.
17
,
(
8
)
939
-
948
.
Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A et al.
(
2011
)
.
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis
.
MULT SCLER J
vol.
17
,
(
8
)
970
-
979
.
Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL et al.
(
2011
)
.
[Retracted] Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies
.
Multiple Sclerosis International
vol.
2011
,
(
1
)
Jackson SJ, Giovannoni G, Baker D
(
2011
)
.
Fingolimod modulates microglial activation to augment markers of remyelination
.
J Neuroinflammation
vol.
8
,
Ramagopalan SV, Hoang U, Seagroatt V, Handel A, Ebers GC, Giovannoni G, Goldacre MJ
(
2011
)
.
Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study
.
J NEUROL NEUROSUR PS
vol.
82
,
(
6
)
682
-
687
.
Giovannoni G
(
2011
)
.
CSF markers
.
JOURNAL OF NEUROLOGY
.
vol.
258
,
9
-
9
.
Cook S, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Scarramozza M et al.
(
2011
)
.
Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study
.
JOURNAL OF NEUROLOGY
.
vol.
258
,
260
-
260
.
Rammohan K, Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, Kurukulasuriya N et al.
(
2011
)
.
Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
.
JOURNAL OF NEUROLOGY
.
vol.
258
,
21
-
21
.
Giovannoni G
(
2011
)
.
Epstein-Barr Virus and MS
.
Int MS J
vol.
17
,
(
2
)
44
-
49
.
Rieckmann P, Sorensen PS, Comi G, Cook S, Giovannoni G, Rammohan K, Vermersch P, Kurukulasuriya N et al.
(
2011
)
.
Exploring correlations between changes in lymphocyte counts and clinical/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: analyses from the double-blind, 96-week CLARITY study
.
JOURNAL OF NEUROLOGY
.
vol.
258
,
48
-
48
.
Giovannoni G
(
2011
)
.
Promising emerging therapies for multiple sclerosis
.
Neurol Clin
vol.
29
,
(
2
)
435
-
448
.
Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Hamlett A et al.
(
2011
)
.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
.
MULT SCLER J
vol.
17
,
(
5
)
578
-
593
.
Rammohan K, Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, Kurukulasuriya N et al.
(
2011
)
.
Safety of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
.
JOURNAL OF NEUROLOGY
.
vol.
258
,
259
-
259
.
Vermersch P, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Kurukulasuriya N et al.
(
2011
)
.
Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study
.
JOURNAL OF NEUROLOGY
.
vol.
258
,
259
-
259
.
Giovannoni G, Nath A
(
2011
)
.
After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage
.
Neurology
vol.
76
,
(
14
)
1200
-
1201
.
Meager A, Dolman C, Dilger P, Bird C, Giovannoni G, Schellekens H, Thorpe R, Wadhwa M
(
2011
)
.
An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products
.
J INTERF CYTOK RES
vol.
31
,
(
4
)
383
-
392
.
Ramagopalan SV, Handel AE, Giovannoni G, Siegel SR, Ebers GC, Chaplin G
(
2011
)
.
Relationship of UV exposure to prevalence of multiple sclerosis in England
.
NEUROLOGY
vol.
76
,
(
16
)
1410
-
1414
.
Ramagopalan SV, Meier UC, Conacher M, Ebers GC, Giovannoni G, Crawford DH, McAulay KA
(
2011
)
.
Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis
.
Arch Neurol
vol.
68
,
(
4
)
469
-
472
.
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V et al.
(
2011
)
.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
.
Lancet Neurol
vol.
10
,
(
4
)
329
-
337
.
Giovannoni G
(
2011
)
.
Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis
.
MULT SCLER J
vol.
17
,
(
3
)
259
-
261
.
Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M
(
2011
)
.
Therapies for multiple sclerosis: considerations in the pediatric patient
.
NAT REV NEUROL
vol.
7
,
(
2
)
109
-
122
.
Maghzi A-H, Marta M, Bosca I, Etemadifar M, Dobson R, Maggiore C, Giovannoni G, Meier U-C
(
2011
)
.
Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?
.
Pathophysiology
vol.
18
,
(
1
)
13
-
20
.
Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV
(
2011
)
.
Smoking and Multiple Sclerosis: An Updated Meta-Analysis
.
PLOS ONE
vol.
6
,
(
1
)
Article
e16149
,
Noyce AJ, Bestwick J, Hawkes CH, Schrag A, Knowles CH, Hardy J, Lees AJ, Giovannoni G et al.
(
2011
)
.
A pilot study of an algorithm designed to identify Parkinson's disease in the early, non-motor phase
.
MOVEMENT DISORDERS
.
vol.
26
,
S54
-
S54
.
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R et al.
(
2011
)
.
A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S508
-
S509
.
Noyce AJ, Bestwick J, Hawkes CH, Knowles CH, Hardy J, Lees AJ, Silveira-Moriyama L, Giovannoni G et al.
(
2011
)
.
An algorithm to identify individuals at high-risk of Parkinson's disease in the community
.
MOVEMENT DISORDERS
.
vol.
26
,
S54
-
S55
.
Thomson A, Espasandin M, Denholm T, Giovannoni G
(
2011
)
.
Analysing and redesigning the outpatient experience for people with multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S486
-
S486
.
Kappos L, Gold R, Arnold D, Bar-Or A, Giovannoni G, Selmaj K, Tompkins C, Agarwal S et al.
(
2011
)
.
BG-12 effects on patient-reported outcomes in relapsing-remitting multiple sclerosis: results from the DEFINE study
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S488
-
S489
.
Gold R, Kappos L, Bar-Or A, Arnold D, Giovannoni G, Selmaj K, Yang M, Dawson K
(
2011
)
.
Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S34
-
S34
.
Dobson R, Meier UC, Schmierer K, Giovannoni G
(
2011
)
.
Do siblings have markers of multiple sclerosis risk?
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S86
-
S86
.
Coles A, Brinar V, Arnold DL, Cohen J, Confavreaux C, Fox EJ, Hartung HP, Havrdova E et al.
(
2011
)
.
Efficacy and safety results from CARE-MS I: a phase 3 study comparing alemtuzumab and interferon-β-1a
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S510
-
S510
.
Arnold D, Gold R, Bar-Or A, Kappos L, Giovannoni G, Selmaj K, Zhang R, Dawson K
(
2011
)
.
Efficacy on MRI endpoints of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S369
-
S370
.
Graves RS, Pryce G, Cabranes A, Fernandez-Ruiz J, Bisogno T, Di Marzo V, Cravatt BF, Michael GJ et al.
(
2011
)
.
Fatty acid amide hydrolase as a target for neuroprotection
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S431
-
S431
.
Jackson S, Giovannoni G, Baker D
(
2011
)
.
Fingolimod (FTY720) modulates microglial activation to augment markers of remyelination
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S210
-
S210
.
Marta M, Santos E, Coutinho E, da Silva AM, Correia J, Vasconcelos C, Giovannoni G
(
2011
)
.
INCREASED SERUM IL-8 LEVELS IN BEHCET DISEASE THAN NEUROBEHCET SYNDROME
.
CLIN EXP RHEUMATOL
.
vol.
29
,
173
-
173
.
Ramagopalan S, Disanto G, McAulay K, Giovannoni G, Ebers G
(
2011
)
.
Identification of Epstein-Barr Virus Associated Epigenetic Changes and Association with Multiple Sclerosis
.
NEUROLOGY
.
vol.
76
,
A657
-
A657
.
Ramagopalan S, Ebers G, Meier U, Giovannoni G
(
2011
)
.
Identification of Epstein-Barr Virus associated epigenetic changes and association with multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S10
-
S10
.
Tzartos JS, Khan G, Cruz-Sadaba M, Vossenkamper A, Lonardi S, Sefia E, Meager A, Middledorp J et al.
(
2011
)
.
Innate immune activation is associated with latent Epstein-Barr virus infection in active MS lesions
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S350
-
S350
.
Giovannoni G, Sorensen PS, Butzkueven H, Comi G, Cook S, Rammohan K, Rieckmann P, Vermersch P et al.
(
2011
)
.
Mitigating severe lymphopenia: post hoc analysis of data from the 96-week CLARITY study
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S454
-
S455
.
Meier UC, Giovannoni G
(
2011
)
.
More to come: humoral immune responses in MS
.
Journal of Neuroimmunology
vol.
240-241
,
13
-
21
.
Lidster K, Jackson S, Coffey P, Baker M, Garthwaite J, Selwood D, Giovannoni G, Baker D
(
2011
)
.
Neuroprotection in a novel optic neuritis model
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S435
-
S435
.
Selmaj K, Gold R, Kappos L, Bar-Or A, Arnold D, Giovannoni G, Sweetser M, Novas M et al.
(
2011
)
.
Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S451
-
S451
.
Al-Izki S, Pryce G, Amor S, Gerritsen W, Garthwaite J, Giovannoni G, Selwood DL, Baker D
(
2011
)
.
Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S209
-
S210
.
Pryce G, Visintin C, Lutz B, Marsicano G, Giovannoni G, Selwood DL, Baker D
(
2011
)
.
Selective targeting of spasticity by CNS-excluded cannabinoids
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S247
-
S247
.
Marta M, Santos E, Coutinho E, da Silva AM, Correia J, Vasconcelos C, Giovannoni G
(
2011
)
.
VIRAL INFECTIONS IN NEUROBEHCET SYNDROME
.
CLIN EXP RHEUMATOL
.
vol.
29
,
193
-
194
.
Baker D, Pryce G, Visintin C, Pertwee RG, Tanner C, Ross R, Irving A, Sisay S et al.
(
2011
)
.
VSN16R a novel agent for the control of spasticity
.
MULTIPLE SCLEROSIS JOURNAL
vol.
17
,
S243
-
S243
.
Dobson R, Meier UC, Marta M, Ramagopalan S, Giovannoni G
(
2011
)
.
Vitamin D deficiency - do we follow our own advice?
.
CLINICAL MEDICINE
vol.
11
,
(
6
)
521
-
523
.
Maghzi A-H, Marta M, Bosca I, Savoj M-R, Etemadifar M, Giovannoni G, Meier U-C
(
2010
)
.
2 Epstein–Barr Virus and Multiple Sclerosis Wrong Place, Wrong Time?
.
Neuroinflammation
,
Elsevier
Maghzi AH, Marta M, Bosca I, Savoj MR, Etemadifar M, Giovannoni G, Meier UC
(
2010
)
.
Epstein–Barr Virus and
Multiple Sclerosis:
Wrong Place, Wrong Time?
.
Elsevier
Petzold A, Mondria T, Kuhle J, Rocca MA, Cornelissen J, Boekhorst PT, Lowenberg B, Giovannoni G et al.
(
2010
)
.
Evidence for Acute Neurotoxicity after Chemotherapy
.
ANN NEUROL
vol.
68
,
(
6
)
806
-
815
.
Dobson R, Feldmann M, Thompson AJ, Giovannoni G, Miller DH, Thompson EJ, Palmer HE, Miller RF
(
2010
)
.
INCREASED URINARY FREE IMMUNOGLOBULIN LIGHT CHAIN EXCRETION IN PATIENTS WITH MULTIPLE SCLEROSIS
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
81
,
E57
-
E57
.
Marshall C, Giovannoni G
(
2010
)
.
PROGRESSIVE ATAXIA WITH UNUSUAL RADIOGRAPHIC FINDINGS
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
81
,
E34
-
E34
.
Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, Handunnetthi L, Handel AE et al.
(
2010
)
.
A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution
.
GENOME RES
vol.
20
,
(
10
)
1352
-
1360
.
Pollard J, Boundy K, Butzkueven H, King J, Macdonell R, Giovannoni G, Stefano N, Rocak S et al.
(
2010
)
.
Benefits of the serum-free formulation of interferon beta-1a: Lessons from clinical trials
.
MULTIPLE SCLEROSIS
.
vol.
16
,
1282
-
1282
.
Farrell RA, Giovannoni G
(
2010
)
.
Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis
.
J INTERF CYTOK RES
vol.
30
,
(
10
)
715
-
726
.
Rieckmann P, Giovannoni G, Comi G, Cook S, Rammohan K, Sorensen P, Vermersch P, Chang P et al.
(
2010
)
.
Efficacy of short-course oral therapy with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study
.
MULTIPLE SCLEROSIS
.
vol.
16
,
1283
-
1283
.
Rieckmann P, Cook S, Comi G, Giovannoni G, Rammohan K, Sorensen P, Vermersch P, Chang P et al.
(
2010
)
.
Safety and tolerability of short-course oral therapy with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study
.
MULTIPLE SCLEROSIS
.
vol.
16
,
1283
-
1284
.
Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, Sellebjerg F, Tumani H
(
2010
)
.
Routine Cerebrospinal Fluid (CSF) Analysis
.
European Handbook of Neurological Management
,
Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV
(
2010
)
.
An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis
.
PLOS ONE
vol.
5
,
(
9
)
Article
e12496
,
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Chang P et al.
(
2010
)
.
Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
17
,
215
-
215
.
Rieckmann P, Comi G, Cook S, Giovannoni G, Rammohan K, Soelberg-Sorensen P, Vermersch P, Bock D et al.
(
2010
)
.
Consistent efficacy of cladribine tablets across the spectrum of patients with relapsing-remitting multiple sclerosis of differing severity: data from the 96-week, double-blind CLARITY study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
17
,
56
-
56
.
Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Hamlett A et al.
(
2010
)
.
Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
17
,
485
-
485
.
Khaleeli, Healy, Briddon, Lunn, Reilly, Land, Giovannoni
(
2010
)
.
Copper deficiency as a treatable cause of poor balance
.
Praxis
vol.
99
,
(
19
)
1153
-
1156
.
Handel AE, Handunnetthi L, Giovannoni G, Ebers GC, Ramagopalan SV
(
2010
)
.
Genetic and environmental factors and the distribution of multiple sclerosis in Europe
.
EUR J NEUROL
vol.
17
,
(
9
)
1210
-
1214
.
Giovannoni G
(
2010
)
.
The first on the stage: cladribine
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
17
,
14
-
14
.
Rejdak K, Leary SM, Petzold A, Thompson AJ, Miller DH, Giovannoni G
(
2010
)
.
Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis
.
MULT SCLER
vol.
16
,
(
9
)
1066
-
1072
.
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung H et al.
(
2010
)
.
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis
.
Annals of Neurology
vol.
68
,
(
3
)
409
-
411
.
Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G
(
2010
)
.
Neural cell adhesion molecule--description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders
.
J Neuroimmunol
vol.
225
,
(
1-2
)
118
-
122
.
Ramagopalan SV, Hanwell HEC, Giovannoni G, Knappskog PM, Nyland HI, Myhr KM, Ebers GC, Torkildsen O
(
2010
)
.
Vitamin D-Dependent Rickets, HIA-DRB1, and the Risk of Multiple Sclerosis
.
ARCH NEUROL-CHICAGO
vol.
67
,
(
8
)
1034
-
1035
.
Giovannoni G
(
2010
)
.
CSF GFAP: Volcanic ash from anti-aquaporin-4 antibody-mediated destruction of astrocytes
.
Neurology
vol.
75
,
(
3
)
200
-
201
.
Ramagopalan SV, Dobson R, Meier UC, Giovannoni G
(
2010
)
.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
.
Lancet Neurol
vol.
9
,
(
7
)
727
-
739
.
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF et al.
(
2010
)
.
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
.
LANCET NEUROL
vol.
9
,
(
7
)
740
-
750
.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Chang P et al.
(
2010
)
.
Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
.
JOURNAL OF NEUROLOGY
.
vol.
257
,
S21
-
S21
.
Rieckmann P, Comi G, Cook S, Giovannoni G, Rammohan K, Sorensen PS, Vermersch P, Chang P et al.
(
2010
)
.
Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study
.
JOURNAL OF NEUROLOGY
.
vol.
257
,
S142
-
S143
.
Sorensen PS, Rieckmann P, Comi G, Cook S, Giovannoni G, Rammohan K, Vermersch P, Bock D et al.
(
2010
)
.
Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis
.
JOURNAL OF NEUROLOGY
.
vol.
257
,
S143
-
S143
.
Giovannoni G, Cook S, Sørensen PS
(
2010
)
.
Dr. Giovannoni and colleagues reply
.
New England Journal of Medicine
vol.
362
,
(
18
)
1739
-
1740
.
Giovannoni G, Cook S, Sorensen PS, CLARITY Study Grp
(
2010
)
.
Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis REPLY
.
NEW ENGL J MED
vol.
362
,
(
18
)
1739
-
1740
.
Ramagopalan SV, Dyment DA, Giovannoni G, Sadovnick AD, Ebers GC
(
2010
)
.
HLA-DRB1*15, Low Infant Sibling Exposure, and Multiple Sclerosis Gene-Environment Interaction
.
ANN NEUROL
vol.
67
,
(
5
)
694
-
695
.
Hawkes CH, Giovannoni G
(
2010
)
.
The McDonald Criteria for Multiple Sclerosis: time for clarification
.
Mult Scler
vol.
16
,
(
5
)
566
-
575
.
Swedo SE, Schrag A, Gilbert R, Giovannoni G, Robertson MM, Metcalfe C, Ben-Shlomo Y, Gilbert DL
(
2010
)
.
STREPTOCOCCAL INFECTION, TOURETTE SYNDROME, AND OCD: IS THERE A CONNECTION? PANDAS: HORSE OR ZEBRA?
.
Neurology
vol.
74
,
(
17
)
1397
-
1399
.
Khaleeli Z, Healy DG, Briddon A, Lunn MP, Reilly MM, Land J, Giovannoni G
(
2010
)
.
Lesson of the Week Copper deficiency as a treatable cause of poor balance
.
BRIT MED J
vol.
340
,
Article
c508
,
Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A
(
2010
)
.
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
.
LANCET NEUROL
vol.
9
,
(
4
)
438
-
446
.
Guimond C, Dyment DA, Ramagopalan SV, Giovannoni G, Criscuoli M, Yee IM, Ebers GC, Sadovnick AD
(
2010
)
.
Prevalence of MS in Iranian Immigrants to British Columbia, Canada
.
J NEUROL
vol.
257
,
(
4
)
667
-
668
.
Dobson R, Miller RF, Palmer HE, Feldmann M, Thompson EJ, Thompson AJ, Miller DH, Giovannoni G
(
2010
)
.
Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis
.
J Neuroimmunol
vol.
220
,
(
1-2
)
99
-
103
.
Radue E-W, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B et al.
(
2010
)
.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis
.
Journal of the Neurological Sciences
vol.
292
,
(
1-2
)
28
-
35
.
Giovannoni G
(
2010
)
.
Recent developments in oral medications for the treatment of multiple sclerosis
.
Future Neurology
vol.
5
,
(
2
)
167
-
172
.
Giovannoni G
(
2010
)
.
Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 'Spinal Tap'
.
Mult Scler
vol.
16
,
(
3
)
285
-
286
.
Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV
(
2010
)
.
Environmental factors and their timing in adult-onset multiple sclerosis
.
NAT REV NEUROL
vol.
6
,
(
3
)
156
-
166
.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P et al.
(
2010
)
.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
.
N Engl J Med
vol.
362
,
(
5
)
416
-
426
.
Teunissen CE, Tumani HT, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL et al.
(
2010
)
.
Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'
.
MULT SCLER
vol.
16
,
(
2
)
129
-
132
.
Petzold A, Altintas A, Laura C, Bartos A, Achim F, Blankenstein MA, Luc H, Castellazzi M et al.
(
2010
)
.
Neurofilament ELISA validation
.
J IMMUNOL METHODS
vol.
352
,
(
1-2
)
23
-
31
.
Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL et al.
(
2010
)
.
A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking
.
LABORATORIUMSMEDIZIN
vol.
34
,
(
1
)
1
-
12
.
Ramagopalan SV, Sadovnick AD, Ebers GC, Giovannoni G
(
2010
)
.
Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis
.
MULT SCLER
vol.
16
,
(
1
)
127
-
128
.
Handel AE, Handunnetthi L, Giovannoni G, Ebers GC, Ramagopalan SV
(
2010
)
.
Genetic and Environmental Factors and the Distribution of Multiple Sclerosis in Europe
.
ANNALS OF NEUROLOGY
.
vol.
68
,
S56
-
S56
.
Rolls AES, Giovannoni G, Constantinescu CS, Boniface D, Hawkes CH
(
2010
)
.
Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus?
.
EUR NEUROL
vol.
63
,
(
1
)
29
-
35
.
Rejdak K, Jackson S, Giovannoni G
(
2010
)
.
Multiple sclerosis: a practical overview for clinicians
.
Br Med Bull
vol.
95
,
79
-
104
.
Ramagopalan SV, Link J, Byrnes JK, Dyment DA, Giovannoni G, Hintzen RQ, Sundqvist E, Kockum I et al.
(
2009
)
.
HLA-DRB1 and month of birth in multiple sclerosis
.
NEUROLOGY
vol.
73
,
(
24
)
2107
-
2111
.
Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL et al.
(
2009
)
.
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
.
NEUROLOGY
vol.
73
,
(
22
)
1914
-
1922
.
Ramagopalan SV, Giovannoni G
(
2009
)
.
Can we predict multiple sclerosis?
.
Lancet Neurol
vol.
8
,
(
12
)
1077
-
1079
.
Martino D, Defazio G, Giovannoni G
(
2009
)
.
The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder
.
J PSYCHOSOM RES
vol.
67
,
(
6
)
547
-
557
.
Peferoen LAN, Lamers F, Lodder LNR, Gerritsen WH, Huitinga I, Melief J, Giovannoni G, Meier U et al.
(
2009
)
.
Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis
.
Brain
vol.
133
,
(
5
)
e137
-
e137
.
Schrag A, Gilbert R, Giovannoni G, Robertson MM, Metcalfe C, Ben-Shlomo Y
(
2009
)
.
Streptococcal infection, Tourette syndrome, and OCD: is there a connection?
.
Neurology
vol.
73
,
(
16
)
1256
-
1263
.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Chang P et al.
(
2009
)
.
Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
285
,
S114
-
S114
.
Giovannoni G, De Stefano N, Migliaccio M
(
2009
)
.
Development of a new formulation of subcutaneous interferon beta-1a for relapsing-remitting multiple sclerosis: efficacy, safety and immunogenicity results from a comprehensive pre-clinical and clinical trial series
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
285
,
S204
-
S204
.
Munschauer F, Giovannoni G, O'Connor PW, Phillips JT, Polman CH, Pace A, Kim R, Hyde R et al.
(
2009
)
.
Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
285
,
S109
-
S109
.
Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Chang P et al.
(
2009
)
.
MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
285
,
S114
-
S114
.
Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Soelberg-Sorensen P, Chang P et al.
(
2009
)
.
Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
285
,
S206
-
S206
.
Petzold A, Mondria T, Kuhle J, Cornelissen J, Rocca M, Boekhorst PT, Lowenberg B, Giovannoni G et al.
(
2009
)
.
Acute treatment related neurotoxicity in secondary progressive multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S274
-
S274
.
Rammohan K, Vermersch P, Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Chang P et al.
(
2009
)
.
Cladribine tablets produce sustained improvements in relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S249
-
S249
.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Chang P et al.
(
2009
)
.
Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S136
-
S137
.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Chang P et al.
(
2009
)
.
Disease-free status achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S137
-
S137
.
Vermersch P, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Chang P et al.
(
2009
)
.
Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S249
-
S249
.
Sorensen PS, Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Vermersch P, Chang P et al.
(
2009
)
.
Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S137
-
S137
.
Rieckmann P, Comi G, Cook S, Giovannoni G, Rammohan K, Sorensen PS, Vermersch P, Chang P et al.
(
2009
)
.
Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S248
-
S249
.
Batocchi AP, Tavazzi B, Frisullo G, Amorini AM, Nociti V, Plantone D, Patanella AK, Petzold A et al.
(
2009
)
.
Increase of uric acid and purine compounds in serum of multiple sclerosis patients
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S203
-
S204
.
Munschauer F, Giovannoni G, O'Connor PW, Phillips JT, Polman CH, Pace A, Hyde R, Kim R
(
2009
)
.
Natalizumab improves disability on the Multiple Sclerosis Functional Composite in a randomised, double-blind, placebo-controlled study of patients with relapsing multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S124
-
S125
.
Maghzi AH, Meier U, Holden D, Marta M, Kantor A, Waubant E, Giovannoni G, Goelz S
(
2009
)
.
Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S73
-
S73
.
Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sorensen PS, Chang P et al.
(
2009
)
.
Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S20
-
S20
.
Tzartos J, Khan G, Vossenkaemper A, Meager T, Sefia E, Clemens M, Giovannoni G, Esiri M et al.
(
2009
)
.
The anti-viral cytokine interferon-alpha is expressed in acute MS lesions and associated with the presence of Epstein-Barr virus infection
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S276
-
S276
.
Farrell R, Worthington V, Creeke P, Giovannoni G
(
2009
)
.
What do we do with positive neutralising antibody tests in subjects with MS?
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S242
-
S242
.
Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK, BioMS Study Grp
(
2009
)
.
Cerebrospinal fluid biomarkers in multiple sclerosis
.
NEUROBIOL DIS
vol.
35
,
(
2
)
117
-
127
.
Martino D, Dale RC, Gilbert DL, Giovannoni G, Leckman JF
(
2009
)
.
Immunopathogenic Mechanisms in Tourette Syndrome: A Critical Review
.
MOVEMENT DISORD
vol.
24
,
(
9
)
1267
-
1279
.
Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K et al.
(
2009
)
.
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI
.
NEUROLOGY
vol.
73
,
(
1
)
32
-
38
.
Al-Izki S, Pryce G, Giovannoni G, Baker D
(
2009
)
.
Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography
.
Mult Scler
vol.
15
,
(
7
)
795
-
801
.
Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Preto V et al.
(
2009
)
.
Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients
.
CLIN BIOCHEM
vol.
42
,
(
10-11
)
1001
-
1006
.
Deisenhammer F, Egg R, Giovannoni G, Hemmer B, Petzold A, Sellebjerg F, Teunissen C, Tumani H
(
2009
)
.
EFNS guidelines on disease-specific CSF investigations
.
EUR J NEUROL
vol.
16
,
(
6
)
760
-
770
.
Salvetti M, Giovannoni G, Aloisi F
(
2009
)
.
Epstein-Barr virus and multiple sclerosis
.
CURR OPIN NEUROL
vol.
22
,
(
3
)
201
-
206
.
Giovannoni G, Munschauer F, O'Connor PW, Phillips JT, Polman CH, Pace A, Kim R, Panzara MA
(
2009
)
.
Natalizumab improves physical disability in patients with relapsing multiple sclerosis
.
JOURNAL OF NEUROLOGY
.
vol.
256
,
S124
-
S124
.
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD et al.
(
2009
)
.
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL ( vol 256, pg 405, 2009)
.
J NEUROL
vol.
256
,
(
6
)
1035
-
1037
.
Luk C, Giovannoni G, Williams DR, Lees AJ, de Silva R
(
2009
)
.
Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies
.
J NEUROSCI METH
vol.
180
,
(
1
)
34
-
42
.
Leary S, Giovannoni G, Howard R, Miller D, Thompson A
(
2009
)
.
Multiple Sclerosis and Demyelinating Diseases
.
Neurology
,
Wiley
Hu MTM, Butterworth R, Giovannoni G, Church A, Logsdail S
(
2009
)
.
Chorea
.
CLIN MED
vol.
9
,
(
2
)
188
-
189
.
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G et al.
(
2009
)
.
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
.
LANCET NEUROL
vol.
8
,
(
3
)
254
-
260
.
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD et al.
(
2009
)
.
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
.
J NEUROL
vol.
256
,
(
3
)
405
-
415
.
Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B, Lynn F, Jurgensen S et al.
(
2009
)
.
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
.
NEUROLOGY
vol.
72
,
(
5
)
402
-
409
.
Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS et al.
(
2009
)
.
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
.
Mult Scler
vol.
15
,
(
2
)
219
-
228
.
Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Yee IM, Giovannoni G, Ebers GC, Sadovnick AD et al.
(
2009
)
.
Association of Infectious Mononucleosis with Multiple Sclerosis
.
NEUROEPIDEMIOLOGY
vol.
32
,
(
4
)
257
-
262
.
Maggiore C, Meier UC, Marta M, Nissim A, Giovannoni G
(
2009
)
.
B Cells and EBV Infection in People with MS
.
NEUROLOGY
.
vol.
72
,
A37
-
A37
.
Farrell R, Worthington V, Fogell-Hahn A, Creeke P, Keir G, Giovannoni G
(
2009
)
.
DEVELOPING IMPROVED GUIDELINES TO INTERPRET ANTI-IFN NEUTRALISING ANTIBODY TITRES: CORRELATION OF IN VIVO MARKERS OF IFNB; BIOACTIVITY (MXA) WITH LUCIFERASE REPORTER GENE NAB TITRES
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
80
,
99
-
100
.
Cavanna AE, Martino D, Orth M, Giovannoni G, Stern JS, Robertson MM, Critchley HD
(
2009
)
.
Neuropsychiatric-developmental model for the expression of tics, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS
.
WORLD J BIOL PSYCHIA
vol.
10
,
(
4
)
1037
-
1038
.
Monaghan TS, McCarthy AJ, Simister RJ, Rakshi JS, Giovannoni G, Costelloe L, Counihan TJ, Murphy RP et al.
(
2009
)
.
OCULAR FLUTTER-OPSOCLONUS-MYOCLONUS SYNDROME IN AN ADULT NEUROLOGICAL PRACTICE: AETIOLOGY AND OUTCOME
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
80
,
103
-
103
.
Cohen BA, Oger J, Gagnon A, Giovannoni G
(
2008
)
.
The implications of immunogenicity for protein-based multiple sclerosis therapies
.
J NEUROL SCI
vol.
275
,
(
1-2
)
7
-
17
.
Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJM et al.
(
2008
)
.
An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss
.
J NEUROIMMUNOL
vol.
201
,
200
-
211
.
Maggiore C, Trillo-Pazos G, Keir G, Pizzolato G, Edomi P, Nissim A, Giovannoni G
(
2008
)
.
Ectopic germinal centres in the brain of people with multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
14
,
S231
-
S231
.
Farrell R, Antony D, Clark D, Garson J, Miller DH, Giovannoni G
(
2008
)
.
Effect of interferon beta and the development of neutralising antibodies, on reactivation of latent EBV, in patients with multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
14
,
S229
-
S229
.
Farrell R, Wadhwa M, Worthington V, Creeke P, Thorpe R, Dilger P, Giovannoni G, Meager A
(
2008
)
.
Evaluation of activity, aggregation and NAB testing with generic interferon beta products: implications for treating multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
14
,
S40
-
S40
.
Jackson S, Al-Izik S, Pryce G, Giovannoni G, Baker D
(
2008
)
.
Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis
.
MULTIPLE SCLEROSIS
.
vol.
14
,
S80
-
S81
.
Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K
(
2008
)
.
High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
14
,
S86
-
S87
.
Havrdova E, Bates D, Galetta SL, Giovannoni G, Lublin F, O'Connor P, Phillips JT, Polman C et al.
(
2008
)
.
Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
14
,
S47
-
S47
.
Munschauer F, Giovannoni G, Lublin F, O'Connor P, Phillips JT, Polman C, Pace A, Kim R et al.
(
2008
)
.
Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability
.
MULTIPLE SCLEROSIS
.
vol.
14
,
S167
-
S168
.
Gnanapavan S, Jackson S, Grant D, Keir G, Giovannoni G
(
2008
)
.
Neural cell adhesion molecule as a biomarker of neuro-regeneration in experimental autoimmune encephalomyelitis
.
MULTIPLE SCLEROSIS
.
vol.
14
,
S281
-
S281
.
Cavanna AE, Draganski B, Martino D, Robertson MM, Defazio G, Monaco F, Giovannoni G, Frackowiak RSJ et al.
(
2008
)
.
The neural correlates of premonitory urges in Tourette syndrome
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
15
,
105
-
105
.
Martino D, Draganski B, Cavanna AE, Robertson MM, Defazio G, Orth M, Giovannoni G, Frackowiak RSJ et al.
(
2008
)
.
Tourette syndrome with and without attention deficit/hyperactivity disorder: a voxel-based morphometry MRI comparison study
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
15
,
121
-
122
.
Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J
(
2008
)
.
Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN beta in multiple sclerosis patients
.
J IMMUNOL METHODS
vol.
336
,
(
2
)
113
-
118
.
Al-Izki S, Pryce G, Jackson S, Giovannoni G, Baker D
(
2008
)
.
Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis
.
JOURNAL OF NEUROIMMUNOLOGY
.
vol.
197
,
173
-
173
.
Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G et al.
(
2008
)
.
Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis
.
BRAIN
vol.
131
,
1736
-
1748
.
Martino D, Draganski B, Cavanna A, Church A, Defazio G, Robertson MM, Frackowiak RSJ, Giovannoni G et al.
(
2008
)
.
Anti-basal ganglia antibodies and Tourette's syndrome: a voxel-based morphometry and diffusion tensor imaging study in an adult population
.
J NEUROL NEUROSUR PS
vol.
79
,
(
7
)
820
-
822
.
Giovannoni G
(
2008
)
.
To test or not to test: NMO-IgG and optic neuritis
.
NEUROLOGY
vol.
70
,
(
23
)
2192
-
2193
.
Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Lublin FD, O'Connor PW, Phillips JT et al.
(
2008
)
.
Complete clinical and magnetic resonance imaging response with natalizumab in multiple sclerosis
.
JOURNAL OF NEUROLOGY
.
vol.
255
,
37
-
37
.
Maggiore C, Trillo-Pazos G, Reynolds R, Giovannoni G, Miller D
(
2008
)
.
Detection of EBV antigens in germinal centres in the brain of people with multiple sclerosis
.
JOURNAL OF NEUROLOGY
.
vol.
255
,
9
-
9
.
Farrell R, Antony D, Clark D, Swanton J, Fisniku L, Khaleeli Z, Thompson A, Miller DH et al.
(
2008
)
.
Investigation of role of peripheral EBV reactivation in driving multiple sclerosis disease activity as measured by gadolinium enhanced MRI
.
JOURNAL OF NEUROLOGY
.
vol.
255
,
20
-
20
.
van de Warrenburg BPC, Church AJ, Martino D, Candler PM, Bhatia KP, Giovannoni G, Quinn NP
(
2008
)
.
Antineuronal antibodies in Parkinson's disease
.
MOVEMENT DISORD
vol.
23
,
(
7
)
958
-
963
.
Kalman B, Church AJ, Giovannoni G
(
2008
)
.
Poststreptococcal Movement Disorders
.
Neuroimmunology in Clinical Practice
,
Wiley
Hintzen RQ, Giovannoni G
(
2008
)
.
CSF analysis in suspected MS - Do bands aid?
.
NEUROLOGY
vol.
70
,
(
13
)
1059
-
1060
.
Farrell R, Anthony D, Clark D, Swanton J, Fisniku L, Khaleeli Z, Garson J, Thompson AJ et al.
(
2008
)
.
Is multiple disease activity, as detected by gadolinium enhanced MRI, associated with virological and immunological evidence of EBV reactivation in peripheral blood?
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
79
,
350
-
351
.
Farrell R, Kapoor R, Leary S, Rudge P, Thompson AJ, Millerand DH, Giovannoni G
(
2008
)
.
Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta
.
MULT SCLER
vol.
14
,
(
2
)
212
-
218
.
Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, Sellebjerg F
(
2008
)
.
Routine Cerebrospinal Fluid (CSF) Analysis
.
European Handbook of Neurological Management
,
Wiley
Gnanapavan S, Keir G, Grant D, Giovannoni G
(
2008
)
.
A sensitive ELISA method for the detection of human neural cell adhesion molecule (NCam) in cerebrospinal fluid
.
NEUROLOGY
.
vol.
70
,
A338
-
A338
.
Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D
(
2008
)
.
Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis
.
J NEUROIMMUNOL
vol.
193
,
(
1-2
)
120
-
129
.
Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G
(
2008
)
.
Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis
.
MULT SCLER
vol.
14
,
(
1
)
59
-
66
.
Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J
(
2008
)
.
Cost-effectiveness analyses of natalizumab (Tysabri (R)) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK
.
PHARMACOECONOMICS
vol.
26
,
(
7
)
617
-
627
.
Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G et al.
(
2008
)
.
Letters to the Editor [3]
.
Journal of International Medical Research
vol.
36
,
(
1
)
204
-
208
.
Herbert J, Kappos L, Calabresi P, Confavreux C, Galetta S, Giovannoni G, Havrdova E, Hutchinson M et al.
(
2008
)
.
Natalizumab reduces multiple sclerosis severity: Analysis of patients from the AFFIRM and SENTINEL studies using the multiple sclerosis severity scale
.
NEUROLOGY
.
vol.
70
,
A212
-
A212
.
Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G et al.
(
2008
)
.
Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
.
J INT MED RES
vol.
36
,
(
1
)
204
-
208
.
Gnanapavan S, Carrol C, Candler P, Allroggen H, Giovannoni G
(
2008
)
.
Paraneoplastic opsoclonus-myoclonus associated with metastatic melanoma and anti-neuroleukin (NLK) antibodies
.
JOURNAL OF NEUROIMMUNOLOGY
.
vol.
197
,
174
-
174
.
Gnanapavan S, Keir G, Mills K, Grant D, Giovannoni G
(
2008
)
.
Reduced cerebrospinal fluid neural cell adhesion molecule (NCam) in neurological disorders, a reflection of the capacity for neuronal regeneration
.
NEUROLOGY
.
vol.
70
,
A338
-
A338
.
Nicholson T, Heyman I, Church A, Giovannoni G
(
2007
)
.
Obsessive-compulsive disorder and catatonia can be caused by antibasal ganglia antibodies
.
COGN BEHAV NEUROL
vol.
20
,
(
4
)
260
-
260
.
Amor S, Giovannoni G
(
2007
)
.
Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis - are we there yet?
.
MULT SCLER
vol.
13
,
(
9
)
1083
-
1085
.
Polman CH, Deisenhammer F, Giovannoni G, Killestein J, Schellekens H
(
2007
)
.
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
.
Neurology
vol.
69
,
(
15
)
1553
-
1555
.
Driebergen R, Jaber A, Aotonelli M, Giovannoni G, Schellekens H, Simsarian J
(
2007
)
.
Development of Rebif (R) New Formulation for MS treatment: consolidated results from preclinical and phase I studies
.
MULTIPLE SCLEROSIS
.
vol.
13
,
S53
-
S53
.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G et al.
(
2007
)
.
Health-related quality of life in multiple sclerosis: Effects of Natalizumab
.
ANN NEUROL
vol.
62
,
(
4
)
335
-
346
.
Herbert J, Kappos L, Giovannoni G, Havrdova E, Hutchinson M, Lublin F, Miller D, O'Connor P et al.
(
2007
)
.
Impact of natalizumab on multiple sclerosis severity: analysis of patients and subgroups from the AFFIRM study using the Multiple Sclerosis Severity Scale
.
MULTIPLE SCLEROSIS
.
vol.
13
,
S169
-
S170
.
Havrdova E, Giovannoni G, Hutchinson M, Kappos L, Lublin F, Miller DH, O'Connor P, Phillips JT et al.
(
2007
)
.
Natalizumab increases the proportion of patients with multiple sclerosis who are disease-free
.
MULTIPLE SCLEROSIS
.
vol.
13
,
S170
-
S170
.
Farrell R, Leary S, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G
(
2007
)
.
Neutralising antibodies to interferon beta are associated with loss of efficacy of treatment and reduced side effects
.
MULTIPLE SCLEROSIS
.
vol.
13
,
S59
-
S59
.
Farrell R, Worthington V, Keir G, Giovannoni G
(
2007
)
.
Testing neutralizing antibodies: The way ahead
.
British Journal of Neuroscience Nursing
vol.
3
,
(
10
)
480
-
480
.
GIOVANNONI G, Panzara MA, Kappos L, Polman CH, O'Connor PW, Confavreux C, Calabresi PA, Miller DH et al.
(
2007
)
.
The Incidence and Significance of Anti-natalizumab: results from AFFIRM and SENTINEL
.
Neurology
vol.
69
,
(
14
)
1391
-
1403
.
Farrell R, Leary S, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G
(
2007
)
.
Evaluation of anti-interferon beta antibodies in subjects with multiple sclerosis attending the national hospital for neurology and neurosurgery, London
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
78
,
1038
-
1038
.
Gnanapavan S, Keir G, Grant D, Giovannoni G
(
2007
)
.
A sensitive ELISA method for the detection of human Neural Cell Adhesion Molecule (NCAM) in cerebrospinal fluid
.
JOURNAL OF NEUROCHEMISTRY
.
vol.
102
,
30
-
30
.
Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G
(
2007
)
.
Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
14
,
21
-
22
.
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J et al.
(
2007
)
.
Neutralising antibodies to interferon beta in multiple sclerosis - Expert panel report
.
J NEUROL
vol.
254
,
(
7
)
827
-
837
.
Teunissen CE, Killestein J, Giovannoni G
(
2007
)
.
Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity
.
BIOMARK MED
vol.
1
,
(
1
)
111
-
119
.
Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J et al.
(
2007
)
.
Immunogenicity and tolerability of an Investigational formulation of interferon-beta 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis
.
CLIN THER
vol.
29
,
(
6
)
1128
-
1145
.
Farrell RA, Giovannoni G
(
2007
)
.
Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis
.
MULT SCLER
vol.
13
,
(
5
)
567
-
577
.
Giovannoni G, Ebers G
(
2007
)
.
Multiple sclerosis: the environment and causation
.
CURR OPIN NEUROL
vol.
20
,
(
3
)
261
-
268
.
Martino D, Defazio G, Church AJ, Dale RC, Giovannoni G, Robertson MM, Orth M
(
2007
)
.
Antineuronal antibody status and phenotype analysis in Tourette's syndrome
.
Movement Disorders
vol.
22
,
(
10
)
1424
-
1429
.
Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW et al.
(
2007
)
.
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
.
NEUROLOGY
vol.
68
,
(
17
)
1390
-
1401
.
Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L et al.
(
2007
)
.
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
.
NEUROLOGY
vol.
68
,
(
16
)
1299
-
1304
.
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD et al.
(
2007
)
.
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells
.
NAT MED
vol.
13
,
(
4
)
492
-
497
.
Chapman MD, Thompson EJ, Candler PM, Dale RC, Church AJ, Giovannoni G
(
2007
)
.
Quantitative demonstration of intrathecal synthesis of high affinity immunoglobulin G in herpes simplex encephalitis using affinity-mediated immunoblotting
.
J NEUROIMMUNOL
vol.
185
,
(
1-2
)
130
-
135
.
Soon D, Altmann DR, Fernando KTM, Giovannoni G, Barkhof F, Polman CH, O'Connor P, Gray B et al.
(
2007
)
.
A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis
.
J NEUROL
vol.
254
,
(
3
)
306
-
314
.
Martino D, Church A, Giovannoni G
(
2007
)
.
Are antibasal ganglia antibodies important, and clinically useful?
.
Practical Neurology
vol.
7
,
(
1
)
32
-
41
.
Giovannoni G, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Polman CH et al.
(
2007
)
.
The immunogenicity of natalizumab in patients with multiple sclerosis: Results from the AFFIRM study
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
78
,
208
-
208
.
Gnanapavan S, Diemel L, Jackson S, Keir G, Giovannoni G
(
2007
)
.
Demyelination and axonal loss in rat brain aggregate cultures enriched with macrophages following inteferon-gamma induced demyelination
.
MULTIPLE SCLEROSIS
.
vol.
13
,
S258
-
S258
.
Gnanapavan S, Giovannoni G
(
2007
)
.
Incorporation of other biomarkers
.
Neurodegeneration in Multiple Sclerosis
.
Editors:
Filippi, M, Rovaris, M, Comi, G
,
183
-
207
.
Marschitz I, Rodl S, Gruber-Sedlmayr U, Church A, Giovannoni G, Zobel G, Mache CJ, Raith J et al.
(
2007
)
.
Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis
.
J NEUROL NEUROSUR PS
vol.
78
,
(
1
)
105
-
107
.
Giovannoni G, Kinkel P, Vartanian T
(
2007
)
.
Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices
.
Reviews in Neurological Diseases
vol.
4
,
(
4
)
184
-
193
.
Rejdak K, Empl M, Giffin NJ, Afridi SK, Petzold A, Stelmasiak Z, Thompson EJ, Goadsby PJ et al.
(
2006
)
.
Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients
.
EUR J NEUROL
vol.
13
,
(
12
)
1346
-
1351
.
Hawkes CH, Giovannoni G, Keir G, Cunnington M, Thompson EJ
(
2006
)
.
Seroprevalence of herpes simplex virus type 2 in multiple sclerosis
.
ACTA NEUROL SCAND
vol.
114
,
(
6
)
363
-
367
.
Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD et al.
(
2006
)
.
Infusion-related hypersensitivity reactions during natalizumab treatment
.
NEUROLOGY
vol.
67
,
(
9
)
1717
-
1718
.
Giovannoni G, Chapman MD, Thompson EJ
(
2006
)
.
The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders
.
J NEUROIMMUNOL
vol.
180
,
(
1-2
)
29
-
32
.
Giovannoni G, Cutter GR, Lunemann J, Martin R, Münz C, Sriram S, Steiner I, Hammerschlag MR et al.
(
2006
)
.
Infectious causes of multiple sclerosis
.
The Lancet Neurology
vol.
5
,
(
10
)
887
-
894
.
Petzold A, Mondira T, Keir G, Lim E, te Boekhorst P, Giovannoni G, Hintzen RQ
(
2006
)
.
Accelerated axonal degeneration after bonemarrow transplantation for aggressive multiple sclerosis?
.
MULTIPLE SCLEROSIS
.
vol.
12
,
S216
-
S216
.
Baker D, Croxford JL, Pryce G, Jackson SM, Ledent C, Marsicano G, Lutz B, Giovannoni G et al.
(
2006
)
.
Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis
.
JOURNAL OF NEUROIMMUNOLOGY
.
vol.
178
,
90
-
91
.
Kallmann BA, Spech E, Kroner A, Petzold A, Miller D, Thompson A, Giovannoni G, Rieckmann P
(
2006
)
.
Differences in TRADD expression indicated by array analysis discriminates between NIS disease subtypes
.
JOURNAL OF NEUROIMMUNOLOGY
.
vol.
178
,
202
-
202
.
Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, Sellebjerg F
(
2006
)
.
Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force
.
EUR J NEUROL
vol.
13
,
(
9
)
913
-
922
.
Giovannoni G
(
2006
)
.
Immune tolerance strategies to reverse the development of neutralising anti-interferon-beta antibodies
.
EUR J NEUROL
vol.
13
,
302
-
302
.
Petzold A, Eikelenboom M, Keir G, Giovannoni G, Polman C, Uitdehaag B, Amorini A, Di Pietro V et al.
(
2006
)
.
Impaired energy metabolism and increased lipid peroxidation in multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
12
,
S60
-
S60
.
Farrell RA, Giovannoni G
(
2006
)
.
Measuring anti-interferon beta neutralising antibodies - A novel cell-based assay
.
MULTIPLE SCLEROSIS
.
vol.
12
,
S205
-
S205
.
Giovannoni G
(
2006
)
.
Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype
.
J NEUROL NEUROSUR PS
vol.
77
,
(
9
)
1001
-
1002
.
Rejdak K, Leary SM, Petzold A, Stelmasiak Z, Thompson AJ, Miller DH, Giovannoni G
(
2006
)
.
Raised urinary neopterin excretion is associated with a better clinical outcome in PP-MS patients treated with interferon beta-1a
.
MULTIPLE SCLEROSIS
.
vol.
12
,
S185
-
S186
.
Hutchinson M, O'Connor PW, Havrdova E, Kappos L, Miller DH, Phillips JT, Polman CH, Lublin FD et al.
(
2006
)
.
The effects of natalizumab on disability and health-related quality of life in patients with relapsing MS
.
EUR J NEUROL
vol.
13
,
38
-
38
.
Hickman SJ, Sanyal A, Manji H, Groves MJ, Giovannoni G
(
2006
)
.
"Double whammy" neuropathy: a 37-year-old woman with burning and weakness in both legs
.
LANCET NEUROL
vol.
5
,
(
7
)
632
-
636
.
Luk CY, Giovannoni G, Lees AJ, de Silva R
(
2006
)
.
P2–155: Development of sensitive and specific ELISAs for three–repeat and four–repeat tau isoforms
.
Alzheimer's & Dementia
vol.
2
,
(
3S_Part_9
)
s279
-
s279
.
Karrenbauer VD, Leoni V, Lim ET, Giovannoni G, Ingle GT, Sastre-Garriga J, Thompson AJ, Rashid W et al.
(
2006
)
.
Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis
.
CLIN NEUROL NEUROSUR
vol.
108
,
(
5
)
456
-
460
.
(
2006
)
.
Editorial introductions
.
Current Opinion in Neurology
vol.
19
,
(
3
)
Rejdak K, Petzold A, Bartosik-Psujek H, Kurzepa J, Stelmasiak Z, Giovannoni G
(
2006
)
.
Expression of ferritin and S-100B in relation to nitric oxide metabolites in the cerebrospinal fluid of relapsing multiple sclerosis patients
.
JOURNAL OF NEUROLOGY
.
vol.
253
,
58
-
59
.
Dale RC, Church AJ, Candler PM, Chapman M, Martino D, Giovannoni G
(
2006
)
.
Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls
.
Neurology
vol.
66
,
(
10
)
Giovannoni G, Cook S, Rieckmann P, Vermersch P, Soelberg-Sorensen P, Comi G, Chang P, Lopez-Bresnahan M et al.
(
2006
)
.
The design of the CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY)
.
JOURNAL OF NEUROLOGY
.
vol.
253
,
99
-
99
.
Candler PM, Dale RC, Griffin S, Church AJ, Wait R, Chapman MD, Keir G, Giovannoni G et al.
(
2006
)
.
Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies
.
J NEUROL NEUROSUR PS
vol.
77
,
(
4
)
507
-
512
.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD et al.
(
2006
)
.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
.
NEW ENGL J MED
vol.
354
,
(
9
)
899
-
910
.
Dale RC, Candler PM, Church AJ, Wait R, Pocock JM, Giovannoni G
(
2006
)
.
Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease
.
J NEUROIMMUNOL
vol.
172
,
(
1-2
)
187
-
197
.
Martino D, Church AJ, Defazio G, Dale RC, Quinn NP, Robertson MM, Livrea P, Orth M et al.
(
2006
)
.
Corrigendum to: Soluble adhesion molecules in Gilles de la Tourette's syndrome (vol 234, pg 79, 2005)
.
J NEUROL SCI
vol.
241
,
(
1-2
)
111
-
+
.
Smith K, Sharief M
(
2006
)
.
Multiple Sclerosis
.
Giovannoni G
(
2006
)
.
Multiple sclerosis cerebrospinal fluid biomarkers
.
DISEASE MARKERS
.
vol.
22
,
187
-
196
.
Giovannoni G
(
2006
)
.
Multiple sclerosis related fatigue
.
J NEUROL NEUROSUR PS
vol.
77
,
(
1
)
2
-
3
.
Giovannoni G
(
2006
)
.
PANDAS: overview of the hypothesis
.
Advances in Neurology
vol.
99
,
159
-
165
.
Hawkes CH, Giovannoni G, Thompson EJ, Cunnington M
(
2006
)
.
Raised prevalence of herpes simplex type-2 antibody in multiple sclerosis
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
77
,
131
-
131
.
Giovannoni G, O'Connor P, Havrdova E, Hutchinson M, Kappos L, Miller D, PhillipS JT, Polman C et al.
(
2006
)
.
The immunogenicity of natalizumab in patients with multiple sclerosis
.
CLINICAL IMMUNOLOGY
.
vol.
119
,
S116
-
S116
.
Petzold A, Eikelenboom MJ, Keir G, Polman CH, Uitdehaag BMJ, Thompson EJ, Giovannoni G
(
2006
)
.
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
.
MULT SCLER
vol.
12
,
(
3
)
325
-
328
.
Kappos L, O'Connor PW, Havrdova E, Hutchinson M, Miller DH, Phillips JT, Polman CH, Lublin FD et al.
(
2005
)
.
Prognostic indicators of future disease activity in patients with relapsing multiple sclerosis (MS): an analysis from the AFFIRM study
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
238
,
S75
-
S75
.
Miller DH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Phillips JT, Polman CH, Lublin FD et al.
(
2005
)
.
The effects of baseline disease activity on magnetic resonance imaging (MRI) outcomes in the AFFIRM study
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
238
,
S75
-
S76
.
Galetta SL, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Polman CH et al.
(
2005
)
.
The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
238
,
S71
-
S72
.
Rejdak K, Leary SM, Stelmasiak Z, Miller DH, Thompson AJ, Giovannoni G
(
2005
)
.
Urinary nitric oxide metabolites and neopterin as markers of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients
.
JOURNAL OF THE NEUROLOGICAL SCIENCES
.
vol.
238
,
S244
-
S244
.
Farrell R, Heaney D, Giovannoni G
(
2005
)
.
Emerging therapies in multiple sclerosis
.
Expert Opinion on Emerging Drugs
vol.
10
,
(
4
)
797
-
816
.
Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, Keir G, Thompson EJ, Giovannoni G
(
2005
)
.
Acute axonal damage predicts clinical outcome in patients with multiple sclerosis
.
MULT SCLER
vol.
11
,
(
5
)
532
-
536
.
Dale RC, Heyman I, Giovannoni G, Church AJ
(
2005
)
.
Incidence of anti-brain antibodies in children with obsessive-compulsive disorder
.
BRIT J PSYCHIAT
vol.
187
,
314
-
319
.
Martino D, Branson JA, Church AJ, Candler PM, Livrea P, Giovannoni G, Dale RC
(
2005
)
.
Soluble adhesion molecules in acute disseminated encephalomyelitis
.
PEDIATR NEUROL
vol.
33
,
(
4
)
255
-
258
.
Hawkes CH, Giovannoni G, Thompson EJ, Cunnington M
(
2005
)
.
Raised prevalence of herpes simplex type-2 antibody in multiple sclerosis
.
MULTIPLE SCLEROSIS
.
vol.
11
,
S135
-
S135
.
Rejdak K, Petzold A, Chard D, Griffin C, Miszkiel KA, Davis G, Rashid W, Miller DH et al.
(
2005
)
.
Raised serum nitric oxide metabolites are related to disease activity in patients with multiple sclerosis: 1-year follow-up study
.
EUR J NEUROL
vol.
12
,
320
-
320
.
Soon D, Altmann DR, Barkhof F, Fernando KTM, Giovannoni G, Gray B, O'Connor PW, Panzara MA et al.
(
2005
)
.
Subtle blood brain barrier leakage in non-enhancing lesions in relapsing multiple sclerosis: multi-centre study of patients in a therapeutic trial
.
MULTIPLE SCLEROSIS
.
vol.
11
,
S2
-
S2
.
Giovannoni G
(
2005
)
.
What is required for a biomarker to become a good surrogate outcome?
.
MULTIPLE SCLEROSIS
.
vol.
11
,
S10
-
S11
.
Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G, Thompson EJ, Miller DH et al.
(
2005
)
.
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis
.
MULT SCLER
vol.
11
,
(
4
)
492
-
494
.
Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D
(
2005
)
.
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis
.
J NEUROIMMUNOL
vol.
165
,
(
1-2
)
41
-
52
.
Martino D, Church AJ, Defazio G, Dale RC, Quinn NP, Robertson MM, Livrea P, Orth M et al.
(
2005
)
.
Soluble adhesion molecules in Gilles de la Tourette's syndrome
.
J NEUROL SCI
vol.
234
,
(
1-2
)
79
-
85
.
Giovannoni G, Goodman A
(
2005
)
.
Neutralizing anti-IFN-beta antibodies - How much more evidence do we need to use them in practice?
.
NEUROLOGY
vol.
65
,
(
1
)
6
-
8
.
Giovannoni G
(
2005
)
.
Anti-neuronal antibodies and movement disorders
.
J NEUROIMMUNOL
vol.
163
,
(
1-2
)
5
-
7
.
Wills A, Dale R, Giovannoni G
(
2005
)
.
Gluten ataxia and post-streptococcal central nervous system syndromes: Emerging immune-mediated disorders of the central nervous system?
.
Current Treatment Options in Neurology
vol.
7
,
(
3
)
183
-
189
.
Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Öhman S, Racke MK et al.
(
2005
)
.
Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis: A Consensus Statement
.
JAMA Neurology
vol.
62
,
(
6
)
865
-
870
.
Davies S, Nicholson T, Laura M, Giovannoni G, Altmann DM
(
2005
)
.
Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis
.
J NEUROPATH EXP NEUR
vol.
64
,
(
5
)
371
-
377
.
Martino D, Tanner A, Defazio G, Church AJ, Bhatia KP, Giovannoni G, Dale RC
(
2005
)
.
Tracing Sydenham's chorea: historical documents from a British paediatric hospital
.
ARCH DIS CHILD
vol.
90
,
(
5
)
507
-
511
.
Plecko B, Gruber-Sedlmayr U, Marschitz I, Rödl S, Mache C, Church A, Giovannoni G, Grubbauer H et al.
(
2005
)
.
Severe autoimmune chorea with positive antibasalganglia antibodies (ABGA) following herpesencephalitis: Treatment with plasmapheresis and corticosteroids
.
Neuropediatrics
vol.
36
,
(
02
)
Lim ET, Schmierer K, Grant D, Keir G, Thompson EJ, Miller DH, Giovannoni G
(
2005
)
.
A comparison of the immunology and histopathology in post mortem multiple sclerosis brain
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
76
,
615
-
616
.
Giovannoni G
(
2005
)
.
Erratum: PANDAS: Visão geral da hipótese (Revista Brasileira de Psiquiatria 26, 4 (222-223))
.
Revista Brasileira de Psiquiatria
vol.
27
,
(
1
)
Giovannoni G
(
2005
)
.
PANDAS: visão geral da hipótese
.
Brazilian Journal of Psychiatry
vol.
26
,
(
4
)
222
-
223
.
Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RHC, Polman CH, Uitdehaag BMJ, Thompson EJ et al.
(
2005
)
.
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
.
J NEUROL NEUROSUR PS
vol.
76
,
(
2
)
206
-
211
.
Martino D, Church AJ, Dale RC, Giovannoni G
(
2005
)
.
Antibasal ganglia antibodies and PANDAS
.
MOVEMENT DISORD
vol.
20
,
(
1
)
116
-
117
.
Martino D, Giovannoni G
(
2005
)
.
Autoaggressive immune-mediated movement disorders
.
Advances in Neurology
vol.
96
,
320
-
335
.
Chapman MD, Hartley JC, Furrows SJ, Ridgeway GL, Thompson EJ, Church AJ, Candler PM, Giovannoni G
(
2005
)
.
Lack of serum oligoclonal antibody responses to Chlamydophila pneumoniae in multiple sclerosis
.
EUR NEUROL
vol.
53
,
(
2
)
81
-
83
.
Chapman MD, Hughes LE, Wilson CD, Namnyak S, Thompson EJ, Giovannoni G
(
2005
)
.
No evidence for production of intrathecal immunoglobulin g against Acinetobacter or Pseudomonas in multiple sclerosis
.
EUR NEUROL
vol.
53
,
(
1
)
27
-
31
.
Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RHC, Barkhof F, Polman CH et al.
(
2004
)
.
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis
.
NEUROLOGY
vol.
63
,
(
8
)
1439
-
1445
.
Lim ET, Petzold A, Leary SM, Altmann DR, Keir G, Thompson EJ, Miller DH, Thompson AJ et al.
(
2004
)
.
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
.
Journal of Negative Results in BioMedicine
vol.
3
,
(
1
)
Giovannoni G, Green A, Keir G, Thompson EJ
(
2004
)
.
Urinary myelin basic protein‐like material as a correlate of the progression of multiple sclerosis
.
Annals of Neurology
vol.
40
,
(
1
)
128
-
129
.
Edwards MJ, Dale RC, Church AJ, Trikouli E, Quinn NP, Lees AJ, Giovannoni G, Bhatia KP
(
2004
)
.
Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies
.
MOVEMENT DISORD
vol.
19
,
(
10
)
1190
-
1196
.
Harrison NA, Church A, Nisbet A, Rudge P, Giovannoni G
(
2004
)
.
Late recurrences of Sydenham's chorea are not associated with anti-basal ganglia antibodies
.
J NEUROL NEUROSUR PS
vol.
75
,
(
10
)
1478
-
1479
.
Spech E, Kallmann B, Kroner A, Petzold A, Miller D, Thompson A, Giovannoni G, Toyka K et al.
(
2004
)
.
Unterschiede im Genexpressionsmuster bei schubförmiger und primär progredienter Multipler Sklerose
.
Aktuelle Neurologie
vol.
31
,
(
S 1
)
Pryce G, Jackson SM, Hankey DRJ, Giovannoni G, Baker D
(
2004
)
.
Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression
.
JOURNAL OF NEUROIMMUNOLOGY
.
vol.
154
,
78
-
78
.
Pryce G, O'Neill JK, Hankey DRJ, East E, Amor S, Giovannoni G, Baker B
(
2004
)
.
Immunological tolerance that eliminates relapses, fails to halt secondary progression in a chronic multiple sclerosis model
.
JOURNAL OF NEUROIMMUNOLOGY
.
vol.
154
,
62
-
62
.
Giovannoni G
(
2004
)
.
Is it time to consider rationalising IFN-beta treatment in individuals with multiple sclerosis?
.
J NEUROL NEUROSUR PS
vol.
75
,
(
9
)
1234
-
1234
.
Zwemmer JNP, Eikelenboom MJ, Kay A, Petzold A, Thompson EJ, Giovannoni G, Barkhof E, Uitdehaag BMJ et al.
(
2004
)
.
No association of apoE concentration in CSF with clinical arid MR1 characteristics in MS
.
MULTIPLE SCLEROSIS
.
vol.
10
,
S212
-
S213
.
Giovannoni G
(
2004
)
.
Optimising MS disease-modifying therapies: antibodies in perspective
.
J NEUROL
vol.
251
,
30
-
35
.
Rejdak K, Leary SM, Nelissen I, Opdenakker G, Dubois B, Thompson AJ, Giovannoni G
(
2004
)
.
Urinary neopterin is a sensitive marker of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients
.
EUR J NEUROL
vol.
11
,
120
-
120
.
Bennett DLH, McCabe DJH, Stevens JM, Mifsud V, Kitchen ND, Giovannoni G
(
2004
)
.
Tumefactive neuro-Behçet disease
.
Neurology
vol.
63
,
(
4
)
Edwards MJ, Trikouli E, Martino D, Bozi M, Dake RC, Church AJ, Schrag A, Lees AJ et al.
(
2004
)
.
Anti-basal ganglia antibodies in patients with atypical dystonia and tics: A prospective study
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
75
,
1216
-
1216
.
Martino D, Giovannoni G
(
2004
)
.
Antibasal ganglia antibodies and their relevance to movement disorders
.
CURR OPIN NEUROL
vol.
17
,
(
4
)
425
-
432
.
Lim ET, Sellebjerg F, Sorensen TL, Grant D, Altmann D, Keir G, Thompson EJ, Giovannoni G
(
2004
)
.
Cerebrospinal fluid neurofilament heavy chain levels in acute optic neuritis and multiple sclerosis patients treated with oral high-dose methylpredinolone
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
75
,
1215
-
1215
.
Edwards MJ, Trikouli E, Martino D, Bozi M, Dale RC, Church AJ, Schrag A, Lees AJ et al.
(
2004
)
.
Anti-basal ganglia antibodies in patients with atypical dystonia and tics - A prospective study
.
NEUROLOGY
vol.
63
,
(
1
)
156
-
158
.
Church AJ, Dale RC, Giovannoni G
(
2004
)
.
Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders?
.
ARCH DIS CHILD
vol.
89
,
(
7
)
611
-
614
.
Dale RC, Heyman I, Surtees RAH, Church AJ, Giovannoni G, Goodman R, Neville BGR
(
2004
)
.
Dyskinesias and associated psychiatric disorders following streptococcal infections
.
ARCH DIS CHILD
vol.
89
,
(
7
)
604
-
610
.
Edwards MJ, Dale RC, Church AJ, Giovannoni G, Bhatia KP
(
2004
)
.
A dystonic syndrome associated with anti-basal ganglia antibodies
.
J NEUROL NEUROSUR PS
vol.
75
,
(
6
)
914
-
916
.
Spech E, Kallmann B, Kroner A, Petzold A, Miller D, Thompson A, Giovannoni G, Toyka K et al.
(
2004
)
.
Gene expression analysis indicates distinct immune pattern in relapsing remitting (RR) and primary progressive (PP) MS disease type
.
JOURNAL OF NEUROLOGY
.
vol.
251
,
175
-
175
.
Rejdak K, Petzold A, Sharpe MA, Kay AD, Kerr M, Keir G, Thompson EJ, Giovannoni G
(
2004
)
.
Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage
.
J NEUROL SCI
vol.
219
,
(
1-2
)
71
-
76
.
Giovannoni G, Keir G, Thompson E
(
2004
)
.
The clinical significance of an intrathecal monoclonal immunoglobulin band: A follow-up study: Reply from the Authors
.
Neurology
vol.
62
,
(
7
)
Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ
(
2004
)
.
An ELISA for glial fibrillary acidic protein
.
J IMMUNOL METHODS
vol.
287
,
(
1-2
)
169
-
177
.
Pereira AC, Edwards MJ, Buttery PC, Hawkes CH, Quinn NP, Giovannoni G, Hadjivassiliou M, Bhatia KP
(
2004
)
.
Choreic syndrome and coeliac disease: A hitherto unrecognised association
.
MOVEMENT DISORD
vol.
19
,
(
4
)
478
-
482
.
Giovannoni G
(
2004
)
.
Toward better diagnosis of progressive supranuclear palsy: Cerebrospinal fluid biomarkers
.
MOVEMENT DISORDERS
.
vol.
19
,
361
-
362
.
Giovannoni G, Davies G, Keir G, Thompson E
(
2004
)
.
The clinical significance of an intrathecal monoclonal immunoglobulin band: A follow-up study: Reply from the authors
.
Neurology
vol.
62
,
(
4
)
675
-
676
.
Miranda M, Cardoso F, Giovannoni G, Church A
(
2004
)
.
Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies
.
J NEUROL NEUROSUR PS
vol.
75
,
(
2
)
327
-
328
.
Giovannoni G, Deisenhammer F
(
2004
)
.
Neutralising antibodies against interferon beta in multiple sclerosis
.
LANCET
vol.
363
,
(
9403
)
166
-
167
.
Lim ET, Grant D, Pashenkov M, Keir G, Thompson EJ, Soderstrom M, Giovannoni G
(
2004
)
.
Cerebrospinal fluid levels of brain specific proteins in optic neuritis
.
MULT SCLER
vol.
10
,
(
3
)
261
-
265
.
Furrows SJ, Hartley JC, Bell J, Silver N, Losseff N, Stevenson S, Chapman M, Thompson EJ et al.
(
2004
)
.
Chlamydophila pneumoniae infection of the central nervous system in patients with multiple sclerosis
.
J NEUROL NEUROSUR PS
vol.
75
,
(
1
)
152
-
154
.
Dale RC, Church AJ, Surtees RAH, Lees AJ, Adcock JE, Harding B, Neville BGR, Giovannoni G
(
2004
)
.
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity
.
BRAIN
vol.
127
,
21
-
33
.
Deisenhammer F, Giovannoni G
(
2004
)
.
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis
.
MULT SCLER J
vol.
10
,
(
6
)
Giovannoni G
(
2004
)
.
Management of secondary-progressive multiple sclerosis
.
CNS DRUGS
vol.
18
,
(
10
)
653
-
669
.
Petzold A, Brassat D, Mas P, Rejdak K, Keir G, Giovannoni G, Thompson EJ, Clanet M
(
2004
)
.
Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis
.
MULT SCLER
vol.
10
,
(
3
)
281
-
283
.
Giovannoni G
(
2003
)
.
Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies
.
NEUROLOGY
.
vol.
61
,
S13
-
S17
.
Polman CH, Petkau J, White R, Thompson A, Miller DH, Dahlke F, Kappos L
(
2003
)
.
Neutralizing antibodies during treatment of secondary progressive MS with interferon &bgr;-1b
.
Neurology
vol.
61
,
(
7
)
Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A et al.
(
2003
)
.
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
.
BRAIN
vol.
126
,
2191
-
2202
.
Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ
(
2003
)
.
Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta 1a
.
J NEUROL
vol.
250
,
(
9
)
1037
-
1043
.
Empl M, Redjak K, Giovannoni G, Goadsby PJ, Kaube H
(
2003
)
.
Urinary nitric oxide metabolites in migraineurs
.
CEPHALALGIA
.
vol.
23
,
636
-
637
.
Tengah DSNAP, Church A, Giovannoni G, Fry L, Turner B, Wills AJ
(
2003
)
.
An anti-spinal antibody in dermatitis herpetiformis patients
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
74
,
1180
-
1180
.
Giovannoni G, Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, Miller DH
(
2003
)
.
Beta-interferon in multiple sclerosis: An assessment of the ABN stopping criteria in clinical practice
.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
.
vol.
74
,
1177
-
1178
.
Giovannoni G, Deisenhammer F, Munschauer FE
(
2003
)
.
Neutralising antibodies to interferon beta - Reply
.
J NEUROL NEUROSUR PS
vol.
74
,
(
8
)
1162
-
1163
.
Ortenzi C
(
2003
)
.
Neutralising antibodies to interferon β
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
74
,
(
8
)
Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ
(
2003
)
.
A specific ELISA for measuring neurofilament heavy chain phosphoforms
.
J IMMUNOL METHODS
vol.
278
,
(
1-2
)
179
-
190
.
Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G
(
2003
)
.
Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre
.
J NEUROL NEUROSUR PS
vol.
74
,
(
7
)
946
-
949
.
Empl M, Giovannoni G
(
2003
)
.
Nitric oxide and headache: related, but how?
.
CEPHALALGIA
vol.
23
,
(
6
)
405
-
406
.
Rejdak K, Petzold A, Sharpe MA, Kay AD, Kerr M, Stelmasiak Z, Thompson EJ, Giovannoni G
(
2003
)
.
Cerebrospinal fluid nitrite/nitrate predicts poor outcome in patients with subarachnoid hemorrhage (SAH)
.
JOURNAL OF NEUROCHEMISTRY
.
vol.
85
,
25
-
25
.
Giovannoni G, Baker D
(
2003
)
.
Inflammatory disorders of the central nervous system
.
CURR OPIN NEUROL
vol.
16
,
(
3
)
347
-
350
.
Pryce G, Giovannoni G, Baker D
(
2003
)
.
Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice
.
NEUROSCI LETT
vol.
341
,
(
2
)
164
-
166
.
Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G
(
2003
)
.
Quantification of neurodegeneration by measurement of brain-specific proteins
.
J NEUROIMMUNOL
vol.
138
,
(
1-2
)
45
-
48
.
Baker D, Pryce G, Giovannoni G, Thompson AJ
(
2003
)
.
The therapeutic potential of cannabis
.
LANCET NEUROL
vol.
2
,
(
5
)
291
-
298
.
Church AJ, Dale RC, Lees AJ, Giovannoni G, Robertson MM
(
2003
)
.
Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis
.
J NEUROL NEUROSUR PS
vol.
74
,
(
5
)
602
-
607
.
Rejdak K, Petzold A, Sharpe MA, Smith M, Keir G, Stelmasiak Z, Thompson EJ, Giovannoni G
(
2003
)
.
Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury
.
J NEUROL SCI
vol.
208
,
(
1-2
)
1
-
7
.
Davies G, Keir G, Thompson EJ, Giovannoni G
(
2003
)
.
The clinical significance of an intrathecal monoclonal immunoglobulin band - A follow-up study
.
NEUROLOGY
vol.
60
,
(
7
)
1163
-
1166
.
Church AJ, Dale RC, Cardoso F, Candler PM, Chapman MD, Allen ML, Klein NJ, Lees AJ et al.
(
2003
)
.
CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome?
.
J NEUROIMMUNOL
vol.
136
,
(
1-2
)
149
-
153
.
Eikelenboom MJ, Petzold A, Lazeron RHC, Silber E, Sharief M, Thompson EJ, Barkhof F, Giovannoni G et al.
(
2003
)
.
Multiple sclerosis - Neurofilament light chain antibodies are correlated to cerebral atrophy
.
NEUROLOGY
vol.
60
,
(
2
)
219
-
223
.
Giovannoni G, Bever CT
(
2003
)
.
Patients with clinically isolated syndromes suggestive of MS - Does MRI allow earlier diagnosis?
.
NEUROLOGY
vol.
60
,
(
1
)
6
-
7
.
Trip SA, Wroe SJ, Davies G, Giovannoni G
(
2003
)
.
Primary CNS mantle cell lymphoma associated with an isolated CSF monoclonal IgG band
.
EUR NEUROL
vol.
49
,
(
3
)
187
-
188
.
Giovannoni G
(
2003
)
.
The Yin and Yang of inflammation in multiple sclerosis
.
EARLY INDICATORS, EARLY TREATMENTS, NEUROPROTECTION IN MULTIPLE SCLEROSIS
.
Editors:
Hommes, OR, Comi, G
,
181
-
189
.
Stewart VC, Giovannoni G, Land JM, McDonald WI, Clark JB, Heales SJR
(
2002
)
.
Pretreatment of Astrocytes with Interferon‐α/β Impairs Interferon‐γ Induction of Nitric Oxide Synthase
.
Journal of Neurochemistry
vol.
68
,
(
6
)
2547
-
2551
.
Giovannoni G, Munschauer FE, Deisenhammer F
(
2002
)
.
Neutralising antibodies to interferon beta during the treatment of multiple sclerosis
.
J NEUROL NEUROSUR PS
vol.
73
,
(
5
)
465
-
469
.
Rejdak K, Bartosik-Psujek H, Dobosz B, Kocki T, Grieb P, Giovannoni G, Turski WA, Stelmasiak Z
(
2002
)
.
Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients
.
NEUROSCI LETT
vol.
331
,
(
1
)
63
-
65
.
Church AJ, Cardoso F, Dale RC, Lees AJ, Thompson EJ, Giovannoni G
(
2002
)
.
Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea
.
NEUROLOGY
vol.
59
,
(
2
)
227
-
231
.
Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RHC, Cuzner ML, Polman CH et al.
(
2002
)
.
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations
.
BRAIN
vol.
125
,
1462
-
1473
.
Dale RC, Church AJ, Benton S, Surtees RA, Lees A, Thompson EJ, Giovannoni G, Neville BG
(
2002
)
.
Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis
.
DEV MED CHILD NEUROL
vol.
44
,
(
7
)
485
-
489
.
Dale RC, Church AJ, Surtees RAH, Thompson EJ, Giovannoni G, Neville BGR
(
2002
)
.
Post-streptococcal autoimmune neuropsychiatric disease presenting as paroxysmal dystonic choreoathetosis
.
MOVEMENT DISORD
vol.
17
,
(
4
)
817
-
820
.
Giovannoni G
(
2002
)
.
The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis
.
Neurology
vol.
58
,
(
10
)
Sellebjerg F, Giovannoni G, Hand A, Madsen HO, Jensen CV, Garred P
(
2002
)
.
Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis
.
J NEUROIMMUNOL
vol.
125
,
(
1-2
)
198
-
203
.
Derry C, Dale RC, Thom M, Miller DH, Giovannoni G
(
2002
)
.
Unihemispheric cerebral vasculitis mimicking Rasmussen's encephalitis
.
NEUROLOGY
vol.
58
,
(
2
)
327
-
328
.
Ramachandran V, Church A, Giovannoni G, Bhatia KP
(
2002
)
.
Anti-basal ganglia antibodies are absent in patients with primary blepharospasm
.
NEUROLOGY
vol.
58
,
(
1
)
150
-
150
.
Tengah DSNAP, Unsworth DJ, Fry L, Giovannoni G, Church A, Turner B, Holmes GKT, Wills AJ
(
2002
)
.
Dermatitis herpetiformis, coeliac disease, and neurological dysfunction
.
J NEUROL NEUROSUR PS
vol.
72
,
(
1
)
142
-
142
.
Dale RC, Church AJ, Cardoso F, Goddard E, Cox TC, Chong WK, Williams A, Klein NJ et al.
(
2001
)
.
Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies
.
ANN NEUROL
vol.
50
,
(
5
)
588
-
595
.
Giovannoni G, Thorpe J
(
2001
)
.
Is it multiple sclerosis or not?
.
NEUROLOGY
vol.
57
,
(
8
)
1357
-
1358
.
Giovannoni G, Thompson AJ, Miller DH, Thompson EJ
(
2001
)
.
Fatigue is not associated with raised inflammatory markers in multiple sclerosis
.
NEUROLOGY
vol.
57
,
(
4
)
676
-
681
.
Giovannoni G
(
2001
)
.
Human swayback disease: expanding the spectrum of diseases associated with abnormal copper metabolism
.
J NEUROL
vol.
248
,
(
8
)
707
-
707
.
Giovannoni G, Miller DH, Losseff NA, Sailer M, Lewellyn-Smith N, Thompson AJ, Thompson EJ
(
2001
)
.
Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis
.
J NEUROL
vol.
248
,
(
6
)
487
-
495
.
Giovannoni G, Morris PR, Keir G
(
2001
)
.
Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis
.
Annals of Neurology
vol.
47
,
(
5
)
684
-
685
.
Chamoun V, Zeman A, Blennow K, Fredman P, Wallin A, Keir G, Giovannoni G, Thompson EJ
(
2001
)
.
Haptoglobins as markers of blood-CSF barrier dysfunction: the findings in normal CSF
.
J NEUROL SCI
vol.
182
,
(
2
)
117
-
121
.
Homann CN, Suppan K, Wenzel K, Giovannoni G, Ivanic G, Horner S, Ott E, Hartung HP
(
2001
)
.
The bradykinesia akinesia incoordination test (BRAIN TEST©), an objective and user‐friendly means to evaluate patients with Parkinsonism
.
Movement Disorders
vol.
15
,
(
4
)
641
-
647
.
Palmer HE, Giovannoni G, Stanford MR, Wallace GR, Graham EM
(
2001
)
.
Urinary neopterin in idiopathic retinal vasculitis
.
BRIT J OPHTHALMOL
vol.
85
,
(
1
)
30
-
33
.
Green AJE, Giovannoni G, Hall-Crags MA, Thompson EJ, Miller RF
(
2000
)
.
Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease
.
SEX TRANSM INFECT
vol.
76
,
(
6
)
443
-
446
.
Giovannoni G, Silver NC, Good CD, Miller DH, Thompson EJ
(
2000
)
.
Immunological Time-Course of Gadolinium-Enhancing MRI Lesions in Patients with Multiple Sclerosis
.
European Neurology
vol.
44
,
(
4
)
222
-
228
.
Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F et al.
(
2000
)
.
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
.
Brain
vol.
123
,
(
11
)
2321
-
2337
.
Rook GAW, Ristori G, Salvetti M, Giovannoni G, Thompson EJ, Stanford JL
(
2000
)
.
Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune diseases
.
Trends in Immunology
vol.
21
,
(
10
)
503
-
508
.
Miller RF, Green AJE, Giovannoni G, Thompson EJ
(
2000
)
.
Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients
.
Sexually Transmitted Infections
vol.
76
,
(
5
)
LUCHETTI A, AMADI A, GOBBI G, BERTANI G
(
2000
)
.
Visual field defects associated with vigabatrin monotherapy in children
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
69
,
(
4
)
Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ
(
2000
)
.
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
68
,
(
4
)
Giovannoni G
(
2000
)
.
Multiple sclerosis and the optometrist
.
Ophthalmic & Physiological Optics
vol.
20
,
(
2
)
s14
-
s15
.
Giovannoni G
(
2000
)
.
Multiple sclerosis and the optometrist
.
Ophthalmic & Physiological Optics
vol.
20
,
(
s1
)
s14
-
s15
.
Giovannoni G, van Schalkwyk J, Fritz VU, Lees AJ
(
1999
)
.
Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
67
,
(
5
)
Akinola AB, Land JM, Mathias CJ, Giovannoni G, Magnifico F, Puvi-Rajasingham S, Smith GDP, Watson L
(
1999
)
.
Contribution of nitric oxide to exercise-induced hypotension in human sympathetic denervation
.
Clinical Autonomic Research
vol.
9
,
(
5
)
263
-
269
.
Giovannoni G, Silver NC, O'Riordan J, Miller RF, Heales SJR, Land JM, Elliot M, Feldmann M et al.
(
1999
)
.
Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease
.
Multiple Sclerosis Journal
vol.
5
,
(
5
)
335
-
341
.
Kieseier BC, Seifert T, Giovannoni G, Hartung H-P
(
1999
)
.
Matrix metalloproteinases in inflammatory demyelination
.
Neurology
vol.
53
,
(
1
)
20
-
25
.
Giovannoni G, Silver NC, O'Riordan J, Miller RF, Heales SJR, Land JM, Elliot M, Feldmann M et al.
(
1999
)
.
Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease
.
Multiple Sclerosis Journal
vol.
5
,
(
5
)
335
-
341
.
Green AJ, Giovannoni G, Miller RF, Harrison MJ, Thompson EJ
(
1999
)
.
Cerebrospinal fluid S-100b concentrations in patients with HIV infection
.
AIDS
vol.
13
,
(
1
)
139
-
140
.
Kieseier BC, Giovannoni G, Hartung HP
(
1999
)
.
Immunological surrogate markers of disease activity in multiple sclerosis
.
vol.
50
,
570
-
583
.
Giovannoni G, Miller DH
(
1999
)
.
Multiple sclerosis and its treatment
.
Clinical Medicine
vol.
33
,
(
4
)
315
-
322
.
Giovannoni G, Silver NC, Good CD, Feldmann M, Miller DH, Thompson EJ
(
1998
)
.
Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis
.
Journal of Neuroimmunology
vol.
90
,
(
1
)
Giovannoni G, Green AJ, Thompson EJ
(
1998
)
.
Are there any body fluid markers of brain atrophy in multiple sclerosis?
.
Multiple Sclerosis Journal
vol.
4
,
(
3
)
138
-
142
.
Giovannoni G, Heales SJR, Land JM, Thompson EJ
(
1998
)
.
The potential role of nitric oxide in multiple sclerosis
.
Multiple Sclerosis Journal
vol.
4
,
(
3
)
212
-
216
.
Giovannoni G, Thompson EJ
(
1998
)
.
Urinary markers of disease activity in multiple sclerosis
.
Multiple Sclerosis Journal
vol.
4
,
(
3
)
247
-
253
.
Giovannoni G, Kieseier B, Hartung HP
(
1998
)
.
Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
64 Suppl 1
,
s31
-
s36
.
Giovannoni G, Miller RF, Heales SJR, Land JM, Harrison MJG, Thompson EJ
(
1998
)
.
Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction
.
Journal of the Neurological Sciences
vol.
156
,
(
1
)
53
-
58
.
Giovannoni G
(
1998
)
.
Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis
.
Multiple Sclerosis Journal
vol.
4
,
(
1
)
27
-
30
.
Moshage H, Jansen PLM
(
1998
)
.
Adaptation of the Nitrate and Griess Reaction Methods for the Measurement of Serum Nitrate plus Nitrate Levels
.
Annals of Clinical Biochemistry International Journal of Laboratory Medicine
vol.
35
,
(
1
)
154
-
155
.
Giovannoni G, Heales SJR
(
1998
)
.
Authors' Reply
.
Annals of Clinical Biochemistry International Journal of Laboratory Medicine
vol.
35
,
(
1
)
155
-
155
.
Giovannoni G
(
1997
)
.
The immunopathogenesis of multiple sclerosis
.
Baillière's Clinical Neurology
vol.
6
,
(
3
)
387
-
407
.
Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, Miller DH, Feldmann M et al.
(
1997
)
.
Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging
.
Neurology
vol.
48
,
(
6
)
1557
-
1565
.
Giovannoni G, Land JM, Keir G, Thompson EJ, Heales SJR
(
1997
)
.
Adaptation of the Nitrate Reductase and Griess Reaction Methods for the Measurement of Serum Nitrate plus Nitrite Levels
.
Annals of Clinical Biochemistry International Journal of Laboratory Medicine
vol.
34
,
(
2
)
193
-
198
.
Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thompson AJ, Keir G, Feldmann M et al.
(
1997
)
.
Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis
.
Brain
vol.
120
,
(
1
)
1
-
13
.
Giovannoni G, Heales SJR, Silver NC, O'Riordan J, Miller RF, Land JM, Clark JB, Thompson EJ
(
1997
)
.
Raised serum nitrate and nitrite levels in patients with multiple sclerosis
.
Journal of the Neurological Sciences
vol.
145
,
(
1
)
77
-
81
.
Giovannoni G, Hartung H-P
(
1996
)
.
The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome
.
Current Opinion in Neurology
vol.
9
,
(
3
)
165
-
177
.
Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ, Keir G, Miller DH et al.
(
1996
)
.
Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
60
,
(
1
)
Giovannoni G, Thompson EJ
(
1996
)
.
The detection and significance of cerebrospinal fluid oligoclonal IgG
.
Cerebrospinal Fluid Analysis in Multiple Sclerosis
,
Springer Nature
Giovannoni G, Fritz VU
(
1993
)
.
Transient ischemic attacks in younger and older patients. A comparative study of 798 patients in South Africa
.
Stroke
vol.
24
,
(
7
)
947
-
953
.